Endocrinology & Diabetes — MCQs

Q: A 46-year-old man presents with recurrent episodes of severe flushing and diarrhea. CT shows liver metastases and a pancreatic mass. Chromogranin A is markedly elevated. What is the most likely primary tumor?

Pancreatic neuroendocrine tumor. ***Pancreatic neuroendocrine tumor*** - The classic presentation of recurrent **flushing** and **diarrhea**, combined with a **pancreatic mass** and **liver metastases**, is highly characteristic of a functional **neuroendocrine tumor (NET)**, specifically a **carcinoid syndrome**. - Markedly elevated **Chromogranin A** is a widely used and sensitive biochemical marker for **neuroendocrine tumors**, confirming this diagnosis. *Pancreatic adenocarcinoma* - This tumor typically presents with symptoms such as **jaundice**, **weight loss**, and **abdominal pain**, not **flushing** and **diarrhea**. - **Chromogranin A** is not elevated in pancreatic adenocarcinoma; **CA 19-9** is a more common tumor marker. *Hepatocellular carcinoma* - While **liver metastases** are mentioned, the primary tumor is a **pancreatic mass**, not a primary liver tumor. - It does not typically cause **flushing** and **diarrhea**, nor is **Chromogranin A** a marker for hepatocellular carcinoma. *Cholangiocarcinoma* - This is a cancer of the **bile ducts** and usually presents with **jaundice**, **pruritus**, and **dark urine**, not **flushing** and **diarrhea**. - The primary mass is in the **pancreas**, not the bile ducts, and **Chromogranin A** is not elevated in cholangiocarcinoma. *Gastrinoma* - A **gastrinoma** is a type of pancreatic neuroendocrine tumor that primarily causes **Zollinger-Ellison syndrome**, characterized by severe **peptic ulcer disease** and **diarrhea** due to excessive gastrin. - While it's a NET, the prominent **flushing** is not a typical feature of gastrinoma; this symptom strongly points towards a tumor producing other vasoactive substances (e.g., serotonin, VIP) consistent with a broader **carcinoid syndrome** presentation.

Q: A 59-year-old woman presents with bone pain and fatigue. Blood tests show calcium 3.3 mmol/L, low albumin, and normal PTH. She has a history of breast cancer 5 years ago. What is the most likely mechanism?

PTH-related protein. ***PTH-related protein***- This is the most common cause of **Humoral Hypercalcemia of Malignancy (HHM)**, especially in solid tumors like breast cancer, where **PTHrP** acts as a systemic hormone, mimicking the effects of **parathyroid hormone** on bone and kidney.- The presentation of **severe hypercalcemia** (3.3 mmol/L) with normal or **suppressed PTH** strongly indicates a PTH-independent mechanism, making HHM due to PTHrP the primary diagnosis over primary hyperparathyroidism.*Parathyroid hormone excess*- **Primary Hyperparathyroidism** causes hypercalcemia due to an adenoma or hyperplasia resulting in *high* or *inappropriately normal* circulating levels of **PTH**.- In this patient, the PTH level is normal (implying suppression by the high calcium), which effectively rules out PTH excess as the direct cause of the hypercalcemia.*Vitamin D excess*- Causes hypercalcemia by increasing **intestinal calcium absorption** and promoting bone resorption, identifiable by significantly elevated levels of **25(OH)D** or active **1,25(OH)₂D**.- While possible, this mechanism is far less likely than malignancy-associated hypercalcemia in a patient with a known history of breast cancer.*Bone metastases*- Breast cancer commonly metastasizes to bone, causing **osteolytic lesions** that release calcium via local cytokine-mediated osteoclast activation.- Although common, hypercalcemia caused solely by local osteolysis tends to be less severe than the level seen here; pronounced hypercalcemia with suppressed PTH is the hallmark presentation of **humoral hypercalcemia (PTHrP)**.*Sarcoidosis*- This granulomatous disease causes hypercalcemia via ectopic production of **1-alpha-hydroxylase** by activated macrophages, leading to unregulated synthesis of active **1,25-dihydroxyvitamin D**.- This mechanism is not typically associated with breast cancer and is usually accompanied by other features of sarcoidosis, such as pulmonary symptoms or cutaneous lesions.

Q: A 43-year-old man presents with recurrent episodes of severe sweating, palpitations, and headache. His BP during episodes is 240/130 mmHg. What is the most appropriate preoperative management?

Alpha-blockers then beta-blockers. ***Alpha-blockers then beta-blockers***- The clinical presentation (paroxysmal **hypertension**, headache, palpitations, and sweating) is highly suggestive of a **pheochromocytoma**.- Preoperative stabilization requires adequate **alpha-adrenergic blockade** first (e.g., phenoxybenzamine or doxazosin) to control blood pressure and allow for volume expansion, followed by **beta-blockade** to manage tachycardia or arrhythmias.*Beta-blockers only*- Using beta-blockers alone is contraindicated as it causes **unopposed alpha-adrenergic stimulation**, leading to severe **vasoconstriction** and potentially a fatal hypertensive crisis or pulmonary edema.- Beta-blockers are only instituted *after* achieving complete alpha-blockade and adequate blood pressure control, typically to manage persistent tachycardia.*Alpha-blockers only*- While alpha-blockade is the essential first step, it is usually insufficient for full preoperative management, as patients often require subsequent **beta-blockade** to control catecholamine-induced tachycardia and arrhythmias.- Complete preparation requires both classes of medication to fully mitigate cardiovascular risk before surgery.*ACE inhibitors*- These medications target the **renin-angiotensin-aldosterone system** and are ineffective at blocking the direct severe vasoconstrictive effects of excessive circulating catecholamines.- They may also increase the risk of severe **hypotension** after tumor removal if the patient is relatively volume-depleted from prolonged vasoconstriction.*Calcium channel blockers*- While some CCBs (like nicardipine) can be used as **adjuncts** for blood pressure control, they cannot replace the mandatory initial step of **alpha-adrenergic blockade** and volume repletion.- They do not address the need for full adrenergic receptor blockade necessary to prevent cardiovascular catastrophe during surgical manipulation of the tumor.

Q: A 44-year-old woman presents with fatigue, muscle weakness, and weight loss. She has hyperpigmentation of palmar creases. Blood tests show Na+ 128 mmol/L, K+ 5.6 mmol/L. What is the most appropriate diagnostic test?

Synacthen stimulation test. ***Synacthen stimulation test*** - Also known as the **ACTH stimulation test**, this is the **gold standard** for diagnosing adrenal insufficiency, as the clinical signs (hyperpigmentation, hyponatremia, hyperkalemia) strongly suggest **Primary Adrenal Insufficiency** (Addison's disease). - The test assesses the adrenal gland's reserve capacity to produce cortisol; an insufficient rise in cortisol following the injection of synthetic **ACTH (Synacthen)** confirms the diagnosis. *Dexamethasone suppression test* - This test is primarily used to confirm or exclude **Cushing syndrome** (hypercortisolism) by checking if cortisol production can be suppressed by exogenous steroids. - It is inappropriate for suspected adrenal insufficiency, as it does not evaluate the maximum functional capacity of the adrenal glands. *24-hour urine cortisol* - This test measures the total amount of free cortisol excreted over a day and is typically used as a screening tool for **Cushing syndrome**. - While very low values might suggest adrenal failure, it is less sensitive and specific for diagnosing adrenal insufficiency compared to the **Synacthen test**. *Adrenal antibodies* - Detecting adrenal antibodies (e.g., against **21-hydroxylase**) is crucial for determining the **autoimmune etiology** of primary adrenal insufficiency. - However, measuring antibodies is a step in determining the *cause* of the disease, not the definitive *diagnostic test* for glandular failure. *ACTH levels* - Plasma **ACTH** measurement is essential for distinguishing between primary (high ACTH) and secondary (low ACTH) insufficiency *after* the diagnosis is confirmed by the Synacthen test. - It serves as a differentiation tool, but cannot confirm the initial diagnosis of adrenal insufficiency, which requires assessing the cortisol response to stimulation.

Q: A 64-year-old woman presents with bone pain and fatigue. Blood tests show calcium 3.1 mmol/L, phosphate 0.7 mmol/L, and suppressed PTH. She has a history of sarcoidosis. What is the most likely cause of hypercalcemia?

Granulomatous disease. ***Granulomatous disease*** - Sarcoidosis, a common granulomatous disease, causes non-PTH mediated hypercalcemia due to the autonomous expression of **1-alpha-hydroxylase** by activated macrophages within the granulomas. - This enzyme overproduces **1,25-dihydroxyvitamin D (calcitriol)**, leading to increased intestinal calcium absorption and subsequent **suppression of PTH**. *Primary hyperparathyroidism* - This condition is characterized by an elevated or inappropriately normal **parathyroid hormone (PTH)** level in the setting of hypercalcemia, typically due to a parathyroid adenoma. - The patient's lab results show **suppressed PTH**, which effectively rules out primary hyperparathyroidism. *Malignancy* - Malignancy frequently causes hypercalcemia, often through osteolytic bone destruction or the secretion of **Parathyroid Hormone-related Protein (PTHrP)**, which also suppresses PTH. - Although PTH is suppressed, the strong history of **sarcoidosis** (a known non-malignant cause of calcitriol-mediated hypercalcemia) makes granulomatous disease the most probable specific diagnosis. *Vitamin D intoxication* - This typically results from massive exogenous intake of vitamin D, leading to extremely high levels of serum **25-hydroxyvitamin D** and subsequent elevation of serum calcium. - While it causes suppressed PTH and hypercalcemia, the known diagnosis of sarcoidosis provides a strong, intrinsic explanation that must be prioritized over exogenous intake. *Milk-alkali syndrome* - This syndrome is caused by the substantial intake of **calcium** and absorbable **alkali**, resulting in hypercalcemia, suppressed PTH, and often metabolic alkalosis. - The history provided emphasizes sarcoidosis rather than excessive antacid or calcium supplementation, making this diagnosis less likely.

Q: A 47-year-old woman presents with fatigue, muscle weakness, and depression. She has purple striae and central obesity. 24-hour urine cortisol is elevated. What is the next most appropriate test?

Dexamethasone suppression test. ***Dexamethasone suppression test*** - An elevated 24-hour urine cortisol confirms hypercortisolism; the next step is to determine the underlying cause, which the **dexamethasone suppression test** helps to differentiate. - This test assesses the feedback control of the **hypothalamic-pituitary-adrenal axis** to differentiate among pituitary Cushing's disease, ectopic ACTH production, and adrenal tumors. *MRI pituitary* - **MRI pituitary** is primarily used for **localization** of a pituitary adenoma after ACTH-dependent Cushing's syndrome has been established. - It is not the initial test to *determine the cause* of hypercortisolism after it has been confirmed. *ACTH levels* - **ACTH levels** are crucial to differentiate between **ACTH-dependent** (pituitary or ectopic) and **ACTH-independent** (adrenal) causes of Cushing's syndrome. - While important, a **dexamethasone suppression test** is often performed first or concurrently to provide functional insight into cortisol suppressibility. *Adrenal CT* - **Adrenal CT** is performed to **localize an adrenal adenoma** or hyperplasia once ACTH-independent Cushing's syndrome (low ACTH) has been identified. - It is a localization step, not the primary diagnostic test to determine the *type* of Cushing's syndrome after initial confirmation of hypercortisolism. *CRH stimulation test* - The **CRH stimulation test** is typically used to help differentiate between **pituitary Cushing's disease** and **ectopic ACTH production** in cases of ACTH-dependent Cushing's syndrome. - It is a more specialized test performed after initial confirmation and differentiation steps like the dexamethasone suppression test and ACTH levels.

Q: A 45-year-old man presents with recurrent episodes of severe sweating, headache, and palpitations. His BP during attacks reaches 220/120 mmHg. 24-hour urine catecholamines are elevated. What is the most likely diagnosis?

Pheochromocytoma. ***Pheochromocytoma*** - The highly suggestive clinical presentation includes the classic paroxysmal triad of severe **headache**, generalized **sweating**, and **palpitations** (tachycardia), often coinciding with **hypertensive crises** (220/120 mmHg).- The diagnosis is biochemically confirmed by finding significant evidence of excessive catecholamine production, such as **elevated 24-hour urine catecholamines** or metanephrines.*Essential hypertension*- Essential hypertension is a diagnosis of exclusion that typically does not present with severe, intermittent, and paroxysmal symptomatic crises.- It is not characterized by pathologically high levels of **catecholamines** or their metabolites in the urine or plasma.*Panic disorder*- Panic disorder can cause symptoms mimicking sympathetic overdrive (palpitations, sweating), but it rarely causes the severe, transient **hypertensive crises** seen in this patient (e.g., 220/120 mmHg).- Panic attacks are excluded as the primary cause by the finding of high levels of circulating and **urinary catecholamines**.*Hyperthyroidism*- While hyperthyroidism causes palpitations and sweating, the hypertension is usually predominantly **systolic** (leading to a wide pulse pressure), not spiking to 220/120 mmHg.- Diagnosis relies on elevated **thyroid hormone levels** (T3/T4) and a suppressed TSH, not elevated catecholamines.*Cocaine use*- Acute cocaine intoxication causes severe sympathetic hyperactivity and hypertension, but this is usually transient and related to recent drug ingestion.- If intoxication were the cause, laboratory findings would typically show evidence of drug use or metabolites, rather than chronic baseline elevation of **catecholamines** suggestive of a secreting tumor.

Q: A 29-year-old woman presents with episodes of severe anxiety, tremor, and palpitations. These occur mainly when fasting. Blood glucose during episodes is 2.1 mmol/L. Insulin and C-peptide are elevated. What is the most likely diagnosis?

Insulinoma. ***Insulinoma*** - The presentation fulfills **Whipple's triad** (symptoms of hypoglycemia, low blood glucose, relief upon glucose administration) occurring specifically with **fasting**. - The key diagnostic findings are **fasting hypoglycemia** (2.1 mmol/L) combined with inappropriately **elevated insulin and C-peptide**, confirming excessive *endogenous* insulin secretion from a pancreatic **β-cell tumor**. *Panic disorder* - Although the symptoms (anxiety, tremor, and palpitations) mimic adrenergic symptoms of hypoglycemia, the coexisting **severe hypoglycemia** rules out pure panic disorder. - Panic disorder is a psychiatric diagnosis and does not cause underlying metabolic derangements like low blood glucose or hyperinsulinemia. *Factitious hypoglycemia* - If the patient were using **exogenous insulin**, the C-peptide level would be **suppressed or low**, as commercial insulin preparations do not typically contain C-peptide. - While sulfonylurea abuse (a form of factitious hypoglycemia) can raise both insulin and C-peptide, **insulinoma** remains the primary organic diagnosis when these findings occur spontaneously, especially with severe fasting symptoms. *Reactive hypoglycemia* - This condition is characterized by hypoglycemia occurring **postprandially** (2–4 hours after a meal) due to rapid glucose absorption and delayed insulin response, not during **fasting**. - It is often seen after gastric surgeries or in the initial stages of diabetes, and typically presents with milder symptoms. *Adrenal insufficiency* - Adrenal insufficiency causes hypoglycemia primarily through lack of **cortisol**, which is a counter-regulatory hormone to insulin. - Hypoglycemia secondary to this condition would present with **suppressed** or low insulin and C-peptide levels, as the pancreas is not producing excess insulin.

Q: A 67-year-old woman presents with bone pain and confusion. Serum calcium is 3.4 mmol/L, phosphate is low, and PTH is elevated. Parathyroid scan shows increased uptake. What is the most appropriate treatment?

Parathyroidectomy. ***Parathyroidectomy*** - The presence of severe hypercalcemia (3.4 mmol/L), elevated PTH, and end-organ damage (bone pain, confusion) are clear indications for definitive surgical management of **Primary Hyperparathyroidism** (PHPT). - Parathyroidectomy is the curative treatment for PHPT, effectively removing the source of excess PTH production (likely an **adenoma**, localized by the scan) and normalizing calcium levels long-term. *IV fluids and bisphosphonates* - These agents are used for the initial, acute management of **hypercalcemic crisis** to rapidly reduce serum calcium, but they are not the definitive curative treatment for the underlying PHPT. - Bisphosphonates inhibit osteoclast activity, but the failure to address the sustained excess PTH means high calcium levels will recur shortly without definitive surgical intervention. *Cinacalcet* - Cinacalcet is a **calcimimetic** that increases the sensitivity of the calcium-sensing receptor, reducing PTH secretion and serum calcium. - It is typically reserved for PHPT patients who are poor surgical candidates or have intractable secondary hyperparathyroidism, not the **first-line curative treatment**. *High-dose vitamin D* - Vitamin D should be avoided as it would exacerbate the patient's hypercalcemia by increasing **intestinal calcium absorption** and mobilizing calcium from bone. - It is used to treat conditions causing **hypocalcemia** (like hypoparathyroidism or vitamin D deficiency), which is the opposite of this clinical scenario. *Corticosteroids* - Corticosteroids are primarily used to treat hypercalcemia associated with **malignancy** or **granulomatous diseases** (e.g., sarcoidosis) by reducing calcitriol production. - They are generally ineffective in managing the high calcium levels driven by increased PTH secretion caused by a **parathyroid adenoma**.

Q: A 49-year-old woman presents with recurrent episodes of severe flushing and diarrhea. CT shows multiple liver lesions and a pancreatic mass. Chromogranin A is elevated. What is the most likely diagnosis?

Neuroendocrine tumor. ***Neuroendocrine tumor***- The combination of **severe flushing** and secretory **diarrhea** (suggestive of **carcinoid syndrome**), coupled with a pancreatic mass and liver metastases, is highly specific for a functional Neuroendocrine Tumor (NET).- The elevated **Chromogranin A** confirms the neuroendocrine origin of the tumor, as this protein is stored and released by neurosecretory granules in NET cells.*Pancreatic adenocarcinoma*- This common pancreatic malignancy typically presents with **painless jaundice**, severe back pain, or weight loss, but **lacks the specific hormonal symptoms** of flushing and diarrhea.- The primary tumor marker for adenocarcinoma is usually **CA 19-9**, not Chromogranin A.*Hepatocellular carcinoma*- This primary liver cancer arises most often in the setting of chronic liver disease/cirrhosis and presents with mass effects or systemic decline, but **flushing and diarrhea are absent**.- The liver lesions in this case are likely **metastases** arising from the primary pancreatic neuroendocrine tumor, not primary HCC.*Cholangiocarcinoma*- This cancer of the bile ducts manifests primarily as **obstructive jaundice** and right upper quadrant pain.- It is not associated with the syndrome of flushing and diarrhea or the release of hormones that lead to elevated **Chromogranin A**.*Lymphoma*- Lymphoma typically presents with systemic **B symptoms** (**fever, night sweats, weight loss**) and significant lymphadenopathy.- It does not produce the hormones that cause flushing and diarrhea, nor is it associated with elevated serum **Chromogranin A**.

Endocrinology & Diabetes UK Medical PG Practice Questions and MCQs

Question 1: A 46-year-old man presents with recurrent episodes of severe flushing and diarrhea. CT shows liver metastases and a pancreatic mass. Chromogranin A is markedly elevated. What is the most likely primary tumor?

A. Pancreatic adenocarcinoma
B. Pancreatic neuroendocrine tumor (Correct Answer)
C. Hepatocellular carcinoma
D. Cholangiocarcinoma
E. Gastrinoma

Explanation: ***Pancreatic neuroendocrine tumor*** - The classic presentation of recurrent **flushing** and **diarrhea**, combined with a **pancreatic mass** and **liver metastases**, is highly characteristic of a functional **neuroendocrine tumor (NET)**, specifically a **carcinoid syndrome**. - Markedly elevated **Chromogranin A** is a widely used and sensitive biochemical marker for **neuroendocrine tumors**, confirming this diagnosis. *Pancreatic adenocarcinoma* - This tumor typically presents with symptoms such as **jaundice**, **weight loss**, and **abdominal pain**, not **flushing** and **diarrhea**. - **Chromogranin A** is not elevated in pancreatic adenocarcinoma; **CA 19-9** is a more common tumor marker. *Hepatocellular carcinoma* - While **liver metastases** are mentioned, the primary tumor is a **pancreatic mass**, not a primary liver tumor. - It does not typically cause **flushing** and **diarrhea**, nor is **Chromogranin A** a marker for hepatocellular carcinoma. *Cholangiocarcinoma* - This is a cancer of the **bile ducts** and usually presents with **jaundice**, **pruritus**, and **dark urine**, not **flushing** and **diarrhea**. - The primary mass is in the **pancreas**, not the bile ducts, and **Chromogranin A** is not elevated in cholangiocarcinoma. *Gastrinoma* - A **gastrinoma** is a type of pancreatic neuroendocrine tumor that primarily causes **Zollinger-Ellison syndrome**, characterized by severe **peptic ulcer disease** and **diarrhea** due to excessive gastrin. - While it's a NET, the prominent **flushing** is not a typical feature of gastrinoma; this symptom strongly points towards a tumor producing other vasoactive substances (e.g., serotonin, VIP) consistent with a broader **carcinoid syndrome** presentation.

Question 2: A 59-year-old woman presents with bone pain and fatigue. Blood tests show calcium 3.3 mmol/L, low albumin, and normal PTH. She has a history of breast cancer 5 years ago. What is the most likely mechanism?

A. Parathyroid hormone excess
B. PTH-related protein (Correct Answer)
C. Vitamin D excess
D. Bone metastases
E. Sarcoidosis

Explanation: ***PTH-related protein***- This is the most common cause of **Humoral Hypercalcemia of Malignancy (HHM)**, especially in solid tumors like breast cancer, where **PTHrP** acts as a systemic hormone, mimicking the effects of **parathyroid hormone** on bone and kidney.- The presentation of **severe hypercalcemia** (3.3 mmol/L) with normal or **suppressed PTH** strongly indicates a PTH-independent mechanism, making HHM due to PTHrP the primary diagnosis over primary hyperparathyroidism.*Parathyroid hormone excess*- **Primary Hyperparathyroidism** causes hypercalcemia due to an adenoma or hyperplasia resulting in *high* or *inappropriately normal* circulating levels of **PTH**.- In this patient, the PTH level is normal (implying suppression by the high calcium), which effectively rules out PTH excess as the direct cause of the hypercalcemia.*Vitamin D excess*- Causes hypercalcemia by increasing **intestinal calcium absorption** and promoting bone resorption, identifiable by significantly elevated levels of **25(OH)D** or active **1,25(OH)₂D**.- While possible, this mechanism is far less likely than malignancy-associated hypercalcemia in a patient with a known history of breast cancer.*Bone metastases*- Breast cancer commonly metastasizes to bone, causing **osteolytic lesions** that release calcium via local cytokine-mediated osteoclast activation.- Although common, hypercalcemia caused solely by local osteolysis tends to be less severe than the level seen here; pronounced hypercalcemia with suppressed PTH is the hallmark presentation of **humoral hypercalcemia (PTHrP)**.*Sarcoidosis*- This granulomatous disease causes hypercalcemia via ectopic production of **1-alpha-hydroxylase** by activated macrophages, leading to unregulated synthesis of active **1,25-dihydroxyvitamin D**.- This mechanism is not typically associated with breast cancer and is usually accompanied by other features of sarcoidosis, such as pulmonary symptoms or cutaneous lesions.

Question 3: A 43-year-old man presents with recurrent episodes of severe sweating, palpitations, and headache. His BP during episodes is 240/130 mmHg. What is the most appropriate preoperative management?

A. Beta-blockers only
B. Alpha-blockers only
C. Alpha-blockers then beta-blockers (Correct Answer)
D. ACE inhibitors
E. Calcium channel blockers

Explanation: ***Alpha-blockers then beta-blockers***- The clinical presentation (paroxysmal **hypertension**, headache, palpitations, and sweating) is highly suggestive of a **pheochromocytoma**.- Preoperative stabilization requires adequate **alpha-adrenergic blockade** first (e.g., phenoxybenzamine or doxazosin) to control blood pressure and allow for volume expansion, followed by **beta-blockade** to manage tachycardia or arrhythmias.*Beta-blockers only*- Using beta-blockers alone is contraindicated as it causes **unopposed alpha-adrenergic stimulation**, leading to severe **vasoconstriction** and potentially a fatal hypertensive crisis or pulmonary edema.- Beta-blockers are only instituted *after* achieving complete alpha-blockade and adequate blood pressure control, typically to manage persistent tachycardia.*Alpha-blockers only*- While alpha-blockade is the essential first step, it is usually insufficient for full preoperative management, as patients often require subsequent **beta-blockade** to control catecholamine-induced tachycardia and arrhythmias.- Complete preparation requires both classes of medication to fully mitigate cardiovascular risk before surgery.*ACE inhibitors*- These medications target the **renin-angiotensin-aldosterone system** and are ineffective at blocking the direct severe vasoconstrictive effects of excessive circulating catecholamines.- They may also increase the risk of severe **hypotension** after tumor removal if the patient is relatively volume-depleted from prolonged vasoconstriction.*Calcium channel blockers*- While some CCBs (like nicardipine) can be used as **adjuncts** for blood pressure control, they cannot replace the mandatory initial step of **alpha-adrenergic blockade** and volume repletion.- They do not address the need for full adrenergic receptor blockade necessary to prevent cardiovascular catastrophe during surgical manipulation of the tumor.

Question 4: A 44-year-old woman presents with fatigue, muscle weakness, and weight loss. She has hyperpigmentation of palmar creases. Blood tests show Na+ 128 mmol/L, K+ 5.6 mmol/L. What is the most appropriate diagnostic test?

A. Dexamethasone suppression test
B. Synacthen stimulation test (Correct Answer)
C. 24-hour urine cortisol
D. Adrenal antibodies
E. ACTH levels

Explanation: ***Synacthen stimulation test*** - Also known as the **ACTH stimulation test**, this is the **gold standard** for diagnosing adrenal insufficiency, as the clinical signs (hyperpigmentation, hyponatremia, hyperkalemia) strongly suggest **Primary Adrenal Insufficiency** (Addison's disease). - The test assesses the adrenal gland's reserve capacity to produce cortisol; an insufficient rise in cortisol following the injection of synthetic **ACTH (Synacthen)** confirms the diagnosis. *Dexamethasone suppression test* - This test is primarily used to confirm or exclude **Cushing syndrome** (hypercortisolism) by checking if cortisol production can be suppressed by exogenous steroids. - It is inappropriate for suspected adrenal insufficiency, as it does not evaluate the maximum functional capacity of the adrenal glands. *24-hour urine cortisol* - This test measures the total amount of free cortisol excreted over a day and is typically used as a screening tool for **Cushing syndrome**. - While very low values might suggest adrenal failure, it is less sensitive and specific for diagnosing adrenal insufficiency compared to the **Synacthen test**. *Adrenal antibodies* - Detecting adrenal antibodies (e.g., against **21-hydroxylase**) is crucial for determining the **autoimmune etiology** of primary adrenal insufficiency. - However, measuring antibodies is a step in determining the *cause* of the disease, not the definitive *diagnostic test* for glandular failure. *ACTH levels* - Plasma **ACTH** measurement is essential for distinguishing between primary (high ACTH) and secondary (low ACTH) insufficiency *after* the diagnosis is confirmed by the Synacthen test. - It serves as a differentiation tool, but cannot confirm the initial diagnosis of adrenal insufficiency, which requires assessing the cortisol response to stimulation.

Question 5: A 64-year-old woman presents with bone pain and fatigue. Blood tests show calcium 3.1 mmol/L, phosphate 0.7 mmol/L, and suppressed PTH. She has a history of sarcoidosis. What is the most likely cause of hypercalcemia?

A. Primary hyperparathyroidism
B. Malignancy
C. Granulomatous disease (Correct Answer)
D. Vitamin D intoxication
E. Milk-alkali syndrome

Explanation: ***Granulomatous disease*** - Sarcoidosis, a common granulomatous disease, causes non-PTH mediated hypercalcemia due to the autonomous expression of **1-alpha-hydroxylase** by activated macrophages within the granulomas. - This enzyme overproduces **1,25-dihydroxyvitamin D (calcitriol)**, leading to increased intestinal calcium absorption and subsequent **suppression of PTH**. *Primary hyperparathyroidism* - This condition is characterized by an elevated or inappropriately normal **parathyroid hormone (PTH)** level in the setting of hypercalcemia, typically due to a parathyroid adenoma. - The patient's lab results show **suppressed PTH**, which effectively rules out primary hyperparathyroidism. *Malignancy* - Malignancy frequently causes hypercalcemia, often through osteolytic bone destruction or the secretion of **Parathyroid Hormone-related Protein (PTHrP)**, which also suppresses PTH. - Although PTH is suppressed, the strong history of **sarcoidosis** (a known non-malignant cause of calcitriol-mediated hypercalcemia) makes granulomatous disease the most probable specific diagnosis. *Vitamin D intoxication* - This typically results from massive exogenous intake of vitamin D, leading to extremely high levels of serum **25-hydroxyvitamin D** and subsequent elevation of serum calcium. - While it causes suppressed PTH and hypercalcemia, the known diagnosis of sarcoidosis provides a strong, intrinsic explanation that must be prioritized over exogenous intake. *Milk-alkali syndrome* - This syndrome is caused by the substantial intake of **calcium** and absorbable **alkali**, resulting in hypercalcemia, suppressed PTH, and often metabolic alkalosis. - The history provided emphasizes sarcoidosis rather than excessive antacid or calcium supplementation, making this diagnosis less likely.

Question 6: A 47-year-old woman presents with fatigue, muscle weakness, and depression. She has purple striae and central obesity. 24-hour urine cortisol is elevated. What is the next most appropriate test?

A. MRI pituitary
B. Dexamethasone suppression test (Correct Answer)
C. ACTH levels
D. Adrenal CT
E. CRH stimulation test

Explanation: ***Dexamethasone suppression test*** - An elevated 24-hour urine cortisol confirms hypercortisolism; the next step is to determine the underlying cause, which the **dexamethasone suppression test** helps to differentiate. - This test assesses the feedback control of the **hypothalamic-pituitary-adrenal axis** to differentiate among pituitary Cushing's disease, ectopic ACTH production, and adrenal tumors. *MRI pituitary* - **MRI pituitary** is primarily used for **localization** of a pituitary adenoma after ACTH-dependent Cushing's syndrome has been established. - It is not the initial test to *determine the cause* of hypercortisolism after it has been confirmed. *ACTH levels* - **ACTH levels** are crucial to differentiate between **ACTH-dependent** (pituitary or ectopic) and **ACTH-independent** (adrenal) causes of Cushing's syndrome. - While important, a **dexamethasone suppression test** is often performed first or concurrently to provide functional insight into cortisol suppressibility. *Adrenal CT* - **Adrenal CT** is performed to **localize an adrenal adenoma** or hyperplasia once ACTH-independent Cushing's syndrome (low ACTH) has been identified. - It is a localization step, not the primary diagnostic test to determine the *type* of Cushing's syndrome after initial confirmation of hypercortisolism. *CRH stimulation test* - The **CRH stimulation test** is typically used to help differentiate between **pituitary Cushing's disease** and **ectopic ACTH production** in cases of ACTH-dependent Cushing's syndrome. - It is a more specialized test performed after initial confirmation and differentiation steps like the dexamethasone suppression test and ACTH levels.

Question 7: A 45-year-old man presents with recurrent episodes of severe sweating, headache, and palpitations. His BP during attacks reaches 220/120 mmHg. 24-hour urine catecholamines are elevated. What is the most likely diagnosis?

A. Essential hypertension
B. Pheochromocytoma (Correct Answer)
C. Panic disorder
D. Hyperthyroidism
E. Cocaine use

Explanation: ***Pheochromocytoma*** - The highly suggestive clinical presentation includes the classic paroxysmal triad of severe **headache**, generalized **sweating**, and **palpitations** (tachycardia), often coinciding with **hypertensive crises** (220/120 mmHg).- The diagnosis is biochemically confirmed by finding significant evidence of excessive catecholamine production, such as **elevated 24-hour urine catecholamines** or metanephrines.*Essential hypertension*- Essential hypertension is a diagnosis of exclusion that typically does not present with severe, intermittent, and paroxysmal symptomatic crises.- It is not characterized by pathologically high levels of **catecholamines** or their metabolites in the urine or plasma.*Panic disorder*- Panic disorder can cause symptoms mimicking sympathetic overdrive (palpitations, sweating), but it rarely causes the severe, transient **hypertensive crises** seen in this patient (e.g., 220/120 mmHg).- Panic attacks are excluded as the primary cause by the finding of high levels of circulating and **urinary catecholamines**.*Hyperthyroidism*- While hyperthyroidism causes palpitations and sweating, the hypertension is usually predominantly **systolic** (leading to a wide pulse pressure), not spiking to 220/120 mmHg.- Diagnosis relies on elevated **thyroid hormone levels** (T3/T4) and a suppressed TSH, not elevated catecholamines.*Cocaine use*- Acute cocaine intoxication causes severe sympathetic hyperactivity and hypertension, but this is usually transient and related to recent drug ingestion.- If intoxication were the cause, laboratory findings would typically show evidence of drug use or metabolites, rather than chronic baseline elevation of **catecholamines** suggestive of a secreting tumor.

Question 8: A 29-year-old woman presents with episodes of severe anxiety, tremor, and palpitations. These occur mainly when fasting. Blood glucose during episodes is 2.1 mmol/L. Insulin and C-peptide are elevated. What is the most likely diagnosis?

A. Panic disorder
B. Insulinoma (Correct Answer)
C. Factitious hypoglycemia
D. Reactive hypoglycemia
E. Adrenal insufficiency

Explanation: ***Insulinoma*** - The presentation fulfills **Whipple's triad** (symptoms of hypoglycemia, low blood glucose, relief upon glucose administration) occurring specifically with **fasting**. - The key diagnostic findings are **fasting hypoglycemia** (2.1 mmol/L) combined with inappropriately **elevated insulin and C-peptide**, confirming excessive *endogenous* insulin secretion from a pancreatic **β-cell tumor**. *Panic disorder* - Although the symptoms (anxiety, tremor, and palpitations) mimic adrenergic symptoms of hypoglycemia, the coexisting **severe hypoglycemia** rules out pure panic disorder. - Panic disorder is a psychiatric diagnosis and does not cause underlying metabolic derangements like low blood glucose or hyperinsulinemia. *Factitious hypoglycemia* - If the patient were using **exogenous insulin**, the C-peptide level would be **suppressed or low**, as commercial insulin preparations do not typically contain C-peptide. - While sulfonylurea abuse (a form of factitious hypoglycemia) can raise both insulin and C-peptide, **insulinoma** remains the primary organic diagnosis when these findings occur spontaneously, especially with severe fasting symptoms. *Reactive hypoglycemia* - This condition is characterized by hypoglycemia occurring **postprandially** (2–4 hours after a meal) due to rapid glucose absorption and delayed insulin response, not during **fasting**. - It is often seen after gastric surgeries or in the initial stages of diabetes, and typically presents with milder symptoms. *Adrenal insufficiency* - Adrenal insufficiency causes hypoglycemia primarily through lack of **cortisol**, which is a counter-regulatory hormone to insulin. - Hypoglycemia secondary to this condition would present with **suppressed** or low insulin and C-peptide levels, as the pancreas is not producing excess insulin.

Question 9: A 67-year-old woman presents with bone pain and confusion. Serum calcium is 3.4 mmol/L, phosphate is low, and PTH is elevated. Parathyroid scan shows increased uptake. What is the most appropriate treatment?

A. IV fluids and bisphosphonates
B. Parathyroidectomy (Correct Answer)
C. Cinacalcet
D. High-dose vitamin D
E. Corticosteroids

Explanation: ***Parathyroidectomy*** - The presence of severe hypercalcemia (3.4 mmol/L), elevated PTH, and end-organ damage (bone pain, confusion) are clear indications for definitive surgical management of **Primary Hyperparathyroidism** (PHPT). - Parathyroidectomy is the curative treatment for PHPT, effectively removing the source of excess PTH production (likely an **adenoma**, localized by the scan) and normalizing calcium levels long-term. *IV fluids and bisphosphonates* - These agents are used for the initial, acute management of **hypercalcemic crisis** to rapidly reduce serum calcium, but they are not the definitive curative treatment for the underlying PHPT. - Bisphosphonates inhibit osteoclast activity, but the failure to address the sustained excess PTH means high calcium levels will recur shortly without definitive surgical intervention. *Cinacalcet* - Cinacalcet is a **calcimimetic** that increases the sensitivity of the calcium-sensing receptor, reducing PTH secretion and serum calcium. - It is typically reserved for PHPT patients who are poor surgical candidates or have intractable secondary hyperparathyroidism, not the **first-line curative treatment**. *High-dose vitamin D* - Vitamin D should be avoided as it would exacerbate the patient's hypercalcemia by increasing **intestinal calcium absorption** and mobilizing calcium from bone. - It is used to treat conditions causing **hypocalcemia** (like hypoparathyroidism or vitamin D deficiency), which is the opposite of this clinical scenario. *Corticosteroids* - Corticosteroids are primarily used to treat hypercalcemia associated with **malignancy** or **granulomatous diseases** (e.g., sarcoidosis) by reducing calcitriol production. - They are generally ineffective in managing the high calcium levels driven by increased PTH secretion caused by a **parathyroid adenoma**.

Question 10: A 49-year-old woman presents with recurrent episodes of severe flushing and diarrhea. CT shows multiple liver lesions and a pancreatic mass. Chromogranin A is elevated. What is the most likely diagnosis?

A. Pancreatic adenocarcinoma
B. Neuroendocrine tumor (Correct Answer)
C. Hepatocellular carcinoma
D. Cholangiocarcinoma
E. Lymphoma

Explanation: ***Neuroendocrine tumor***- The combination of **severe flushing** and secretory **diarrhea** (suggestive of **carcinoid syndrome**), coupled with a pancreatic mass and liver metastases, is highly specific for a functional Neuroendocrine Tumor (NET).- The elevated **Chromogranin A** confirms the neuroendocrine origin of the tumor, as this protein is stored and released by neurosecretory granules in NET cells.*Pancreatic adenocarcinoma*- This common pancreatic malignancy typically presents with **painless jaundice**, severe back pain, or weight loss, but **lacks the specific hormonal symptoms** of flushing and diarrhea.- The primary tumor marker for adenocarcinoma is usually **CA 19-9**, not Chromogranin A.*Hepatocellular carcinoma*- This primary liver cancer arises most often in the setting of chronic liver disease/cirrhosis and presents with mass effects or systemic decline, but **flushing and diarrhea are absent**.- The liver lesions in this case are likely **metastases** arising from the primary pancreatic neuroendocrine tumor, not primary HCC.*Cholangiocarcinoma*- This cancer of the bile ducts manifests primarily as **obstructive jaundice** and right upper quadrant pain.- It is not associated with the syndrome of flushing and diarrhea or the release of hormones that lead to elevated **Chromogranin A**.*Lymphoma*- Lymphoma typically presents with systemic **B symptoms** (**fever, night sweats, weight loss**) and significant lymphadenopathy.- It does not produce the hormones that cause flushing and diarrhea, nor is it associated with elevated serum **Chromogranin A**.

Question 11: A 26-year-old woman presents with amenorrhea, galactorrhea, and headaches. MRI shows 1.5cm pituitary mass. Prolactin is 4500 mU/L. What is the most appropriate initial treatment?

A. Transsphenoidal surgery
B. Cabergoline (Correct Answer)
C. Bromocriptine
D. Radiotherapy
E. Observation

Explanation: ***Cabergoline***- **Cabergoline** is the preferred first-line treatment for all symptomatic prolactinomas, including macroprolactinomas (>1 cm), as seen in this patient (1.5 cm). - This **dopamine agonist** effectively suppresses prolactin production, leading to rapid normalization of prolactin levels and significant tumor shrinkage, thereby alleviating symptoms like headache, amenorrhea, and galactorrhea. *Transsphenoidal surgery* - Surgery is reserved for patients who are intolerant of or resistant to **dopamine agonists** or those presenting with large tumors causing significant compression/visual deficits that do not respond rapidly to medical therapy. - Given the high success rate of medical therapy, surgery is not the appropriate **initial** management. *Bromocriptine* - **Bromocriptine** is also a dopamine agonist used for prolactinomas, but **Cabergoline** is generally favored due to its better tolerability profile, reduced side effects, and ability to be dosed less frequently. - While effective, it is often considered a second-line agent if Cabergoline is unavailable or if the patient desires pregnancy and tolerance/cost is an issue (though Cabergoline is now often used in early pregnancy too). *Radiotherapy* - Radiotherapy is typically reserved as a tertiary treatment option for aggressive tumors that fail to respond to both **dopamine agonists** and **transsphenoidal surgery**. - It is not used initially due to potential long-term complications, including **hypopituitarism** and damage to surrounding structures. *Observation* - Observation is only appropriate for patients with asymptomatic **microprolactinomas** (<1 cm) or those with mildly elevated prolactin levels without mass effect or symptomatic hypogonadism. - This patient is highly symptomatic (amenorrhea, galactorrhea, headache) and has a **macroprolactinoma** (1.5 cm), necessitating immediate pharmaceutical intervention.

Question 12: A 59-year-old woman presents with bone pain and fatigue. Serum calcium is 3.1 mmol/l with low albumin. She has a history of breast cancer. What is the most likely cause?

A. Primary hyperparathyroidism
B. Malignancy-related hypercalcemia (Correct Answer)
C. Sarcoidosis
D. Vitamin D toxicity
E. Milk-alkali syndrome

Explanation: ***Malignancy-related hypercalcemia***- The presence of **severe hypercalcemia** (3.1 mmol/l or 12.4 mg/dL) in a patient with a history of **breast cancer** strongly suggests cancer as the underlying cause.- Breast cancer is a common cause of malignancy-related hypercalcemia, often via **osteolytic metastases** leading to direct bone resorption or, less commonly, through the secretion of **Parathyroid hormone-related peptide (PTHrP)**.*Primary hyperparathyroidism*- PHPT typically causes **mild to moderate** hypercalcemia, rarely reaching the severe levels seen here (3.1 mmol/L).- It is characterized by high or inappropriately normal levels of **intact parathyroid hormone (PTH)**, which would differentiate it from PTH-independent HHM.*Sarcoidosis*- Hypercalcemia in sarcoidosis results from granulomas producing **1-alpha-hydroxylase**, leading to excess **1,25-dihydroxyvitamin D** (calcitriol).- Although calcitriol excess causes hypercalcemia, a known history of metastatic malignancy is a far more likely cause of acute, severe hypercalcemia.*Vitamin D toxicity*- This requires excessive, usually iatrogenic, ingestion of Vitamin D leading to high levels of **25-hydroxyvitamin D**.- While it causes severe hypercalcemia, the prominent history of cancer makes malignancy the primary differential diagnosis.*Milk-alkali syndrome*- This condition arises from the ingestion of large amounts of **calcium** and absorbable alkali (antacids), causing hypercalcemia, **metabolic alkalosis**, and renal failure.- The patient's history does not mention excessive calcium or antacid intake, making it less likely than malignancy.

Question 13: A 28-year-old woman presents with amenorrhea and galactorrhea. Visual field testing shows bitemporal hemianopia. Prolactin is 8000 mU/L. What is the most likely diagnosis?

A. Hypothyroidism
B. Prolactinoma (Correct Answer)
C. Craniopharyngioma
D. Empty sella syndrome
E. Sheehan syndrome

Explanation: ***Prolactinoma***- The constellation of **amenorrhea** and **galactorrhea** is classical for hyperprolactinemia, directly correlated with the extremely high **prolactin level (8000 mU/L)**.- The presence of **bitemporal hemianopia** indicates a large tumor (**macroadenoma**) causing compression of the **optic chiasm**.*Hypothyroidism*- While severe **hypothyroidism** can cause modest prolactin elevation due to high **TRH** (Thyrotropin-releasing hormone), it rarely causes prolactin levels this high (typically < 3000 mU/L) or a significant mass effect.- Primary symptoms would include fatigue, weight gain, and cold intolerance, and TSH would be notably elevated.*Craniopharyngioma*- A **craniopharyngioma** is usually a suprasellar mass that causes visual field defects and features of central hypopituitarism.- It is **not** a prolactin-secreting tumor; if prolactin is elevated, it is due to pituitary stalk compression, which typically results in levels **below 2000 mU/L**.*Empty sella syndrome*- This condition results from herniation of the **arachnoid membrane** and CSF into the sella turcica, flattening the pituitary gland.- It typically causes *no* significant endocrine hyperfunction (like pronounced hyperprolactinemia) and is usually asymptomatic, rarely causing visual defects.*Sheehan syndrome*- **Sheehan syndrome** is **pituitary necrosis** following severe postpartum hemorrhage, leading to *hypopituitarism* (hormone deficiency).- While it causes amenorrhea (due to low gonadotropins), it **does not** cause galactorrhea or hyperprolactinemia, and no mass lesion is present.

Question 14: A 45-year-old woman presents with episodes of severe sweating, palpitations, and headache. Her BP during attacks is $220/130 \mathrm{mmHg}$. 24-hour urine metanephrines are elevated. What preoperative medication is required?

A. Beta-blockers alone
B. Alpha-blockers then beta-blockers (Correct Answer)
C. ACE inhibitors
D. Calcium channel blockers
E. No preoperative medication

Explanation: ***Alpha-blockers then beta-blockers*** - Preoperative management of **pheochromocytoma** requires initiating **alpha-blockade** first (e.g., phenoxybenzamine) to control severe hypertension and reverse generalized vasoconstriction caused by excess catecholamines. - Only after adequate alpha-blockade is achieved should a **beta-blocker** be added to manage reflex tachycardia or arrhythmias; giving a beta-blocker alone or first results in **unopposed alpha-adrenergic stimulation**, leading to a severe, potentially fatal hypertensive crisis. *Beta-blockers alone* - Administering a **beta-blocker** before establishing complete **alpha-blockade** is contraindicated in pheochromocytoma. - This results in unopposed stimulation of alpha-receptors by circulating catecholamines, causing heightened **vasoconstriction** and potentially fatal **hypertensive crisis** or pulmonary edema. *ACE inhibitors* - **ACE inhibitors** (e.g., lisinopril) are generally used for essential hypertension, but are ineffective as the primary preoperative control measure for the massive, catecholamine-driven hypertension of **pheochromocytoma**. - They do not block the effects of high circulating **norepinephrine** and **epinephrine** on alpha-adrenergic receptors, which is critical for stabilizing the patient before surgery. *Calcium channel blockers* - **Calcium channel blockers** (CCBs) can be used as an adjunct or second-line therapy for BP control if alpha-blockers are insufficient or poorly tolerated, but they are not the primary mandatory preparation. - They are less effective than dedicated **alpha-blockers** in reversing the primary pathology of widespread **vasoconstriction** caused by high catecholamine levels. *No preoperative medication* - Surgical removal of a **pheochromocytoma** without adequate preoperative **alpha-blockade** carries an extremely high risk (potentially 50% mortality). - Manipulation of the tumor during surgery will cause massive, uncontrolled release of **catecholamines**, leading to catastrophic hypertension, arrhythmias, and cardiovascular collapse.

Question 15: A 38-year-old woman presents with recurrent episodes of severe flushing triggered by alcohol and stress. CT shows multiple liver lesions and a small bowel mass. What is the most appropriate symptom control medication?

A. Antihistamines
B. Beta-blockers
C. Octreotide (Correct Answer)
D. Corticosteroids
E. Proton pump inhibitors

Explanation: ***Octreotide*** - The clinical presentation of recurrent severe flushing, especially when triggered by alcohol and stress, coupled with a small bowel mass and liver lesions, is highly suggestive of **carcinoid syndrome** from a metastatic neuroendocrine tumor. - **Octreotide**, a somatostatin analog, is the most appropriate medication for symptom control as it inhibits the release of vasoactive substances like **serotonin** from the tumor cells, thereby reducing flushing and diarrhea. *Antihistamines* - While histamine can contribute to flushing in some rare types of carcinoid (e.g., gastric), the predominant mediator of flushing in typical midgut carcinoid syndrome is **serotonin** and other kinins, against which antihistamines are largely ineffective. - Antihistamines are primarily used for allergic reactions or mast cell-related conditions, which have a different underlying pathophysiology than carcinoid flushing. *Beta-blockers* - Beta-blockers are primarily used to manage specific cardiac complications of carcinoid syndrome, such as **carcinoid heart disease**, or associated hypertension, not the acute flushing episodes themselves. - They do not directly inhibit the release of vasoactive mediators responsible for the flushing. *Corticosteroids* - Corticosteroids are powerful anti-inflammatory agents but do not address the root cause of carcinoid symptoms by inhibiting the synthesis or release of **serotonin** or other active amines from neuroendocrine tumors. - They are not indicated for the primary management of carcinoid-related flushing or hormonal symptoms. *Proton pump inhibitors* - Proton pump inhibitors (PPIs) are used to reduce gastric acid secretion, which is relevant in conditions like **Zollinger-Ellison syndrome** where there is gastrin hypersecretion. - They have no role in controlling the severe diarrhea or flushing characteristic of typical carcinoid syndrome, which are mediated by excess **serotonin** and other vasoactive peptides.

Question 16: A 49-year-old woman presents with fatigue, muscle weakness, and hypertension. Blood tests show hypokalemia and metabolic alkalosis. Plasma aldosterone is elevated with suppressed renin. What is the most likely diagnosis?

A. Primary hyperaldosteronism (Correct Answer)
B. Secondary hyperaldosteronism
C. Cushing's syndrome
D. Renal artery stenosis
E. Pheochromocytoma

Explanation: ***Primary hyperaldosteronism***- The combination of **hypertension**, unexplained **hypokalemia**, and **metabolic alkalosis** suggests mineralocorticoid excess.- The diagnostic hallmark confirming primary hyperaldosteronism (Conn's syndrome) is the finding of **elevated plasma aldosterone** alongside **suppressed plasma renin activity (PRA)**.*Secondary hyperaldosteronism*- This condition is characterized by stimulation of the **Renin-Angiotensin-Aldosterone System (RAAS)**, resulting in *both* **elevated renin** and elevated aldosterone.- The patient's presentation features **suppressed renin**, ruling out secondary causes like volume depletion or heart failure.*Cushing's syndrome*- This disorder involves excessive cortisol production, leading to features like central obesity, easy bruising, and **proximal muscle weakness** (which overlaps with the given symptoms).- Although severe cortisol excess can cause hypokalemia and hypertension due to mineralocorticoid receptor binding, the defining hormonal pattern here (high aldosterone, low renin) specifically points to primary adrenal aldosterone excess.*Renal artery stenosis*- This condition causes reduced renal perfusion, activating the RAAS and leading to **secondary hyperaldosteronism**.- If renal artery stenosis were the cause, the patient's renin levels would be appropriately **elevated**, rather than suppressed.*Pheochromocytoma*- This tumor produces excess **catecholamines** (epinephrine and norepinephrine), often causing paroxysmal hypertension, palpitations, and severe headaches.- The biochemical evidence here specifically concerns excessive aldosterone secretion with feedback suppression of renin, which is not characteristic of a primary catecholamine-producing tumor.

Question 17: A 44-year-old man presents with recurrent peptic ulcers and diarrhea. Serum gastrin is markedly elevated. CT shows a pancreatic mass. What is the most likely diagnosis?

A. Insulinoma
B. Gastrinoma (Correct Answer)
C. Glucagonoma
D. VIPoma
E. Pancreatic adenocarcinoma

Explanation: ***Gastrinoma***- The classic triad of findings—recurrent peptic ulcers, diarrhea, and markedly elevated serum gastrin—along with a pancreatic mass, is highly characteristic of **Zollinger-Ellison syndrome (ZES)**, which is caused by a **gastrinoma**. - Gastrinomas are gastrin-secreting tumors, often found in the pancreas or duodenum, leading to severe gastric acid hypersecretion, subsequent ulceration, and malabsorption-induced diarrhea.*Insulinoma*- This tumor secretes **insulin**, leading to episodes of severe **hypoglycemia** (Whipple's triad: symptoms of hypoglycemia, low plasma glucose, and symptom relief after glucose administration).- It does not cause recurrent peptic ulcers, diarrhea, or hypergastrinemia.*Glucagonoma*- This tumor secretes **glucagon** and is classically associated with **necrolytic migratory erythema** (a characteristic skin rash), **diabetes mellitus**, and often **weight loss**.- It causes hyperglycemia, not hypergastrinemia or peptic ulcers.*VIPoma*- This tumor secretes **vasoactive intestinal peptide (VIP)**, causing the characteristic syndrome of **WDHA** (**W**atery **D**iarrhea, **H**ypokalemia, **A**chlorhydria/Hypochlorhydria).- It causes profuse secretory diarrhea but is not associated with elevated gastrin or recurrent peptic ulcers.*Pancreatic adenocarcinoma*- This is the most common form of pancreatic cancer, typically presenting with **jaundice** (due to biliary obstruction), **weight loss**, and **abdominal pain**.- While it can present as a pancreatic mass, it is an exocrine tumor and does not secrete hormones like gastrin, thus lacking the associated hypergastrinemia and ulcer disease.

Question 18: A 25-year-old woman presents with palpitations, weight loss, and heat intolerance. She has bilateral exophthalmos. TSH is suppressed, free T4 elevated. What is the most specific indication?

A. Thyroid ultrasound
B. Radioiodine uptake scan
C. TSH receptor antibodies (Correct Answer)
D. Anti-TH antibodies
E. Thyroglobulin

Explanation: ***TSH receptor antibodies*** - These antibodies (**TRAb** or **TSIs**) directly stimulate the TSH receptor, causing excessive hormone production, and are highly specific (often >95%) for **Graves' disease**. - The combination of **hyperthyroidism** (suppressed TSH, elevated T4) and **exophthalmos** (Graves' ophthalmopathy) provides a definitive clinical diagnosis, which is confirmed most specifically by detecting these pathogenic antibodies. *Thyroid ultrasound* - While ultrasound can show features consistent with Graves' disease (e.g., diffuse glandular enlargement and increased vascularity, the **"thyroid inferno" sign**), it is a measure of structure and is not specific for the underlying autoimmune cause. - It is primarily used to assess for the presence of **nodules** or to guide fine-needle aspiration, which is less relevant when the clinical picture strongly suggests Graves' disease. *Radioiodine uptake scan* - This test is diagnostic of the etiology of hyperthyroidism, showing **diffuse high uptake** in Graves' disease, differentiating it from thyroiditis or exogenous hormone intake. - However, while highly sensitive and commonly used, measuring the uptake pattern is less specific than directly measuring the TSH receptor antibodies that *cause* the disease. *Anti-TH antibodies* - **Anti-TPO** (Thyroid Peroxidase) and **Anti-Tg** (Thyroglobulin) antibodies indicate generally that an autoimmune thyroid process is present (e.g., Hashimoto's, Graves' disease), but they are not the primary pathogenic antibody in Graves' disease. - High levels of these autoantibodies are found in up to 80% of Graves' patients, but they are not the *most specific* diagnostic determinant compared to TRAb. *Thyroglobulin* - **Thyroglobulin (Tg)** is a large glycoprotein produced by normal and abnormal thyroid tissue and is used primarily as a **tumor marker** following total thyroidectomy for thyroid cancer. - Although serum Tg levels are generally elevated in all causes of endogenous hyperthyroidism, this is not specific for the autoimmune mechanism of Graves' disease.

Question 19: A 36-year-old woman presents with recurrent episodes of severe abdominal pain and confusion. Her urine turns dark during attacks. What is the most likely diagnosis?

A. Acute intermittent porphyria (Correct Answer)
B. Inflammatory bowel disease
C. Familial Mediterranean fever
D. Hereditary angioedema
E. Systemic lupus erythematosus

Explanation: ***Acute intermittent porphyria***- Recurrent episodes of severe **abdominal pain** (often lacking physical findings) combined with acute *neuropsychiatric symptoms* like confusion is characteristic of this condition.- The urine turning **dark** (often described as port-wine colored) during the attack is caused by high levels of porphobilinogen and porphyrins, confirming the diagnosis.*Inflammatory bowel disease*- Primary symptoms are **chronic diarrhea**, **rectal bleeding**, and **weight loss**, indicating chronic inflammation of the GI tract.- While abdominal pain is common, IBD attacks do not cause significant **acute confusion** or the pathognomonic **dark urine** indicative of porphyria.*Familial Mediterranean fever*- Characterized by recurrent, self-limiting episodes of **fever** and **serositis** (**peritonitis**, pleuritis, arthritis), typically lasting 1–3 days.- Though it is a cause of recurrent severe abdominal pain, FMF is not associated with the primary neurological derangements (confusion) or the **dark urine** witnessed in this case.*Hereditary angioedema*- Acute abdominal pain is caused by transient **edema of the bowel wall**, often accompanied by subcutaneous or mucosal swelling of other areas, occasionally involving the larynx.- HAE is a complement deficiency (low C1 inhibitor) and does not produce **confusion** as a primary symptom or cause the chemical changes that result in **dark urine**.*Systemic lupus erythematosus*- Associated with diverse systemic features like **arthritis**, **malar rash**, and **glomerulonephritis**, often diagnosed via autoantibodies (ANA, Anti-dsDNA).- Although neuropsychiatric SLE can cause confusion, it does not typically present with the combination of severe, unexplained abdominal pain and **dark, porphyrin-rich urine**.

Question 20: A 35-year-old woman presents with recurrent hypoglycemic episodes, particularly when fasting. C-peptide and insulin levels are elevated during hypoglycemia. What is the most likely diagnosis?

A. Factitious hypoglycemia
B. Insulinoma (Correct Answer)
C. Adrenal insufficiency
D. Liver disease
E. Alcohol-induced hypoglycemia

Explanation: ***Insulinoma*** - The classic biochemical signature of an **insulinoma** is hypoglycemia with concurrently **elevated insulin and C-peptide levels**, indicating excessive *endogenous* insulin production. - This neuroendocrine tumor autonomously hypersecretes insulin, leading to recurrent **fasting hypoglycemia**. *Factitious hypoglycemia* - If hypoglycemia is due to **exogenous insulin** injection, insulin levels would be high, but C-peptide levels would be **suppressed** due to negative feedback. - If caused by **sulfonylurea use**, C-peptide would be elevated, but a **drug screen** would confirm the presence of the secretagogue. *Adrenal insufficiency* - **Adrenal insufficiency** (cortisol deficiency) causes hypoglycemia by impairing essential glucose counter-regulatory mechanisms like **gluconeogenesis**. - In this condition, hypoglycemia is associated with **low or normal insulin and C-peptide levels**, as hyperinsulinemia is not the cause. *Liver disease* - Severe **liver disease** can cause fasting hypoglycemia due to the liver's inability to perform adequate **gluconeogenesis** and glycogenolysis. - Insulin and C-peptide levels would typically be low or **within the normal fasting range**, not elevated, as the body attempts to suppress insulin. *Alcohol-induced hypoglycemia* - **Alcohol-induced hypoglycemia** occurs because alcohol metabolism inhibits key enzymes required for **gluconeogenesis**. - This type of hypoglycemia involves impaired glucose production, and consequently, both **insulin and C-peptide levels are suppressed**.

Question 21: A 47-year-old woman presents with recurrent episodes of flushing, diarrhea, and wheezing. CT shows liver metastases and a small bowel mass. What is the most appropriate biochemical test?

A. Serum gastrin
B. 24-hour urine 5-HIAA (Correct Answer)
C. Serum chromogranin A
D. Serum VIP
E. Serum glucagon

Explanation: ***24-hour urine 5-HIAA*** - This test measures **5-hydroxyindoleacetic acid** (5-HIAA), the primary stable metabolite of **serotonin**, which is often massively overproduced by functioning **carcinoid tumors**. - The classic triad of **flushing**, **diarrhea**, and **wheezing** indicates **carcinoid syndrome**, which typically occurs when liver metastases prevent hepatic degradation of serotonin. *Serum gastrin* - Elevated **serum gastrin** is the diagnostic marker for **Zollinger-Ellison syndrome** (gastrinoma), which presents primarily with severe peptic ulcer disease and gastroesophageal reflux disease (GERD). - While gastrinomas are neuroendocrine tumors (NETs), they do not cause the characteristic triad of **flushing** and **wheezing** seen in this patient. *Serum chromogranin A* - **Chromogranin A (CgA)** is a general, non-specific marker for neuroendocrine tumors (NETs) and is often used for tumor screening and monitoring treatment response. - Although CgA is often elevated in carcinoid syndrome, the **24-hour urine 5-HIAA test** is the more specific and definitive biochemical test for diagnosing a *functioning* carcinoid tumor. *Serum VIP* - **Vasoactive intestinal peptide (VIP)** is the marker for **VIPoma**, which typically presents with the "WDHA" syndrome: **Watery Diarrhea**, **Hypokalemia**, and **Achlorhydria**. - The primary symptoms of **flushing** and **wheezing** are highly suggestive of serotonin/histamine release (**carcinoid syndrome**), not VIP hypersecretion. *Serum glucagon* - Elevated **serum glucagon** is diagnostic for **Glucagonoma**, a separate NET characterized by **necrolytic migratory erythema**, glucose intolerance (**diabetes mellitus**), and weight loss. - Glucagonoma symptoms do not include the syndrome of **flushing, diarrhea, and wheezing** observed in this patient.

Question 22: A 56-year-old diabetic man presents with a painless foot ulcer with exposed bone. X-ray shows osteolytic changes. What is the most likely complication?

A. Cellulitis
B. Osteomyelitis (Correct Answer)
C. Charcot arthropathy
D. Peripheral arterial disease
E. Neuropathic ulcer

Explanation: ***Osteomyelitis*** - The combination of a deep, chronic ulcer with **exposed bone** and the *painless* nature (due to **diabetic neuropathy**) strongly points to an underlying bone infection. - **Osteolytic changes** on X-ray are characteristic of bone destruction caused by the infectious process, confirming osteomyelitis. *Cellulitis* - This is a **superficial soft tissue infection** with warmth, erythema, and pain, but it does not involve bone. - It does not account for the **exposed bone** or the **osteolytic changes** seen on the X-ray. *Charcot arthropathy* - This is a non-infectious condition leading to **progressive joint destruction** and bony deformities, often in a 'rocker-bottom' foot. - While it involves bone changes, it typically lacks an open ulcer with **exposed bone** indicative of active infection. *Peripheral arterial disease* - This causes **ischemic ulcers** due to poor blood flow, often painful, and is a **risk factor** for infection, but not the infection itself. - It does not directly explain the **exposed bone** or the **osteolytic changes**, which point to established infection. *Neuropathic ulcer* - This is the **initial painless lesion** due to neuropathy and trauma, typically over pressure points. - The presence of **exposed bone** and **bony destruction** on X-ray indicates that the neuropathic ulcer has progressed to osteomyelitis, which is the specific complication here.

Question 23: A 44-year-old woman presents with fatigue, weight gain, and depression. TSH is 25 mUI, free T4 is low. Anti-TPO antibodies are strongly positive. What is the most likely diagnosis?

A. Hashimoto's thyroiditis (Correct Answer)
B. De Quervain's thyroiditis
C. Postpartum thyroiditis
D. Drug-induced hypothyroidism
E. Iodine deficiency

Explanation: ***Hashimoto's thyroiditis*** - The combination of symptoms (fatigue, weight gain, depression) and lab findings (**high TSH**, **low free T4**) confirms primary hypothyroidism. - The presence of strongly **positive Anti-TPO antibodies** is the defining serological characteristic of chronic autoimmune thyroiditis, making Hashimoto's the most likely diagnosis. *De Quervain's thyroiditis* - This subacute condition typically presents with a **painful** and tender thyroid gland, often following a viral illness, which is absent in this case. - It usually exhibits a biphasic clinical course, starting with transient **hyperthyroidism** before potentially entering a hypothyroid phase. *Postpartum thyroiditis* - This condition occurs specifically within **12 months following childbirth** and often transitions through phases of hyper- and hypothyroidism. - The patient's age (44 years old) and lack of recent delivery highly argue against this diagnosis. *Drug-induced hypothyroidism* - This diagnosis requires a history of specific medications known to interfere with thyroid function, such as **Lithium** or **Amiodarone**, which is not provided. - While certain drugs can cause hypothyroidism, the presence of high-titer **Anti-TPO antibodies** strongly suggests a primary autoimmune process rather than a pharmacological cause. *Iodine deficiency* - Iodine deficiency is historically the most common global cause of hypothyroidism but is rare in areas with **iodized salt** programs. - This etiology typically does not involve high levels of autoantibodies like Anti-TPO, which are the hallmark of autoimmune causes.

Question 24: A 37-year-old man presents with recurrent kidney stones and peptic ulcers. Serum calcium is 2.9 mmol/L, gastrin 1200 pg/mL. CT shows a pancreatic mass. What syndrome is this?

A. Zollinger-Ellison syndrome
B. Multiple endocrine neoplasia type 1 (Correct Answer)
C. Carcinoid syndrome
D. Glucagonoma syndrome
E. VIPoma syndrome

Explanation: ***Multiple endocrine neoplasia type 1***- The simultaneous presentation of **hyperparathyroidism** (indicated by hypercalcemia and recurrent kidney stones) and a **gastrinoma** (evidenced by elevated gastrin, peptic ulcers, and a pancreatic mass) is the classic hallmark of **MEN 1 syndrome**.- This syndrome involves tumors of the **parathyroid glands**, **pituitary gland**, and the **enteropancreatic tract** (the "3 Ps"), linking all the patient's symptoms under one diagnosis.*Zollinger-Ellison syndrome*- While the patient clearly has **Zollinger-Ellison syndrome (ZES)** due to high gastrin and peptic ulcers, ZES is frequently the pancreatic component of **MEN 1 syndrome**.- The co-existence of ZES with **hypercalcemia** and recurrent kidney stones (indicating primary hyperparathyroidism) makes **MEN 1** the most encompassing and accurate diagnosis for the overall clinical picture.*Carcinoid syndrome*- This syndrome is characterized by symptoms such as **flushing**, secretory diarrhea, and potentially **tricuspid regurgitation**, which are not reported in this patient's presentation.- It results from the secretion of excessive **serotonin** and other vasoactive substances, typically from neuroendocrine tumors, which does not account for the hypercalcemia or peptic ulcers.*Glucagonoma syndrome*- Glucagonoma syndrome is associated with a distinct presentation, including **necrolytic migratory erythema** (a characteristic rash), mild diabetes mellitus, and weight loss.- The underlying hormonal imbalance is elevated serum **glucagon**, not gastrin and implied high parathyroid hormone (PTH), as seen in this case.*VIPoma syndrome*- VIPoma (Verner-Morrison syndrome) classically causes massive, watery diarrhea, **hypokalemia**, and achlorhydria (the **WDHA syndrome**).- It is caused by the overproduction of **Vasoactive Intestinal Peptide (VIP)**, which does not explain the hypercalcemia, recurrent kidney stones, or peptic ulceration seen here.

Question 25: A 61-year-old woman presents with bone pain and fatigue. Blood tests show calcium 3.2 mmol/L, phosphate 0.8 mmol/L, ALP 350 U/L, PTH 180 pg/mL. What is the most likely diagnosis?

A. Primary hyperparathyroidism (Correct Answer)
B. Malignancy
C. Sarcoidosis
D. Vitamin D intoxication
E. Milk-alkali syndrome

Explanation: ***Primary hyperparathyroidism*** - The classic biochemical triad of high **PTH** (180 pg/mL), elevated serum **calcium** (3.2 mmol/L), and low/low-normal **phosphate** (0.8 mmol/L) strongly points to this diagnosis. - Symptoms like **bone pain** and fatigue are common manifestations of chronic hypercalcemia and increased bone turnover, indicated by the elevated **Alkaline Phosphatase (ALP)**. *Malignancy* - Hypercalcemia related to malignancy (e.g., humoral hypercalcemia of malignancy) is typically mediated by **Parathyroid Hormone-related Peptide (PTHrP)**. - A key differentiating feature is that PTHrP production leads to severe hypercalcemia with appropriately **suppressed PTH** levels (low or undetectable), contrary to the findings here. *Sarcoidosis* - This condition causes hypercalcemia due to extra-renal production of activated **1,25-dihydroxycholecalciferol** (Vitamin D) by activated macrophages. - The resultant high calcium levels would suppress the parathyroid glands, leading to **low PTH** levels. *Vitamin D intoxication* - Excessive Vitamin D intake causes hypercalcemia and often **hyperphosphatemia** due to increased intestinal absorption of both minerals. - The high calcium concentration directly inhibits the parathyroid glands, resulting in **suppressed PTH** levels. *Milk-alkali syndrome* - This syndrome results from the ingestion of large amounts of **calcium** (usually carbonate) and absorbable **alkali**, leading to hypercalcemia and metabolic alkalosis. - Hypercalcemia from any PTH-independent cause, including milk-alkali syndrome, leads to **suppressed PTH** levels.

Question 26: A 26-year-old woman presents with amenorrhea, galactorrhea, and visual field defects. Prolactin level is 15,000 mU/L. MRI shows a 3cm pituitary mass. What is the most appropriate initial treatment?

A. Transsphenoidal surgery
B. Cabergoline (Correct Answer)
C. Bromocriptine
D. Radiotherapy
E. Octreotide

Explanation: ***Cabergoline***- **Dopamine agonists** are the standard first-line treatment for virtually all prolactinomas, including **macroprolactinomas** causing mass effect like visual field defects.- Cabergoline is preferred over bromocriptine due to its better efficacy, less frequent dosing (twice weekly), and improved tolerability, leading to rapid tumor shrinkage and normalization of **prolactin** levels.*Transsphenoidal surgery*- Surgery is indicated primarily for prolactinomas that are resistant to **dopamine agonists** or those presenting with acute complications like pituitary **apoplexy** or rapid visual loss despite medical therapy.- It is generally less effective than dopamine agonists for prolactin reduction and carries higher risks of complications, including **hypopituitarism**.*Bromocriptine*- Bromocriptine is an effective **dopamine agonist** for prolactinomas but is typically reserved as a second choice if cabergoline is unavailable or poorly tolerated.- It requires daily or twice-daily dosing and has a higher incidence of gastrointestinal and central nervous system side effects compared to **cabergoline**.*Radiotherapy*- Radiotherapy is typically a tertiary treatment option reserved for cases of refractory or **malignant prolactinomas** that have failed both optimal medical therapy (dopamine agonists) and surgical resection.- Its effects are slow (taking months to years), and it carries significant risks, including inducing **hypopituitarism** and increasing the risk of secondary tumors.*Octreotide*- Octreotide is a **somatostatin analog** used primarily for tumors that express somatostatin receptors, such as **GH-producing adenomas** (Acromegaly) or TSH-producing tumors.- It is generally ineffective as a primary treatment for prolactinomas, which respond best to **dopamine agonists**.

Question 27: A 38-year-old woman presents with fatigue, weight loss, and hyperpigmentation. Blood tests show Na⁺ 125 mmol/L, K⁺ 5.8 mmol/L, glucose 3.2 mmol/L. Morning cortisol is low. What is the most appropriate diagnostic test?

A. Dexamethasone suppression test
B. Synacthen stimulation test (Correct Answer)
C. 24-hour urine cortisol
D. Adrenal antibodies
E. ACTH levels

Explanation: ***Synacthen stimulation test***- This test (using synthetic ACTH, **cosyntropin**) is the definitive way to confirm the diagnosis of **adrenal insufficiency** by assessing the adrenal cortex's functional reserve.- In this patient with low basal cortisol and severe electrolyte abnormalities, failure of cortisol to rise adequately post-stimulation confirms the gland's inability to produce glucocorticoids.*Dexamethasone suppression test*- This test is used to evaluate for **Cushing's syndrome** (hypercortisolism), where an abnormally high cortisol level persists despite dexamethasone administration.- It is designed to suppress the hypothalamic-pituitary-adrenal (HPA) axis, which is the opposite goal of diagnosing hypocortisolism.*24-hour urine cortisol*- This measurement is primarily used to screen for **Cushing's syndrome** by assessing total free cortisol excretion over a day.- While useful for assessing overall cortisol output, it is not the standard test for confirming the functional reserve of the adrenal gland in suspected insufficiency.*Adrenal antibodies*- Tests for autoantibodies (e.g., **21-hydroxylase antibodies**) help determine the **etiology** (autoimmune Addison's disease), which is the most common cause in developed countries.- These antibodies confirm the cause but are not the necessary initial functional test for diagnosing adrenal failure itself.*ACTH levels*- Measuring ACTH is crucial for distinguishing between **primary** (ACTH high) and **secondary/tertiary** (ACTH low) adrenal insufficiency after the diagnosis is confirmed.- While essential for etiological classification, the **Synacthen test** remains the gold standard for initially confirming the functional failure of the adrenal gland.

Question 28: A 43-year-old woman presents with a 6-month history of weight gain, purple striae, and proximal muscle weakness. Her blood glucose is elevated and she has developed hypertension. 24-hour urine cortisol is raised. What is the most appropriate initial investigation?

A. MRI pituitary
B. Dexamethasone suppression test (Correct Answer)
C. ACTH levels
D. Adrenal CT
E. Midnight salivary cortisol

Explanation: ***Dexamethasone suppression test*** - The patient's clinical presentation of **weight gain**, **purple striae**, **proximal muscle weakness**, **hypertension**, and **elevated blood glucose**, combined with a **raised 24-hour urine cortisol**, strongly indicates **Cushing's syndrome**. - The **low-dose dexamethasone suppression test** is the most appropriate initial investigation to *confirm* endogenous hypercortisolism by assessing the feedback inhibition of the HPA axis, differentiating true Cushing's from pseudo-Cushing states. *MRI pituitary* - **MRI pituitary** is a **localization study** used to identify pituitary adenomas (Cushing's disease) and is only warranted *after* the biochemical diagnosis of Cushing's syndrome is confirmed and classified as **ACTH-dependent**. - Performing an MRI before confirming hypercortisolism and establishing ACTH dependency can lead to misinterpretation or unnecessary interventions. *ACTH levels* - Measuring **ACTH levels** is the next critical step *after* confirming hypercortisolism to determine the **etiology** (ACTH-dependent vs. ACTH-independent) of Cushing's syndrome. - However, the initial priority after screening is to biochemically *confirm* hypercortisolism using a dynamic test like the dexamethasone suppression test, rather than immediately determining the source. *Adrenal CT* - An **Adrenal CT** is a **localization study** used when ACTH levels are *low*, indicating an **ACTH-independent** cause of Cushing's syndrome, such as an adrenal adenoma or carcinoma. - It is inappropriate to proceed directly to adrenal imaging without first confirming hypercortisolism and determining ACTH dependency. *Midnight salivary cortisol* - **Midnight salivary cortisol** is primarily a **screening test** for endogenous hypercortisolism, often used as an alternative or alongside 24-hour urine cortisol. - Since a **raised 24-hour urine cortisol** has already indicated possible hypercortisolism, a *confirmatory* dynamic test like the dexamethasone suppression test is more appropriate than another screening test.

Question 29: A 45-year-old woman presents with fatigue, weight gain, and depression over 6 months. She also complains of dry skin, constipation, and feeling cold. Blood tests show TSH 18 mU/L, free T4 7 pmol/L. What is the most appropriate treatment?

A. Liothyronine
B. Levothyroxine (Correct Answer)
C. Combined T3/T4 therapy
D. No treatment required
E. Thyroidectomy

Explanation: ***Levothyroxine***- This is the standard first-line treatment for **primary hypothyroidism**, confirmed by the elevated **TSH** (18 mU/L) and low **free T4** (7 pmol/L), which aligns with the patient’s classic symptoms (fatigue, weight gain, cold intolerance, dry skin, constipation).- **Levothyroxine** is synthetic **T4** with a long half-life, allowing for convenient once-daily dosing and ensuring stable, predictable serum hormone levels.*Liothyronine*- *Liothyronine* is synthetic **T3** (triiodothyronine) and is generally avoided as monotherapy due to its **short half-life**, which can lead to fluctuating serum levels and potential cardiac side effects.- It is typically reserved for specific short-term uses, such as preparing for radioiodine scanning, or in rare cases where patients do not adequately respond to T4 monotherapy.*Combined T3/T4 therapy*- This approach is not standard initial therapy for hypothyroidism and lacks strong evidence of clinical superiority over **Levothyroxine** monotherapy for most patients.- It may be considered only for a select group of patients who remain symptomatic despite achieving TSH normalization on optimal T4 monotherapy.*No treatment required*- Treatment is unequivocally mandatory as the patient is highly symptomatic and exhibits **frank biochemical hypothyroidism** (TSH > 10 mU/L and low free T4).- Untreated hypothyroidism can lead to severe complications, including **myxedema coma**, significant cardiovascular issues, and progressive cognitive decline.*Thyroidectomy*- **Thyroidectomy** is a surgical intervention primarily used for conditions such as **thyroid cancer**, large compressive goiters, or refractory hyperthyroidism.- It is never used to treat primary hypothyroidism; rather, it is a procedure that can *cause* hypothyroidism if not already present, necessitating lifelong Levothyroxine replacement.

Question 30: A 22-year-old woman presents with palpitations, tremor, and anxiety. She has lost 8kg in weight despite increased appetite. On examination, she has a smooth goiter and her eyes appear prominent. TSH is <0.01 mU/L, free T4 is elevated. What is the most likely diagnosis?

A. Toxic multinodular goiter
B. Graves' disease (Correct Answer)
C. Thyroiditis
D. Thyroid cancer
E. Factitious hyperthyroidism

Explanation: ***Graves' disease***- The constellation of severe hyperthyroid symptoms (**palpitations, tremor, anxiety, weight loss** despite increased appetite), suppressed TSH, elevated free T4, and specific autoimmune features like a **smooth, diffuse goiter** and **prominent eyes (exophthalmos)** is pathognomonic.- This condition is caused by stimulating **TSH receptor antibodies (TRAb)**, leading to uncontrolled thyroid hormone synthesis and release.*Toxic multinodular goiter*- This diagnosis typically presents in **older patients** (over 50) and involves a **heterogeneous, nodular goiter** rather than the smooth, diffuse enlargement seen here.- Although it causes hyperthyroidism, it is not associated with the presence of the specific autoimmune finding of **Graves' ophthalmopathy** (prominent eyes).*Thyroiditis*- Hyperthyroidism in thyroiditis is usually **transient** (due to leakage of preformed hormone) and often presents with a painful gland (subacute thyroiditis) or is followed by hypothyroidism.- It is not an etiologic cause of sustained hyperthyroidism and lacks the key specific finding of **prominent eyes** seen in this patient.*Thyroid cancer*- Most thyroid cancers are **euthyroid** or associated only with mild thyroid dysfunction, typically presenting as a discreet, solitary nodule rather than a smooth, diffuse gland.- It is extremely rare for thyroid carcinoma to present with such florid hyperthyroid symptoms and associated **Graves' ophthalmopathy**.*Factitious hyperthyroidism*- This results from surreptitious ingestion of exogenous thyroid hormone; labs would match (**suppressed TSH, high free T4**), but the autoimmune manifestations would be absent.- Patients with this disorder usually **do not have a goiter** or specific eye findings like **Graves' ophthalmopathy**.

Question 31: A 40-year-old woman presents with fatigue, weight gain, and cold intolerance. She has a family history of autoimmune disease. Blood tests show TSH 25 mU/L, free T4 6 pmol/L, positive anti-TPO antibodies. What is the most likely diagnosis?

A. Hashimoto's thyroiditis (Correct Answer)
B. De Quervain's thyroiditis
C. Postpartum thyroiditis
D. Drug-induced hypothyroidism
E. Iodine deficiency

Explanation: ***Hashimoto's thyroiditis*** - The combination of classic symptoms of **hypothyroidism** (fatigue, weight gain, cold intolerance), laboratory findings of **primary hypothyroidism** (high **TSH**, low **free T4**), and strongly positive **anti-TPO antibodies** is diagnostic. - This is the most common cause of primary hypothyroidism, driven by autoimmune destruction of the thyroid gland, often with a **family history of autoimmune disease**. *De Quervain's thyroiditis* - Typically presents with a **painful** and **tender thyroid gland**, often following an upper respiratory infection. - It usually involves a transient hyperthyroid phase followed by a hypothyroid phase, and **anti-TPO antibodies are typically negative** or mildly elevated. *Postpartum thyroiditis* - Occurs specifically in women **within 12 months after childbirth**, a history not indicated in this case. - While it is an autoimmune process, it often presents with a biphasic course (hyperthyroidism followed by hypothyroidism) and is generally **transient**, unlike the sustained severe hypothyroidism suggested here. *Drug-induced hypothyroidism* - This diagnosis requires a clear history of exposure to specific medications known to cause hypothyroidism, such as **lithium** or **amiodarone**. - Although it can cause low free T4 and high TSH, it is **not typically associated with positive anti-TPO antibodies**, which indicate an underlying autoimmune process. *Iodine deficiency* - Causes hypothyroidism due to insufficient **iodine** to synthesize thyroid hormones, which is rare in developed countries with iodized salt. - While it leads to high TSH and low T4, it is **not associated with positive anti-TPO antibodies**, as it is a nutritional deficiency, not an autoimmune condition.

Question 32: A 60-year-old man with diabetes presents with a painless red eye and gradually worsening vision over several days. Ophthalmoscopy shows new vessel formation on the retina and vitreous hemorrhage. What is the most likely diagnosis?

A. Diabetic retinopathy (Correct Answer)
B. Hypertensive retinopathy
C. Age-related macular degeneration
D. Retinal detachment
E. Acute angle-closure glaucoma

Explanation: ***Diabetic retinopathy*** - The presence of **new vessel formation** (**neovascularization**) and **vitreous hemorrhage** in a patient with **diabetes mellitus** is the hallmark presentation of **proliferative diabetic retinopathy (PDR)**. - PDR causes vision loss when these fragile new vessels bleed into the vitreous (**vitreous hemorrhage**) or cause scarring leading to **tractional retinal detachment**. *Hypertensive retinopathy* - This condition typically manifests with classic signs like **cotton-wool spots**, flame-shaped hemorrhages, and **arteriolar narrowing** due to severe hypertension, not widespread neovascularization. - While hypertension often coexists with diabetes, the primary pathology described (neovascularization leading to bleeding) is specific to the microvascular damage caused by **uncontrolled hyperglycemia**. *Age-related macular degeneration* - This disease primarily affects the **macula** and central vision, causing distortion (**metamorphopsia**) and blurring, usually progressing slowly over time. - While the 'wet' form involves **choroidal neovascularization**, this neovascularization is localized subretinally, generally causing subretinal hemorrhage rather than large **vitreous hemorrhage**. *Retinal detachment* - Symptoms of retinal detachment usually include sudden onset of numerous **floaters**, light flashes (**photopsia**), and a **curtain or shadow** obscuring vision. - While proliferative diabetic retinopathy is a common cause of **tractional retinal detachment**, the primary findings here (neovascularization and hemorrhage) point to the underlying **proliferative disease** rather than just the resultant mechanical detachment. *Acute angle-closure glaucoma* - This is characterized by an **acute, painful** red eye, severe visual loss, ciliary flush, and a fixed mid-dilated pupil, differentiating it from the painless, gradual onset seen here. - The mechanism involves a sudden spike in intraocular pressure due to compromised outflow, and it does not typically feature the **retinal neovascularization** and **vitreous hemorrhage** described.

Question 33: A 30-year-old woman presents with palpitations, heat intolerance, and weight loss. She has bilateral exophthalmos and pretibial myxedema. TSH is suppressed, free T4 is elevated. What is the most specific test to confirm the diagnosis?

A. Thyroid ultrasound
B. Radioiodine uptake scan
C. TSH receptor antibodies (Correct Answer)
D. Anti-TPO antibodies
E. Thyroglobulin levels

Explanation: ***TSH receptor antibodies*** - The clinical presentation, including **palpitations**, **heat intolerance**, **weight loss**, **bilateral exophthalmos**, and **pretibial myxedema**, along with suppressed TSH and elevated free T4, are pathognomonic for **Graves' disease**. - **TSH receptor antibodies** (**TRAb** or **TSI**) are highly specific for Graves' disease, as they are the autoimmune antibodies that stimulate the TSH receptor, leading to excessive thyroid hormone production. *Thyroid ultrasound* - A thyroid ultrasound provides anatomical information about the thyroid gland, such as size, presence of nodules, and blood flow (**diffuse hypervascularity** in Graves'). - However, it does not specifically confirm the autoimmune etiology of **Graves' disease** and is not the most specific diagnostic test for the underlying cause. *Radioiodine uptake scan* - A **radioiodine uptake scan** (RAIU) measures the thyroid gland's activity and helps differentiate causes of hyperthyroidism (e.g., high uptake in Graves' vs. low uptake in thyroiditis). - While useful for diagnosis, it is less specific than TRAb for confirming Graves' disease, as other conditions like **toxic multinodular goiter** can also show high uptake. *Anti-TPO antibodies* - **Anti-thyroid peroxidase** (**Anti-TPO**) antibodies are commonly found in both **Graves' disease** and **Hashimoto's thyroiditis**. - Although often present in Graves' disease, they are not specific enough to differentiate it from other autoimmune thyroid conditions. *Thyroglobulin levels* - **Thyroglobulin** is a protein produced by thyroid follicular cells, and its levels are often elevated in various forms of hyperthyroidism, including Graves' disease and thyroiditis. - This test is primarily used as a tumor marker for monitoring patients with differentiated **thyroid cancer** after thyroidectomy, not as a specific diagnostic test for Graves' disease.

Question 34: A 45-year-old woman presents with fatigue, weight gain, and depression. She also complains of dry skin and constipation. Blood tests show TSH 12 mU/L, free T4 8 pmol/L. What is the most appropriate treatment?

A. Liothyronine (T3)
B. Levothyroxine (T4) (Correct Answer)
C. Combined T3/T4 therapy
D. Iodine supplementation
E. No treatment needed

Explanation: ***Levothyroxine (T4)***- This is the standard, first-line treatment for primary **hypothyroidism** due to its long half-life, allowing for once-daily dosing and ensuring stable **thyroid hormone** levels.- It acts as a prohormone, being converted peripherally to **active T3** (triiodothyronine) to meet the body's metabolic needs, effectively replacing the deficit confirmed by the high TSH and low free T4.*Liothyronine (T3)*- Liothyronine is **T3**, which has a very short half-life, leading to fluctuating serum concentrations and potentially causing **thyrotoxic symptoms** or cardiac risks if not carefully monitored.- It is generally reserved only for acute conditions like **myxedema coma** or in rare cases where patients do not adequately convert T4 to T3.*Combined T3/T4 therapy*- While some patients are treated with combination therapy, **Levothyroxine monotherapy** remains the gold standard because it effectively normalizes TSH and alleviates symptoms in the majority of patients.- Combination therapy is typically considered only if T4 monotherapy fails to alleviate symptoms, and it requires more complex monitoring due to the risk of **T3 toxicity*.*Iodine supplementation*- Iodine supplementation is only appropriate for **iodine deficiency** etiology of hypothyroidism, which is less common in developed countries and requires specific evaluation.- For the most common cause of hypothyroidism (**Hashimoto's thyroiditis**), the gland is incapable of producing adequate hormone regardless of iodine status, requiring direct hormone replacement.*No treatment needed*- Treatment is mandatory as the patient is symptomatic (fatigue, constipation, depression) and has overt hypothyroidism (TSH >10 mU/L and Low **free T4**).- Untreated overt hypothyroidism leads to progression of symptoms and long-term risks such as **cardiovascular disease** and neurological impairment.

Question 35: A 30-year-old man presents with recurrent kidney stones. His serum calcium is elevated at 2.8 mmol/L (normal 2.2-2.6). PTH is also elevated. What is the most likely diagnosis?

A. Sarcoidosis
B. Primary hyperparathyroidism (Correct Answer)
C. Malignancy
D. Vitamin D toxicity
E. Milk-alkali syndrome

Explanation: ***Primary hyperparathyroidism***- This condition is unambiguously diagnosed by the presence of **hypercalcemia** (serum calcium 2.8 mmol/L) concurrent with an inappropriately **elevated Parathyroid Hormone (PTH)** level.- The classic clinical feature of hyperparathyroidism is **nephrolithiasis** (recurrent kidney stones), fitting the patient's presentation.*Sarcoidosis*- Hypercalcemia in sarcoidosis is mediated by large amounts of calcitriol (1,25(OH)₂D) produced by activated macrophages, increasing intestinal calcium absorption.- This high calcium level would cause severe **suppression of PTH** via negative feedback, which contradicts the elevated PTH seen in this patient.*Malignancy*- Malignancy-related hypercalcemia (often **Humoral Hypercalcemia of Malignancy**) is usually due to the secretion of **Parathyroid Hormone-related Protein (PTHrP)**.- While PTHrP mimics PTH action, the high resultant calcium would lead to a **suppressed native PTH** level.*Vitamin D toxicity*- Excessive intake of Vitamin D leads to hypercalcemia by promoting calcium absorption and bone resorption.- Diagnosis involves high levels of **25-hydroxyvitamin D** and a profoundly **suppressed PTH** level due to negative feedback.*Milk-alkali syndrome*- This is caused by excessive ingestion of calcium and absorbable alkali, leading to hypercalcemia, metabolic alkalosis, and renal failure.- Like other non-PTH disorders, the resulting hypercalcemia drives PTH levels to become **suppressed**.

Question 36: A 22-year-old woman presents with palpitations, tremor, and anxiety. She mentions her periods have become irregular. On examination, her pulse is 120 bpm and she has a smooth goiter. Free T4 is elevated, TSH is suppressed. What is the next most appropriate investigation?

A. Thyroid ultrasound
B. Radioiodine uptake scan
C. TSH receptor antibodies (Correct Answer)
D. Anti-TPO antibodies
E. Fine needle aspiration

Explanation: ***TSH receptor antibodies*** - Given the patient's age (22), symptoms of hyperthyroidism (palpitations, tremor, anxiety, irregular periods, pulse 120 bpm), suppressed TSH, elevated Free T4, and a **smooth goiter**, the leading diagnosis is **Graves' disease**. - Measuring **TSH receptor antibodies (TRAb)** is the most specific, non-invasive test to confirm Graves' disease, as these stimulating autoantibodies are the direct cause of the hyperfunction. *Thyroid ultrasound* - Ultrasound is useful for evaluating the **morphology** of the thyroid gland (e.g., size, nodularity) and assessing the gland's blood flow (increased vascularity in Graves'). - It is typically utilized after biochemical confirmation and specific antibody testing if nodularity is suspected or to monitor response to treatment, but it does not confirm the underlying **etiology**. *Radioiodine uptake scan* - This scan distinguishes between disorders of increased thyroid hormone **synthesis** (Graves' or toxic nodules, resulting in high uptake) and hormone **release** (thyroiditis, resulting in low uptake). - While accurate, it is generally reserved for cases where antibody testing is inconclusive or contraindicated, or when differentiating between **Graves' disease** and **toxic multinodular goiter**. *Anti-TPO antibodies* - **Anti-TPO antibodies** are markers of general thyroid autoimmunity and cellular destruction, strongly associated with **Hashimoto's thyroiditis** (causing hypothyroidism). - While they may be present in Graves' disease, they are neither specific for nor diagnostic of the **stimulatory** hyperthyroid state and thus are not the priority investigation. *Fine needle aspiration* - **Fine needle aspiration (FNA)** is an invasive procedure indicated almost exclusively for the evaluation of suspicious or dominant **thyroid nodules** to rule out malignancy. - Since the patient has a **smooth goiter** (diffuse enlargement) and confirmed hyperthyroidism, FNA is not indicated at this stage.

Question 37: A 25-year-old woman presents with amenorrhea for 6 months, galactorrhea, and headaches. Visual field testing shows bitemporal hemianopia. What is the most likely diagnosis?

A. Polycystic ovary syndrome
B. Prolactinoma (Correct Answer)
C. Craniopharyngioma
D. Hypothyroidism
E. Pregnancy

Explanation: ***Prolactinoma***- The triad of **amenorrhea**, **galactorrhea**, and signs of a mass lesion (headache, **bitemporal hemianopia**) is the classic presentation of a **prolactin-secreting pituitary macroadenoma** (prolactinoma).- The mass compresses the **optic chiasm**, causing the characteristic **bitemporal hemianopia**, while excessive prolactin inhibits GnRH release, leading to amenorrhea and stimulating breast milk production (galactorrhea).*Polycystic ovary syndrome*- PCOS causes **amenorrhea** (or oligomenorrhea) due to anovulation and is associated with **hyperandrogenism** (hirsutism), not usually galactorrhea.- This condition is an ovarian and metabolic disorder that does not involve structural mass effects on the pituitary or **optic chiasm** that cause visual field defects.*Craniopharyngioma*- While this suprasellar tumor commonly causes chiasmal compression leading to **bitemporal hemianopia**, it primarily causes symptoms of **hypopituitarism** (hormone deficiencies) and growth issues.- It is typically not the cause of isolated **hyperprolactinemia** and galactorrhea, unless it severely disrupts the pituitary stalk.*Hypothyroidism*- Severe primary hypothyroidism can elevate prolactin levels through increased **TRH** stimulation, potentially causing secondary amenorrhea and galactorrhea.- However, hypothyroidism is a generalized endocrine disorder and does not cause a localized **mass effect** resulting in visual field loss like bitemporal hemianopia.*Pregnancy*- Pregnancy causes amenorrhea and galactorrhea (due to high estrogen/progesterone and prolactin levels, respectively), but it should be ruled out first. - It is a physiological state and is not associated with the pathological **suprasellar mass lesion** causing **bitemporal hemianopia** described in this patient.

Question 38: A 45-year-old woman presents with fatigue, hair loss, and cold intolerance. Blood tests show TSH 15 mU/L (normal 0.4-4.0), free T4 8 pmol/L (normal 10-22). Anti-TPO antibodies are positive. What is the most likely diagnosis?

A. Hashimoto's thyroiditis (Correct Answer)
B. De Quervain's thyroiditis
C. Pituitary adenoma
D. Iodine deficiency
E. Drug-induced hypothyroidism

Explanation: ***Hashimoto's thyroiditis***- The combination of severe **primary hypothyroidism** (high TSH, low free T4) and the presence of **Anti-TPO antibodies** is pathognomonic for Hashimoto's thyroiditis, the most common cause of hypothyroidism.- Clinical symptoms like **fatigue**, cold intolerance, and **hair loss** are classic manifestations of decreased circulating thyroid hormone levels.*De Quervain's thyroiditis*- This condition is a **subacute granulomatous thyroiditis** typically presenting with painful thyroid tenderness and often follows a viral illness.- While it can cause transient hypothyroidism, the initial phase is usually **hyperthyroidism**, and it is not characterized by persistently high autoantibody titers.*Pituitary adenoma*- A pituitary adenoma causing hypocortisolism would lead to **central hypothyroidism** (secondary hypothyroidism), characterized by a low or inappropriately normal TSH level despite low free T4.- This diagnosis is inconsistent with the presented lab results, which show high TSH (indicating a primary failure at the **thyroid gland** level).*Iodine deficiency*- Although severe **iodine deficiency** causes primary hypothyroidism and TSH elevation, it would typically present without the high titers of **Anti-TPO antibodies**.- This etiology is rare in regions with adequate salt iodination and usually leads to a large, **endemic goiter**.*Drug-induced hypothyroidism*- This diagnosis is excluded as there is no mention of relevant drug exposure (e.g., **amiodarone** or **lithium**) in the patient's history.- While drug-induced hypothyroidism can cause TSH elevation, the presence of strong **autoantibody positivity** points toward an underlying autoimmune disease.

Question 39: A 25-year-old woman presents with palpitations and anxiety. She has lost 5kg in weight despite increased appetite. On examination, her pulse is 110 bpm and irregular. What investigation would be most helpful?

A. 24-hour Holter monitor
B. Echocardiogram
C. Thyroid function tests (Correct Answer)
D. Full blood count
E. Urea and electrolytes

Explanation: ***Thyroid function tests***- These symptoms—palpitations, anxiety, significant weight loss despite increased appetite, and an irregular pulse—are highly classic presentations of **hyperthyroidism** (thyrotoxicosis).- The irregular pulse (tachycardia) is likely due to **atrial fibrillation** secondary to thyrotoxicosis, making thyroid function tests (TSH, free T3/T4) the essential step to establish the primary diagnosis.*24-hour Holter monitor*- While the irregular pulse requires further evaluation, the Holter monitor only confirms the cardiac rhythm (e.g., **atrial fibrillation**) but does not identify the underlying systemic cause of the patient's hyperdynamic state.- In this clinical scenario, treatment of the underlying **thyrotoxicosis** is mandatory and directly guided by the thyroid hormone levels.*Echocardiogram*- An echocardiogram assesses cardiac structure and function, which may show changes like **thyrotoxic cardiomyopathy** or valvular disease.- However, the systemic hypermetabolic symptoms point strongly to an endocrine disorder, which must be investigated first before detailed structural assessment.*Full blood count*- A full blood count (FBC) primarily screens for **anemia** or indications of infection/hematologic malignancy. - It is not the primary diagnostic test for hypermetabolic symptoms like weight loss, anxiety, and palpitations indicative of thyroid imbalance.*Urea and electrolytes*- This screens for renal function and electrolyte imbalances (e.g., hypokalemia), which can affect heart rhythm but do not explain the patient's defining **hypermetabolic state** and weight loss.- While important for completeness, it is not the most helpful initial test for diagnosing the cause of this clinical presentation.

Question 40: A 55-year-old man with diabetes presents with a painless ulcer on his right great toe. On examination, he has absent foot pulses and reduced sensation to monofilament testing. What is the most important initial investigation?

A. Ankle-brachial pressure index (Correct Answer)
B. HbA1c
C. X-ray of foot
D. Wound culture
E. Doppler ultrasound

Explanation: ***Ankle-brachial pressure index*** - The presence of a **painless ulcer**, **absent foot pulses**, and **reduced sensation** in a diabetic patient strongly suggests **peripheral artery disease (PAD)** and **diabetic neuropathy**. The **Ankle-brachial pressure index (ABPI)** is the most important initial investigation to assess for PAD. - ABPI measures the ratio of blood pressure in the ankle to that in the arm, providing a crucial non-invasive assessment of **vascular compromise** to determine if arterial insufficiency is contributing to the ulcer. *HbA1c* - While **HbA1c** is important for assessing long-term **glycemic control** in diabetes, it is not the most immediate or crucial investigation for managing an existing foot ulcer that presents with signs of vascular insufficiency and neuropathy. - Poor glycemic control contributes to microvascular and macrovascular complications, but addressing the immediate cause of the ulcer (vascular status) takes precedence for initial investigation. *X-ray of foot* - An **X-ray of the foot** is useful for identifying **osteomyelitis** or **Charcot neuroarthropathy**, which are common complications of diabetic foot ulcers. - However, the primary concern with absent pulses and a painless ulcer is vascular supply, and an X-ray would not directly assess the arterial blood flow. *Wound culture* - A **wound culture** is essential for identifying bacterial infection and guiding antibiotic therapy, especially in a diabetic foot ulcer. - Yet, assessing the underlying vascular status with ABPI is more critical as the initial step because adequate blood supply is fundamental for wound healing, regardless of infection. *Doppler ultrasound* - A **Doppler ultrasound** is an excellent follow-up investigation to visualize blood flow, assess arterial stenosis, and map the vascular anatomy if the ABPI is abnormal. - However, the **ABPI** is generally considered the most important **initial screening tool** for PAD due to its simplicity and ability to quantitatively assess overall limb perfusion before proceeding to more detailed imaging.

Question 41: A 22-year-old woman presents with a 2-week history of palpitations, weight loss, heat intolerance, and tremor. On examination, she has a smooth goiter and eye signs including lid lag. TSH is <0.01 mU/L, free T4 is elevated. What is the most likely diagnosis?

A. Toxic multinodular goiter
B. Graves' disease (Correct Answer)
C. Thyroiditis
D. Toxic adenoma
E. Factitious hyperthyroidism

Explanation: ***Graves' disease***- The combination of classic hyperthyroid symptoms (palpitations, weight loss, heat intolerance, tremor), a **smooth goiter**, and characteristic **eye signs (lid lag)** strongly indicates Graves' disease. - The lab results of **suppressed TSH** and **elevated free T4** confirm hyperthyroidism, consistent with this autoimmune condition mediated by TSH receptor antibodies.*Toxic multinodular goiter*- This condition typically affects **older individuals** and presents with an **irregular, nodular** thyroid gland on palpation, not a smooth goiter. - It is not associated with **Graves' ophthalmopathy** or eye signs like lid lag, which are autoimmune features.*Thyroiditis*- While thyroiditis can cause hyperthyroidism, it is often associated with **neck pain** or tenderness and typically presents with a **transient phase** of hyperthyroidism. - It does not usually cause sustained **ophthalmopathy** or a smooth, diffuse goiter in the manner seen in Graves' disease.*Toxic adenoma*- This is characterized by a **single, autonomously functioning thyroid nodule**, in contrast to the diffuse goiter described. - Toxic adenoma does not involve the autoimmune process that causes **Graves' ophthalmopathy** or other characteristic eye signs.*Factitious hyperthyroidism*- In this condition, the hyperthyroidism is due to exogenous thyroid hormone intake, which would result in a **small or non-palpable thyroid gland** due to TSH suppression, not a goiter. - The presence of **eye signs** (ophthalmopathy) is also inconsistent, as this lacks the autoimmune basis of Graves' disease.

Question 42: A 65-year-old man with type 2 diabetes presents for routine review. His HbA1c is 75 mmol/mol (9.0%) despite maximum tolerated metformin. His eGFR is 45 ml/min/1.73m². What is the most appropriate next step?

A. Add gliclazide
B. Add sitagliptin
C. Add empagliflozin (Correct Answer)
D. Start insulin
E. Add pioglitazone

Explanation: ***Add empagliflozin***1. This patient has poor glycemic control (HbA1c 9.0%) and underlying moderate **Chronic Kidney Disease (CKD)** (eGFR 45 ml/min/1.73m²), making an **SGLT2 inhibitor** the preferred second-line agent after metformin failure.2. **Empagliflozin** is recommended in major guidelines (ADA/EASD/NICE) for T2DM patients with CKD because it provides established **cardiovascular** and **renal protection** independent of glycemic effects, and is safe and beneficial at this eGFR level.*Add gliclazide*1. Sulfonylureas like gliclazide significantly increase the risk of **hypoglycemia**, which is exacerbated in the setting of **CKD** due to reduced renal clearance.2. Modern diabetes management guidelines prioritize agents like **SGLT2 inhibitors** as second-line therapy when CKD is present, given their lower risk profile and specific organ protection benefits.*Add sitagliptin*1. DPP-4 inhibitors are generally safe and have a low hypoglycemia risk, but they require a **dose reduction** in patients with an eGFR below 50 ml/min/1.73m².2. Although a tenable option, **sitagliptin** does not offer the robust, guideline-mandated level of **cardiorenal protection** seen with empagliflozin in patients with established CKD.*Start insulin*1. Insulin is associated with increased risks of **hypoglycemia** and **weight gain**, and is typically considered after failure of optimal dual or triple oral therapy.2. It is usually reserved for patients with more severe decompensation (HbA1c >10%) or presence of catabolism, which is not described here, making it an overly aggressive initial second-step choice. *Add pioglitazone*1. Pioglitazone (a TZD) is associated with an increased risk of **fluid retention**, leading to cautious use or contraindication in patients at risk of or with **congestive heart failure**.2. It also causes **weight gain** and does not provide the robust **renal protective benefits** that SGLT2 inhibitors offer in patients with CKD.

Question 43: A 41-year-old woman presents with recurrent kidney stones and bone pain. Serum calcium is 2.9 mmol/L, phosphate 0.7 mmol/L, PTH 85 pg/mL (elevated). What is the most likely diagnosis?

A. Primary hyperparathyroidism (Correct Answer)
B. Secondary hyperparathyroidism
C. Tertiary hyperparathyroidism
D. Sarcoidosis
E. Malignancy

Explanation: ***Primary hyperparathyroidism***- The patient's presentation with **recurrent kidney stones** and **bone pain** are classic symptoms often associated with hypercalcemia, known as "stones" and "bones" respectively.- The laboratory findings of **hypercalcemia** (2.9 mmol/L), **hypophosphatemia** (0.7 mmol/L), and an **elevated PTH** (85 pg/mL) despite hypercalcemia are pathognomonic for primary hyperparathyroidism, indicating autonomous PTH secretion.*Secondary hyperparathyroidism*- This condition is characterized by **elevated PTH** in response to persistent **hypocalcemia**, typically due to conditions like **chronic kidney disease** or severe Vitamin D deficiency.- The patient's **hypercalcemia** (2.9 mmol/L) directly contradicts the defining feature of secondary hyperparathyroidism, which is a compensatory response to low calcium.*Tertiary hyperparathyroidism*- Tertiary hyperparathyroidism develops from **long-standing secondary hyperparathyroidism** where the parathyroid glands become autonomous, leading to **PTH-dependent hypercalcemia**.- While it features hypercalcemia and elevated PTH, the crucial differentiating factor is the absence of a preceding history of chronic hypocalcemia or **end-stage renal disease**, which is not mentioned in this patient's history.*Sarcoidosis*- Sarcoidosis can cause **hypercalcemia** due to the extrarenal production of **1,25-dihydroxyvitamin D** (calcitriol) by activated macrophages.- In sarcoidosis-induced hypercalcemia, the elevated calcium is Vitamin D-mediated, which would typically lead to **suppressed PTH levels**, not the elevated PTH seen here.*Malignancy*- Malignancy is a common cause of hypercalcemia, often through the secretion of **parathyroid hormone-related peptide (PTHrP)**, or direct **bone metastases**.- Hypercalcemia of malignancy, whether PTHrP-mediated or due to osteolytic lesions, typically results in a **suppressed or low-normal PTH level**, as the hypercalcemia is not driven by the parathyroid glands themselves.

Question 44: A 46-year-old woman presents with fatigue, muscle weakness, and hyperpigmentation of her palmar creases and buccal mucosa. Blood pressure is 95/60 mmHg. Na+ 128 mmol/L. K+ 5.2 mmol/L. What is the most likely diagnosis?

A. Addison's disease (Correct Answer)
B. Cushing's syndrome
C. Conn's syndrome
D. Hypothyroidism
E. Chronic kidney disease

Explanation: ***Addison's disease***- This diagnosis is strongly supported by the classic triad of **hyperpigmentation** (due to elevated ACTH/MSH), **hypotension**, and laboratory findings of **hyperkalemic hyponatremia**.- The deficiency of **mineralocorticoids** (aldosterone) leads to renal sodium wasting and potassium retention, while **glucocorticoid** (cortisol) deficiency causes fatigue and muscle weakness.*Cushing's syndrome*- This condition is characterized by **hypercortisolism** and typically presents with symptoms like central obesity, hyperglycemia, and notably, **hypertension** and often **hypokalemia**.- These clinical and laboratory features directly contradict the patient's presentation of hypotension and hyperkalemia.*Conn's syndrome*- Also known as primary **hyperaldosteronism**, this syndrome involves excessive aldosterone production, leading to **hypertension** and significant **hypokalemia**.- The patient's findings of hypotension and hyperkalemia are the direct opposite of what would be expected in Conn's syndrome.*Hypothyroidism*- While hypothyroidism can cause fatigue and mild hyponatremia, it typically presents with distinct symptoms like **cold intolerance**, weight gain, and **bradycardia**.- It does not cause the characteristic primary hyperpigmentation of mucous membranes or the severe hyperkalemia seen in Addison's disease.*Chronic kidney disease*- Although CKD can manifest with fatigue, electrolyte abnormalities (e.g., hyperkalemia, hyponatremia), and hypotension, it does not cause the **primary hyperpigmentation** observed in this patient.- The specific hyperpigmentation of palmar creases and buccal mucosa is indicative of elevated pituitary ACTH/MSH, which is not a feature of CKD.

Question 45: A 35-year-old man presents with recurrent peptic ulcers and diarrhea. Serum gastrin is markedly elevated. CT shows a pancreatic mass. What is the most likely diagnosis?

A. Insulinoma
B. Gastrinoma (Correct Answer)
C. Glucagonoma
D. VIPoma
E. Pancreatic adenocarcinoma

Explanation: ***Gastrinoma***- The presence of **recurrent peptic ulcers**, diarrhea, and markedly **elevated serum gastrin levels** is the classic triad defining **Zollinger-Ellison syndrome (ZES)**, which is caused by a gastrin-secreting tumor (**gastrinoma**).- The visualization of a **pancreatic mass** confirms the location of this neuroendocrine tumor, which drives excessive gastric acid secretion leading to refractory ulcer disease.*Insulinoma*- This tumor secretes **insulin** and typically presents with symptoms related to **hypoglycemia** (e.g., sweating, confusion, palpitations), particularly **fasting hypoglycemia**.- Diagnosis is based on the **Whipple triad** and elevated insulin/C-peptide levels, not gastrointestinal symptoms like refractory ulcers, or elevated gastrin.*Glucagonoma*- This tumor secretes **glucagon** and is classically associated with the diagnostic rash **necrolytic migratory erythema**, as well as **diabetes mellitus** and **weight loss**.- It does not cause acid hypersecretion or peptic ulcers; the clinical picture is dictated by glucagon excess.*VIPoma*- This tumor secretes **Vasoactive Intestinal Peptide (VIP)** and causes **Verner-Morrison syndrome** (pancreatic cholera).- The hallmark presentation is profuse, lifelong watery **diarrhea** associated with **hypokalemia** and **achlorhydria** (WDHA syndrome), lacking the high gastrin and peptic ulceration seen here.*Pancreatic adenocarcinoma*- This is an exocrine tumor that typically presents with non-specific constitutional symptoms like **weight loss** and **new-onset diabetes**, or features of bile duct obstruction like painless **jaundice**.- It does not cause a hormonal syndrome resulting in elevated gastrin and peptic ulcers, as it is not a neuroendocrine tumor.

Question 46: A 44-year-old man presents with recurrent episodes of severe sweating, palpitations, and headache lasting 15-20 minutes. His BP during an episode is 220/130 mmHg. 24-hour urine catecholamines are elevated. What is the most likely diagnosis?

A. Essential hypertension
B. Pheochromocytoma (Correct Answer)
C. Panic disorder
D. Hyperthyroidism
E. Renal artery stenosis

Explanation: ***Pheochromocytoma***- The classic triad of symptoms (headache, sweating, and palpitations), especially when episodic and associated with severe **paroxysmal hypertension** (220/130 mmHg), is highly suggestive of a **catecholamine-producing tumor**.- The definitive biochemical confirmation is the elevated **24-hour urine catecholamines** (or metanephrines), which are metabolites of epinephrine and norepinephrine produced by the tumor.*Essential hypertension*- This condition typically causes sustained, not episodic, hypertension and usually lacks the severe paroxysmal symptoms (sweating, palpitations, headache).- Essential hypertension does not cause a significant elevation in **24-hour urine catecholamines**.*Panic disorder*- While panic attacks can mimic the symptoms (palpitations, sweating), they usually lack the extreme, persistent elevation in **blood pressure** seen in this patient (220/130 mmHg).- **24-hour urine catecholamines** would be normal or only transiently elevated during an episode, not markedly high as indicated here.*Hyperthyroidism*- Hyperthyroidism can cause palpitations, sweating, and mild hypertension, but the paroxysmal and severe nature of the hypertension is less common.- Hyperthyroidism is associated with elevated **thyroid hormone levels** (T3, T4) and suppressed TSH, not primary elevation of catecholamines.*Renal artery stenosis*- This condition causes secondary hypertension, often resistant, due to activation of the **renin-angiotensin-aldosterone system**.- It typically presents with sustained or difficult-to-control hypertension and would not cause the classic triad of paroxysmal symptoms or elevated **urine catecholamines**.

Question 47: A 43-year-old woman presents with fatigue, weight gain, and depression 6 months postpartum. She also complains of dry skin and constipation. TSH is 18 mIU/L, free T4 8 pmol/L. What is the most appropriate treatment?

A. Liothyronine (T3)
B. Levothyroxine (T4) (Correct Answer)
C. Combined T3/T4 therapy
D. Iodine supplementation
E. No treatment needed

Explanation: ***Levothyroxine (T4)*** - The patient presents with classic symptoms of **primary hypothyroidism** (fatigue, weight gain, dry skin, constipation, depression postpartum) and overt laboratory findings (**TSH 18 mIU/L**, low **free T4**). **Levothyroxine (T4)** is the standard first-line treatment for primary hypothyroidism. - Levothyroxine is a synthetic T4 that provides a stable precursor, which the body can convert to active T3, restoring euthyroid state effectively and safely. *Liothyronine (T3)* - **Liothyronine (T3)** has a very short half-life, leading to rapid fluctuations in serum levels and potential for adverse effects such as **palpitations** and **anxiety**. - It is not recommended as monotherapy for the initial treatment of uncomplicated primary hypothyroidism. *Combined T3/T4 therapy* - Combination therapy is generally reserved for a select group of patients who remain symptomatic despite optimal **Levothyroxine (T4)** monotherapy and normalized **TSH** levels. - It is not the recommended starting regimen for newly diagnosed hypothyroidism. *Iodine supplementation* - **Iodine supplementation** is indicated only for hypothyroidism caused by severe **iodine deficiency**, which is not suggested by the clinical context (postpartum, likely autoimmune thyroiditis). - In autoimmune thyroiditis, excess iodine can potentially exacerbate the condition. *No treatment needed* - The patient's severe symptoms and laboratory results (**TSH 18 mIU/L**, low fT4) clearly indicate **overt primary hypothyroidism** that requires immediate treatment. - Untreated overt hypothyroidism carries significant risks, including **cardiac dysfunction**, **myxedema coma**, and severe neurological impairment.

Question 48: A 46-year-old woman presents with fatigue, weight gain, and cold intolerance. She has a family history of autoimmune disease. TSH is 25 mU/L, free T4 6 pmol/L, positive anti-TPO antibodies. What is the most likely diagnosis?

A. Hashimoto's thyroiditis (Correct Answer)
B. De Quervain's thyroiditis
C. Postpartum thyroiditis
D. Drug-induced hypothyroidism
E. Iodine deficiency

Explanation: ***Hashimoto's thyroiditis***- The combination of severe **hypothyroidism** (high TSH, low Free T4) and the presence of **positive anti-TPO antibodies** is pathognomonic for chronic autoimmune thyroiditis, or Hashimoto's thyroiditis.- This condition is the most common cause of primary hypothyroidism in iodine-sufficient areas and often has a **family history of autoimmune disease***De Quervain's thyroiditis*- This form of thyroiditis typically presents with a **painful and tender thyroid gland**, often preceded by a **viral respiratory infection**.- Thyroid function usually starts with a transient **hyperthyroid phase** before potentially progressing to hypothyroidism.*Postpartum thyroiditis*- This condition occurs specifically within **12 months following delivery**, miscarriage, or abortion, which is not applicable to a non-postpartum 46-year-old woman.- While autoantibodies like **anti-TPO** are often involved, the timing is critical for this diagnosis.*Drug-induced hypothyroidism*- This diagnosis requires a history of exposure to drugs known to inhibit thyroid hormone synthesis, such as **lithium**, **amiodarone**, or certain **tyrosine kinase inhibitors**.- Although drugs can cause hypothyroidism, the presentation here is most specifically tied to an autoimmune cause due to the high titer of **anti-TPO antibodies***Iodine deficiency*- While iodine deficiency causes widespread hypothyroidism and goiter, it rarely presents with highly positive titers of **anti-TPO antibodies**.- In developed nations, **autoimmune thyroid destruction** (Hashimoto's) is statistically much more common than severe iodine deficiency as the cause of primary hypothyroidism.

Question 49: A 42-year-old woman presents with fatigue, cold intolerance, and weight gain. She has a goiter and her TSH is 25 mU/L with low free T4. Anti-TPO antibodies are strongly positive. What is the most likely diagnosis?

A. Hashimoto's thyroiditis (Correct Answer)
B. De Quervain's thyroiditis
C. Postpartum thyroiditis
D. Iodine deficiency
E. Drug-induced hypothyroidism

Explanation: ***Hashimoto's thyroiditis***- The constellation of symptoms (fatigue, cold intolerance, weight gain), **primary hypothyroidism** (High **TSH**, Low **Free T4**), goiter, and strongly positive **Anti-TPO antibodies** is pathognomonic for **Hashimoto's thyroiditis**.- This is the most common cause of primary hypothyroidism in **iodine-sufficient** regions, resulting from chronic autoimmune destruction of the thyroid gland.*De Quervain's thyroiditis*- This condition typically presents with a **tender** or **painful** thyroid gland, often following a viral upper respiratory infection, which is not described in this patient.- **De Quervain's** often starts with a transient **hyperthyroid** phase due to follicular destruction, differentiating it from the chronic hypothyroid state presented here.*Postpartum thyroiditis*- This condition occurs exclusively within **1 year after childbirth**; given the patient's age and lack of recent obstetric history, this is less likely.- While it can be destructive and cause hypothyroidism, it is often a **transient** process, unlike the chronic, established hypothyroidism suggested by the severely elevated TSH.*Iodine deficiency*- While severe iodine deficiency causes goiter and hypothyroidism (High TSH, Low T4), it is not an autoimmune process.- A diagnosis of iodine deficiency would not be associated with the high titers of **Anti-TPO antibodies** observed in this patient.*Drug-induced hypothyroidism*- Hypothyroidism induced by drugs (e.g., **amiodarone**, **lithium**) satisfies the TSH/T4 criteria but lacks the definitive autoimmune signature of strongly positive **Anti-TPO antibodies**.- This diagnosis requires a history of exposure to causative medication, which is not provided, and the specific autoantibody profile strongly favors **Hashimoto's**.

Question 50: A 58-year-old woman presents with bone pain and fatigue. Blood tests show calcium 3.1 mmol/L, albumin 35 g/L, and creatinine 180 μmol/L. She has a history of breast cancer treated 5 years ago. What is the most likely cause of hypercalcemia?

A. Primary hyperparathyroidism
B. Malignancy (Correct Answer)
C. Sarcoidosis
D. Vitamin D toxicity
E. Milk-alkali syndrome

Explanation: ***Malignancy***- The history of **breast cancer**, which commonly metastasizes to bone, along with severe hypercalcemia (3.1 mmol/L) and **bone pain**, strongly points to malignancy-associated hypercalcemia.- **Hypercalcemia of malignancy** can occur due to **osseous metastases** or the secretion of **Parathyroid hormone-related peptide (PTHrP)**, leading to increased bone resorption and renal calcium reabsorption, and can cause **acute kidney injury** (creatinine 180 μmol/L).*Primary hyperparathyroidism*- This is typically associated with **milder, chronic hypercalcemia** and often a normal or only slightly elevated creatinine, not the severe hypercalcemia and significant renal dysfunction seen here.- While a common cause of hypercalcemia, the patient's history of **breast cancer** and the severity of symptoms make malignancy a more acute and likely cause.*Sarcoidosis*- Hypercalcemia in sarcoidosis is due to unregulated **1-alpha-hydroxylase activity** in activated macrophages, leading to increased **1,25-dihydroxyvitamin D** synthesis and calcium absorption.- This condition would typically present with other systemic features like **pulmonary disease** or lymphadenopathy, which are not described in the clinical picture.*Vitamin D toxicity*- This condition results from excessive intake of **exogenous vitamin D**, leading to increased intestinal absorption of calcium and severe hypercalcemia.- There is no mention of excessive vitamin D supplementation or overdose in the patient's history.*Milk-alkali syndrome*- This syndrome is caused by the ingestion of large amounts of **calcium and absorbable alkali**, leading to hypercalcemia, **metabolic alkalosis**, and renal insufficiency.- This etiology is not suggested by the patient's history and is less likely given the clear history of **breast cancer**.

Question 51: A 37-year-old woman presents with recurrent episodes of severe flushing and diarrhea triggered by alcohol and stress. CT shows multiple liver lesions. 24-hour urine 5-HIAA is markedly elevated. What is the most appropriate treatment for symptom control?

A. Octreotide (Correct Answer)
B. Ondansetron
C. Loperamide
D. Propranolol
E. Diphenhydramine

Explanation: ***Octreotide***- This is a synthetic **somatostatin analog** that inhibits the release of **serotonin** and other vasoactive peptides from the neuroendocrine tumor cells, providing effective control over severe flushing and diarrhea associated with carcinoid syndrome.- It is the first-line medical therapy for symptomatic management of **carcinoid syndrome**, especially given the evidence of metastatic disease (liver lesions) which is typically the cause of systemic symptoms.*Ondansetron*- As a **5-HT3 receptor antagonist**, ondansetron primarily targets nausea and vomiting, making it inadequate to combat the widespread **secretory diarrhea** and **vasomotor flushing** caused by systemic serotonin and kinin release.- It blocks receptor-mediated effects but does not inhibit the actual excessive secretion of the vasoactive substances by the tumor.*Loperamide*- Loperamide is an opioid-receptor agonist used to slow gut motility and increase fluid absorption, useful for mild or non-secretory diarrhea.- While it may reduce diarrhea frequency, it does not address the underlying pathology (excessive secretion of humoral mediators) and is not the appropriate first-line symptomatic control for severe, life-threatening **carcinoid syndrome** diarrhea.*Propranolol*- This **beta-adrenergic antagonist** is occasionally used to manage atypical carcinoid flushing that may be mediated by catecholamines or is refractory to standard therapy.- It does not control the key symptoms of secretory diarrhea or block the bulk release of **serotonin** which drives the classic manifestations of this syndrome.*Diphenhydramine*- This is a first-generation **H1 antihistamine** and would primarily target histamine-mediated effects.- While histamine plays a role in flushing in some foregut carcinoids (e.g., gastric), it is ineffective against the diarrhea and flushing primarily driven by excessive **serotonin** and kinin release in the majority of carcinoid cases.

Question 52: A 41-year-old man presents with recurrent kidney stones and peptic ulcers. Serum calcium is 2.9 mmol/L and gastrin is markedly elevated. CT shows a pancreatic mass. What is the most likely syndrome?

A. Zollinger-Ellison syndrome
B. Multiple endocrine neoplasia type 1 (Correct Answer)
C. Carcinoid syndrome
D. Glucagonoma syndrome
E. VIPoma syndrome

Explanation: ***Multiple endocrine neoplasia type 1*** - This syndrome is defined by tumors of the '3 Ps': **Parathyroid**, **Pituitary**, and **Pancreatic** (or duodenal) tumors. - The combination of **primary hyperparathyroidism** (leading to hypercalcemia and kidney stones) and a **gastrinoma** (leading to markedly elevated gastrin and peptic ulcers/Zollinger-Ellison syndrome) is pathognomonic for **MEN 1**. *Zollinger-Ellison syndrome* - While the patient certainly has features of **Zollinger-Ellison syndrome** (high gastrin, peptic ulcers, pancreatic mass), this diagnosis fails to explain the concurrent **hypercalcemia** and recurrent kidney stones. - Given the involvement of both the gastrointestinal tract and the parathyroid glands, **MEN 1** is the superior, overarching diagnosis. *Carcinoid syndrome* - This syndrome usually involves GI or bronchial tumors producing excessive **serotonin**, leading to cutaneous **flushing**, diarrhea, and carcinoid heart disease. - It does not cause primary **hypercalcemia** or a markedly elevated **gastrin** level leading to peptic ulcers. *Glucagonoma syndrome* - Characterized by overproduction of **glucagon**, presenting classically with **necrolytic migratory erythema**, diabetes mellitus, anemia, and weight loss. - This clinical picture does not include primary **hyperparathyroidism** or **Zollinger-Ellison syndrome** features. *VIPoma syndrome* - Caused by tumors secreting **Vasoactive Intestinal Peptide (VIP)**, resulting in the classic **WDHA syndrome** (Watery Diarrhea, Hypokalemia, Achlorhydria). - The main symptoms here (hypercalcemia and peptic ulcers) are inconsistent with the profound secretory diarrhea that defines a VIPoma.

Question 53: A 43-year-old woman presents with fatigue, muscle weakness, and hypertension. Blood was show hypokalemia and metabolic alkalosis. Plasma aldosterone is elevated with suppressed renin. What is the most likely diagnosis?

A. Primary hyperaldosteronism (Correct Answer)
B. Secondary hyperaldosteronism
C. Cushing's syndrome
D. Renal artery stenosis
E. Pheochromocytoma

Explanation: ***Primary hyperaldosteronism***- The combination of **hypertension**, **hypokalemia**, and **metabolic alkalosis** strongly suggests excess mineralocorticoid activity (aldosterone).- The key diagnostic findings are **elevated plasma aldosterone** coupled with **suppressed plasma renin activity** (PRA), indicating aldosterone production independent of the Renin-Angiotensin System. *Secondary hyperaldosteronism*- This condition is characterized by **elevated renin** activity, as aldosterone overproduction is a response to RAAS stimulation (e.g., renovascular disease or decreased effective circulating volume).- While it causes hypertension and hypokalemia, both renin and aldosterone levels would be **high**, contradicting the suppressed renin found in the patient. *Cushing's syndrome*- Cushing's involves excess **cortisol**, typically presenting with centripetal obesity, striae, and proximal myopathy, features not emphasized here.- While cortisol excess can cause hypertension and mild hypokalemia (via mineralocorticoid receptor activity), the primary endocrine abnormality in this patient is specific dysregulation of aldosterone and renin. *Renal artery stenosis*- This causes decreased renal perfusion, leading to activation of the **Renin-Angiotensin-Aldosterone System (RAAS)**.- It results in **secondary hyperaldosteronism**, characterized by both **elevated renin** and **elevated aldosterone**, inconsistent with the patient's suppressed renin. *Pheochromocytoma*- This tumor produces excess **catecholamines**, leading to symptoms like paroxysmal hypertension, headaches, palpitations, and excessive sweating.- It does not cause mineralocorticoid-driven findings like the profound **hypokalemia** and **metabolic alkalosis** typical of hyperaldosteronism.

Question 54: A 44-year-old man presents with recurrent episodes of severe flushing, diarrhea, and wheezing. CT shows multiple liver lesions and a small bowel mass. What is the most likely diagnosis?

A. Serum gastrin
B. 24-hour urine 5-HIAA (Correct Answer)
C. Serum chromogranin A
D. Serum insulin
E. Serum glucagon

Explanation: ***24-hour urine 5-HIAA*** - The classic symptoms of **flushing**, **diarrhea**, and **wheezing**, along with a small bowel mass and liver lesions, are highly suggestive of **carcinoid syndrome**. - **5-hydroxyindoleacetic acid (5-HIAA)** is the primary metabolite of serotonin, which is excessively produced by carcinoid tumors, especially when hepatic metastases are present. *Serum gastrin* - **Serum gastrin** is primarily measured to diagnose **Zollinger-Ellison syndrome**, characterized by severe peptic ulcer disease due to gastrinomas. - The patient's presentation with flushing and wheezing is not typical for a gastrinoma. *Serum chromogranin A* - **Serum chromogranin A** is a general marker for **neuroendocrine tumors** and is useful for diagnosis and monitoring. - However, for the specific diagnosis of **carcinoid syndrome** with its classic symptoms, **24-hour urine 5-HIAA** is more specific and sensitive as it directly reflects serotonin overproduction. *Serum insulin* - **Serum insulin** levels are measured to investigate conditions like **insulinomas**, which present with symptoms of **hypoglycemia**. - The patient's symptoms of flushing, diarrhea, and wheezing are not consistent with insulinoma. *Serum glucagon* - **Serum glucagon** is primarily assessed in suspected **glucagonomas**, which typically manifest with symptoms such as **necrolytic migratory erythema**, diabetes, and weight loss. - These clinical features differ significantly from the patient's presentation of carcinoid syndrome.

Question 55: A 63-year-old woman presents with bone pain and fatigue. Blood tests show calcium 3.2 mmol/L, phosphate 0.8 mmol/L, and PTH 180 pg/mL (markedly elevated). What is the most likely diagnosis?

A. Primary hyperparathyroidism (Correct Answer)
B. Secondary hyperparathyroidism
C. Malignancy
D. Sarcoidosis
E. Vitamin D intoxication

Explanation: ***Primary hyperparathyroidism***- This diagnosis is strongly supported by the hallmark triad of **hypercalcemia** (Ca 3.2 mmol/L), **hypophosphatemia** (P 0.8 mmol/L), and **markedly elevated Parathyroid Hormone (PTH)** (180 pg/mL).- The excessive and unregulated secretion of PTH (usually due to an adenoma) inappropriately increases intestinal calcium absorption, kidney calcium reabsorption, and bone resorption, while promoting **renal phosphate wasting**. *Secondary hyperparathyroidism*- This condition is a **compensatory response** to chronic stimulus, primarily **hypocalcemia** (most commonly seen in **Chronic Kidney Disease** or severe Vitamin D deficiency).- While PTH is elevated, the stimulus is low calcium; therefore, the patient would typically exhibit **hypocalcemia** or normocalcemia, contradicting the severe hypercalcemia seen here. *Malignancy*- Malignancy (often due to the secretion of **PTH-related peptide (PTHrP)**, known as humoral hypercalcemia of malignancy) is a common cause of hypercalcemia.- However, PTHrP mimics PTH effects but is **PTH-independent**; therefore, the serum **PTH level would be suppressed** (low or undetectable) due to negative feedback, not markedly elevated. *Sarcoidosis*- Hypercalcemia in sarcoidosis results from the **increased extrarenal production of calcitriol (1,25-OH Vitamin D)** by activated macrophages.- Because this mechanism is PTH-independent, the serum **PTH level would be suppressed** (low), which is inconsistent with the reported PTH of 180 pg/mL. *Vitamin D intoxication*- Excessive intake of Vitamin D leads to increased intestinal absorption of both calcium and phosphate, often resulting in **hyperphosphatemia** or normal phosphate levels.- This is another PTH-independent cause of hypercalcemia, meaning the serum **PTH level would be suppressed** (low), failing to explain the elevated PTH result.

Question 56: A 24-year-old woman presents with amenorrhea, galactorrhea, and bitemporal visual field defects. Prolactin level is 15,000 mU/L. What is the most appropriate initial treatment?

A. Transsphenoidal surgery
B. Radiotherapy
C. Cabergoline (Correct Answer)
D. Bromocriptine
E. Octreotide

Explanation: ***Cabergoline*** - The patient's presentation with **amenorrhea**, **galactorrhea**, and **bitemporal visual field defects**, coupled with a significantly elevated **prolactin level** (15,000 mU/L), is highly indicative of a **macroprolactinoma**. - **Dopamine agonists**, such as **cabergoline**, are the first-line treatment for prolactinomas because they are highly effective in reducing prolactin secretion and shrinking tumor size, thereby alleviating compressive symptoms like visual field defects. *Transsphenoidal surgery* - **Transsphenoidal surgery** is typically reserved for patients who are intolerant to or fail to respond adequately to **dopamine agonists**, or in cases of acute neurological deterioration (e.g., **pituitary apoplexy**) not stabilized by medical therapy. - Given the high efficacy of medical therapy for prolactinomas, surgery is not considered the **most appropriate initial treatment** even in the presence of visual field defects. *Radiotherapy* - **Radiotherapy** is a last-resort treatment option for prolactinomas, usually reserved for patients who have failed both medical therapy and surgical intervention. - It is associated with significant long-term risks, including **panhypopituitarism** and damage to surrounding critical structures, making it unsuitable as an initial treatment. *Bromocriptine* - **Bromocriptine** is also a **dopamine agonist** and an effective treatment for prolactinomas, sharing the same mechanism of action as cabergoline. - However, **cabergoline** is generally preferred due to its superior tolerability, longer half-life (allowing for less frequent dosing, typically twice weekly), and often greater efficacy in reducing prolactin levels and tumor size compared to bromocriptine. *Octreotide* - **Octreotide** is a **somatostatin analog** primarily used in the treatment of **acromegaly** (growth hormone-secreting pituitary tumors) and certain other **neuroendocrine tumors**. - It has no significant role in the initial management of a pure prolactin-secreting pituitary adenoma (prolactinoma), as prolactinomas are responsive to dopamine agonists, not somatostatin analogs.

Question 57: A 35-year-old man presents with recurrent episodes of palpitations, sweating, and tremor lasting 10 minutes. During an episode, his BP is $200/110\mathrm{mmHg}$. 24-hour urine catecholamines are elevated. What is the most likely diagnosis?

A. Panic disorder
B. Hyperthyroidism
C. Pheochromocytoma (Correct Answer)
D. Essential hypertension
E. Carcinoid syndrome

Explanation: ***Pheochromocytoma*** - The recurrent episodes of **palpitations, sweating, tremor**, and severe **episodic hypertension** ($200/110\mathrm{mmHg}$) are classic symptoms of **catecholamine surges**. - The diagnostic confirmation comes from **elevated 24-hour urine catecholamines**, indicating excessive production by an **adrenal medulla tumor**. *Panic disorder* - While sharing symptoms like palpitations and sweating, panic disorder typically does not result in such severe **systolic and diastolic hypertension**. - It is not associated with pathologically elevated urinary **catecholamines** or their metabolites. *Hyperthyroidism* - Symptoms of hyperthyroidism are usually chronic and sustained, including persistent **tachycardia**, rather than brief, recurrent episodes lasting only 10 minutes. - The primary biochemical abnormality is in **thyroid hormones**, not significantly elevated **catecholamines**. *Essential hypertension* - Essential hypertension is characterized by chronic, sustained high blood pressure, not paroxysmal, severe **hypertensive crises** with distinct adrenergic symptoms. - It does not account for the episodic symptoms or the profoundly **elevated urinary catecholamines**. *Carcinoid syndrome* - This syndrome typically presents with distinct symptoms like **flushing, diarrhea**, and **bronchospasm**, which are not seen in this patient. - Diagnosis relies on elevated urinary **5-HIAA**, a serotonin metabolite, rather than catecholamine excess.

Question 58: A 41-year-old woman presents with fatigue, muscle weakness, and hyperpigmentation of her knuckles and axillae. Blood glucose is $18.2\mathrm{mmol/L}$. BMI is $34\mathrm{kg/m^2}$. What is the most likely diagnosis?

A. Type 1 diabetes
B. Type 2 diabetes with acanthosis nigricans (Correct Answer)
C. Cushing's syndrome
D. Addison's disease
E. Hypothyroidism

Explanation: ***Type 2 diabetes with acanthosis nigricans***- The patient's **obesity (BMI 34 kg/m²)**, **marked hyperglycemia (blood glucose 18.2 mmol/L)**, fatigue, and muscle weakness are highly suggestive of **Type 2 diabetes mellitus**.- **Hyperpigmentation of the knuckles and axillae** is characteristic of **acanthosis nigricans**, a skin condition strongly associated with **insulin resistance** and Type 2 diabetes.*Type 1 diabetes*- **Type 1 diabetes** typically manifests in younger, non-obese individuals and is an **autoimmune condition** leading to absolute insulin deficiency, often with abrupt onset.- Although hyperglycemia is present, the patient's **obesity** and **acanthosis nigricans** are classic indicators of **insulin resistance**, making Type 2 diabetes more likely.*Cushing's syndrome*- **Cushing's syndrome** is characterized by **hypercortisolism**, leading to central obesity, moon facies, striae, and often hyperglycemia, but not typically **hyperpigmentation of knuckles and axillae**.- The hyperpigmentation in Cushing's, if present, is usually diffuse and due to high ACTH, but distinct from the friction-area pigmentation seen in acanthosis nigricans.*Addison's disease*- **Addison's disease (primary adrenal insufficiency)** causes diffuse **hyperpigmentation** (due to increased ACTH), fatigue, and muscle weakness, but typically leads to **hypoglycemia**, **hypotension**, and **hyponatremia**, not elevated blood glucose.- The combination of **obesity** and significant **hyperglycemia** makes Addison's disease an unlikely diagnosis.*Hypothyroidism*- **Hypothyroidism** presents with fatigue, weight gain, and muscle weakness, but is not directly associated with **hyperpigmentation of knuckles and axillae** or **severe hyperglycemia** as seen here.- While hypothyroidism can cause generalized skin changes (dryness, pallor), it doesn't manifest as acanthosis nigricans, and hyperglycemia is not a primary symptom.

Question 59: A 37-year-old woman presents with recurrent episodes of severe flushing and diarrhea triggered by alcohol and stress. CT shows multiple liver lesions. 24-hour urine 5-HIAA is markedly elevated. What is the most appropriate treatment for symptom control?

A. Octreotide (Correct Answer)
B. Ondansetron
C. Loperamide
D. Propranolol
E. Diphenhydramine

Explanation: ***Octreotide***- This is a **somatostatin analog** which inhibits the release of **serotonin** and other vasoactive peptides (like kinins) responsible for carcinoid syndrome symptoms (flushing, secretory diarrhea).- It is the **first-line therapy** for controlling symptoms in patients with metastatic **neuroendocrine tumors (NETs)**, which is strongly indicated by the elevated **5-HIAA** and liver lesions.*Ondansetron*- *Ondansetron* is a **5-HT3 receptor antagonist** primarily used as an **anti-emetic** to prevent nausea and vomiting.- It is ineffective against the severe **secretory diarrhea** and **flushing** characteristic of metastatic carcinoid syndrome mediated by excessive circulating hormones.*Loperamide*- *Loperamide* is an **opioid receptor agonist** that works by slowing gut motility to reduce the frequency of diarrhea.- It only provides general symptomatic relief for diarrhea but does not address the underlying pathology (excess **serotonin-mediated secretion**) or the associated severe flushing.*Propranolol*- *Propranolol* is a **beta-blocker** and is not the primary treatment for **serotonin-mediated flushing** seen in carcinoid syndrome.- It does not inhibit the high output of **vasoactive peptides** from the tumor, which are the main cause of the patient's symptoms.*Diphenhydramine*- *Diphenhydramine* is an **H1-antihistamine**; while histamine can occasionally contribute to atypical carcinoid syndrome, the standard severe flushing and diarrhea are driven mainly by **serotonin and kinins**.- Antihistamines are generally ineffective at decreasing the production or release of the primary hormones responsible for the patient's severe, systemic symptoms.

Question 60: A 43-year-old woman presents with fatigue, muscle weakness, and weight loss. She has hyperpigmentation of palmar creases and recent onset of postural hypotension. Na+ 125 mmol/L, K+ 5.8 mmol/L. What is the most appropriate diagnostic test?

A. Dexamethasone suppression test
B. Synacthen stimulation test (Correct Answer)
C. 24-hour urine cortisol
D. Plasma metanephrines
E. Aldosterone:renin ratio

Explanation: ***Synacthen stimulation test***- The patient's presentation (fatigue, weight loss, postural hypotension, **hyperpigmentation**, hyponatremia, and hyperkalemia) is highly suggestive of **primary adrenal insufficiency** (Addison's disease).- The Synacthen test (short **ACTH stimulation test**) is the gold standard for diagnosing adrenal insufficiency by measuring the cortisol response after administering synthetic ACTH; a low response confirms the diagnosis.*Dexamethasone suppression test*- This test is primarily used in the diagnosis of **Cushing's syndrome** (hypercortisolism) and requires administering exogenous synthetic glucocorticoid to assess HPA axis suppression.- It is inappropriate for suspected adrenal insufficiency, which is characterized by hypocortisolism.*24-hour urine cortisol*- This test is also primarily used to diagnose **Cushing's syndrome** (hypercortisolism) by measuring cortisol excretion throughout a day.- While cortisol levels would be low in adrenal insufficiency, a dynamic test (like Synacthen) is required to accurately differentiate primary from secondary etiology and confirm the diagnosis.*Plasma metanephrines*- This test is specifically used to diagnose a **pheochromocytoma**, a tumor of the adrenal medulla that secretes catecholamines like adrenaline and noradrenaline.- This condition typically presents with episodic hypertension, palpitations, and headaches, which are not features of the patient's presentation.*Aldosterone:renin ratio*- This ratio is primarily used to screen for **Primary Aldosteronism (Conn's syndrome)**, a condition characterized by high aldosterone levels leading to hypertension and refractory **hypokalemia**.- The patient exhibits hyponatremia and **hyperkalemia**, classic findings in mineralocorticoid deficiency associated with advanced Addison's disease.

Question 61: A 38-year-old man presents with recurrent kidney stones and peptic ulcers. Serum calcium is 2.9 mmol/L and gastrin is markedly elevated. CT shows a pancreatic mass. What is the most likely syndrome?

A. Zollinger-Ellison syndrome
B. Multiple endocrine neoplasia type 1 (Correct Answer)
C. Carcinoid syndrome
D. Glucagonoma syndrome
E. VIPoma syndrome

Explanation: ***Multiple endocrine neoplasia type 1*** - The constellation of **recurrent kidney stones** (indicating **hypercalcemia** from primary hyperparathyroidism), **peptic ulcers** with **markedly elevated gastrin** (suggesting **gastrinoma**), and a **pancreatic mass** is classic for **Multiple Endocrine Neoplasia type 1 (MEN1)**. - MEN1 is characterized by tumors of the **parathyroid glands**, **pituitary gland**, and **pancreatic endocrine tissues**. The elevated serum calcium confirms hyperparathyroidism, and high gastrin with peptic ulcers points to a gastrinoma, both key features of MEN1. *Zollinger-Ellison syndrome* - While **Zollinger-Ellison syndrome** (ZES) is characterized by **recurrent peptic ulcers** due to **gastrinoma** and **hypergastrinemia**, it does not typically include **hypercalcemia** and **kidney stones** as primary features unless it's part of an MEN1 syndrome. - ZES alone explains the pancreatic mass and high gastrin but fails to account for the **elevated serum calcium** and **kidney stones**, which are strong indicators of primary hyperparathyroidism. *Carcinoid syndrome* - **Carcinoid syndrome** results from the release of **serotonin** and other vasoactive substances by **neuroendocrine tumors**, commonly in the GI tract or lungs, leading to symptoms like **flushing**, **diarrhea**, and **cardiac valvular disease**. - It does not present with **hypercalcemia**, **kidney stones**, **peptic ulcers**, or **elevated gastrin** as primary manifestations. *Glucagonoma syndrome* - **Glucagonoma syndrome** is caused by a **glucagon-producing tumor** of the pancreas, characterized by **necrolytic migratory erythema**, **diabetes mellitus**, **weight loss**, and **venous thrombosis**. - This syndrome does not typically involve **hypercalcemia**, **recurrent kidney stones**, **peptic ulcers**, or **elevated gastrin**. *VIPoma syndrome* - **VIPoma syndrome** is caused by a **VIP-secreting pancreatic tumor**, leading to **watery diarrhea, hypokalemia, and achlorhydria (WDHA syndrome)**. - The patient's presentation with **hypercalcemia**, **kidney stones**, **peptic ulcers**, and **elevated gastrin** is not consistent with the clinical picture of a VIPoma.

Question 62: A 42-year-old woman presents with fatigue, cold intolerance, and weight gain. She has a goiter and her TSH is 25 mU/L with low free T4. Anti-TPO antibodies are strongly positive. What is the most likely diagnosis?

A. Hashimoto's thyroiditis (Correct Answer)
B. De Quervain's thyroiditis
C. Postpartum thyroiditis
D. Index deficiency
E. Drug-induced hypothyroidism

Explanation: ***Hashimoto's thyroiditis*** - The constellation of **hypothyroid symptoms** (fatigue, cold intolerance, weight gain), **goiter**, elevated **TSH (25 mU/L)**, low **Free T4**, and highly positive **Anti-TPO antibodies** is pathognomonic for Hashimoto's thyroiditis.- It is the most common cause of primary hypothyroidism in iodine-sufficient areas and is characterized by autoimmune destruction of the thyroid gland.*De Quervain's thyroiditis* - This condition typically presents with a preceding **upper respiratory tract infection** followed by **painful thyroid enlargement** (painful thyroiditis).- Lab features usually show **initial hyperthyroidism** (due to hormone release from damaged follicles) followed by transient hypothyroidism, and often has a **low radioiodine uptake**.*Postpartum thyroiditis* - This occurs within one year of childbirth and usually presents as a **transient hyperthyroid phase** (3-6 months postpartum) followed by a **hypothyroid phase**.- While it is autoimmune and Anti-TPO antibodies may be positive, the patient's presentation does not mention recent childbirth, making it less likely as the primary diagnosis without that context.*Index deficiency* - This is not a recognized medical term for a thyroid disorder, therefore it is an incorrect option.- Thyroid disorders result from issues related to **hormone synthesis (like iodine deficiency)**, autoimmune attacks, or pituitary dysfunction, not an "Index deficiency".*Drug-induced hypothyroidism* - Hypothyroidism can be caused by drugs like **amiodarone** (due to high iodine content or direct toxicity) or **lithium**.- While the labs (high TSH, low T4) fit, the strong presence of **Anti-TPO antibodies** strongly suggests an underlying autoimmune etiology (Hashimoto's) rather than a drug being the sole primary cause.

Question 63: A 59-year-old woman presents with bone pain and fatigue. Blood tests show calcium 3.2 mmol/L, phosphate 0.8 mmol/L, and PTH 180 pg/mL (markedly elevated). What is the most likely diagnosis?

A. Primary hyperparathyroidism (Correct Answer)
B. Secondary hyperparathyroidism
C. Malignancy
D. Sarcoidosis
E. Vitamin D intoxication

Explanation: ***Primary hyperparathyroidism***- The coexistence of **hypercalcemia** (Ca 3.2 mmol/L), low or low-normal phosphate (Phos 0.8 mmol/L), and **markedly elevated PTH** (180 pg/mL) is the classic biochemical triad defining primary hyperparathyroidism.- This condition is characterized by an inappropriate, autonomous overproduction of PTH, typically due to a **parathyroid adenoma**.*Secondary hyperparathyroidism*- This condition involves high PTH levels resulting as a compensatory response to chronic **hypocalcemia** or severe Vitamin D deficiency, often seen in **chronic kidney disease**.- While PTH is high, the overall calcium status in secondary hyperparathyroidism is typically normal or low, making the presentation of severe **hypercalcemia** unsuitable.*Malignancy*- Malignancy frequently causes hypercalcemia, often via **Humoral Hypercalcemia of Malignancy (HHOM)**, where tumor cells secrete **PTH-related peptide (PTHrP)**.- A key differentiating feature is that calcium elevation caused by malignancy or PTHrP leads to appropriate feedback, resulting in **suppressed** or low PTH levels.*Sarcoidosis*- Sarcoidosis produces hypercalcemia through the extrarenal, unregulated production of **1,25-dihydroxyvitamin D** (calcitriol) by activated macrophages in the granulomas.- The hypercalcemia induced by excessive calcitriol suppresses the parathyroid glands, leading to **low or suppressed PTH** levels.*Vitamin D intoxication*- Excessive intake of Vitamin D leads to increased intestinal absorption of calcium and phosphate, resulting in **hypercalcemia**.- Vitamin D intoxication also suppresses PTH production, resulting in **low PTH** levels and often concurrent **hyperphosphatemia**, which is not seen here.

Question 64: A 41-year-old man presents with recurrent episodes of severe flushing, diarrhea, and wheezing over 6 months. CT shows multiple liver lesions and a small bowel mass. What is the most appropriate biochemical test?

A. Serum gastrin
B. 24-hour urine 5-HIAA (Correct Answer)
C. Serum chromogranin A
D. Serum insulin
E. Serum glucagon

Explanation: ***24-hour urine 5-HIAA***- This test measures the urinary excretion of **5-hydroxyindoleacetic acid**, the primary metabolite of **serotonin**.- The triad of recurrent **flushing**, **diarrhea**, and **wheezing**, combined with **small bowel** and **liver metastases**, is highly characteristic of **carcinoid syndrome**, caused by excessive serotonin secretion.*Serum gastrin*- This hormone is the primary test for **Zollinger-Ellison syndrome** (ZES), which typically presents with severe, refractory **peptic ulcer disease** and diarrhea.- While ZES is a type of neuroendocrine tumor (NET), the defining features in this patient (**flushing** and **wheezing**) are distinct from typical ZES presentation.*Serum chromogranin A*- CgA is a general marker for **neuroendocrine tumors** (NETs) but is less specific than 5-HIAA for confirming active **carcinoid syndrome**.- It can be elevated in other conditions (e.g., renal failure, chronic atrophic gastritis) and is usually monitored for tumor burden rather than initial syndrome diagnosis.*Serum insulin*- This hormone is evaluated when an **insulinoma** is suspected, which presents primarily with symptoms of **hypoglycemia** (e.g., confusion, tremors, syncope).- The patient’s symptoms are related to hormonal excess (**serotonin**/kinins), not low blood glucose.*Serum glucagon*- This is the biochemical marker for a **glucagonoma**, a rare pancreatic NET.- Glucagonoma typically presents with **diabetes mellitus**, weight loss, and characteristic **necrolytic migratory erythema**, none of which describe this patient.

Question 65: A 61-year-old woman presents with bone pain and fatigue. Blood tests show calcium 3.1 mmol/L, albumin 35 g/L, and creatinine 180 μmol/L. She has a history of breast cancer treated 5 years ago. What is the most likely cause of hypercalcemia?

A. Primary hyperparathyroidism
B. Malignancy (Correct Answer)
C. Sarcoidosis
D. Vitamin D toxicity
E. Milk-alkali syndrome

Explanation: ***Malignancy*** - The patient's history of **breast cancer** (treated 5 years ago), combined with severe **hypercalcemia** (3.1 mmol/L) and symptoms of **bone pain** and **fatigue**, strongly suggests hypercalcemia of malignancy, often due to **bone metastases** or secretion of **parathyroid hormone-related peptide (PTHrP)**. - The elevated **creatinine** (180 μmol/L) further supports malignancy-associated hypercalcemia, as severe hypercalcemia can cause **acute kidney injury** through **nephrogenic diabetes insipidus** and **vasoconstriction**. *Primary hyperparathyroidism* - While it causes hypercalcemia, it typically presents with **milder hypercalcemia** (often <3.0 mmol/L) and **elevated or inappropriately normal PTH levels**, which are not provided here. - Given the patient's significant history of **breast cancer** and the high calcium level, malignancy is a more common and severe cause of hypercalcemia in this context. *Sarcoidosis* - Hypercalcemia in sarcoidosis results from **granuloma-mediated 1-alpha-hydroxylase activity**, leading to increased production of **1,25-dihydroxyvitamin D**. - This diagnosis is less likely without other typical clinical features of sarcoidosis (e.g., pulmonary symptoms, skin lesions, lymphadenopathy) and with a strong history of **breast cancer**. *Vitamin D toxicity* - Requires excessive intake of **vitamin D supplements**, which is not mentioned in the patient's history. - Although it causes hypercalcemia, the prominent history of **breast cancer** makes malignancy a much more probable underlying cause for the presenting symptoms and lab findings. *Milk-alkali syndrome* - This syndrome is caused by the ingestion of large amounts of **calcium** and **absorbable alkali**, often from **calcium carbonate antacids**. - It typically presents with **hypercalcemia**, **metabolic alkalosis**, and **renal insufficiency**, but there is no reported history of excessive calcium or alkali intake to suggest this diagnosis.

Question 66: A 39-year-old woman presents with recurrent episodes of severe abdominal pain, nausea, and confusion. During episodes, her urine turns dark. She has a family history of similar symptoms. What should be avoided during acute attacks?

A. Carbohydrates
B. Barbiturates (Correct Answer)
C. IV fluids
D. Analgesia
E. Antibiotics

Explanation: ***Barbiturates*** - **Barbiturates** are highly potent inducers of the hepatic **cytochrome P450 system**, which subsequently upregulates **\delta-aminolevulinic acid synthase (ALAS1)**, the rate-limiting enzyme in heme synthesis. - This increase in ALAS1 activity leads to an accumulation of neurotoxic porphyrin precursors (**aminolevulinic acid** and **porphobilinogen**), thereby triggering or markedly worsening an acute porphyria attack. *Carbohydrates* - High-dose **intravenous glucose** (IV dextrose) is a primary treatment modality for acute porphyria attacks as glucose suppresses ALAS1 activity and reduces porphyrin precursor production. - Adequate carbohydrate intake is essential, and avoiding them would be contraindicated as it can worsen the catabolic state, potentially precipitating an attack. *IV fluids* - Patients frequently experience **volume depletion** due to vomiting and sometimes **SIADH (syndrome of inappropriate ADH secretion)**, leading to hyponatremia. - **IV fluids** are necessary to maintain hydration and electrolyte balance, particularly managing potentially life-threatening **hyponatremia**. *Analgesia* - Severe **abdominal pain** is a major symptom of acute porphyria, and effective pain relief is crucial for management and patient comfort. - Safe analgesics, such as **opioids** (e.g., morphine), should be used; avoidance of all analgesia would result in unnecessary suffering. *Antibiotics* - While certain antibiotics (e.g., **sulfonamides**, griseofulvin) are strictly porphyrinogenic and must be avoided, many others (e.g., penicillins, cephalosporins) are safe. - Avoiding all antibiotics is unnecessary; appropriate, non-porphyrinogenic antibiotics are used if an **intercurrent infection** triggers the acute attack.

Question 67: A 46-year-old woman presents with fatigue, muscle weakness, and hypertension. Blood tests show hypokalemia, metabolic alkalosis, and elevated aldosterone with suppressed renin. What is the most appropriate initial investigation?

A. CT adrenals (Correct Answer)
B. Aldosterone suppression test
C. Renal artery imaging
D. 24-hour urine aldosterone
E. Adrenal vein sampling

Explanation: ***CT adrenals***- After biochemical confirmation of Primary Aldosteronism (hypertension, hypokalemia, elevated aldosterone, and **suppressed renin**), **CT imaging of the adrenals** is the most appropriate initial step for localization.- This investigation aims to differentiate between a unilateral **Aldosterone-Producing Adenoma (APA)**, which is surgically curable, and bilateral adrenal hyperplasia (BAH), which requires medical management.*Aldosterone suppression test*- This test is part of the **biochemical confirmation** of Primary Aldosteronism, used to confirm non-suppressible aldosterone secretion (e.g., with a saline infusion test).- The patient's presentation already provides strong biochemical evidence (elevated aldosterone with suppressed renin), making the next logical step **localization imaging** rather than further confirmatory tests.*Renal artery imaging*- This investigation is used to diagnose **renovascular hypertension**, a cause of Secondary Aldosteronism.- Secondary Aldosteronism is characterized by **elevated renin** due to decreased renal perfusion, which directly contradicts the patient's finding of **suppressed renin**.*24-hour urine aldosterone*- While a **24-hour urine aldosterone** collection can quantify aldosterone excretion, the initial screening and diagnosis of Primary Aldosteronism typically relies on the **plasma Aldosterone/Renin Ratio (ARR)**.- After biochemical diagnosis, the immediate priority shifts to **localization studies** like adrenal CT to determine the etiology (adenoma vs. hyperplasia), rather than further quantifying aldosterone excretion.*Adrenal vein sampling*- **Adrenal vein sampling (AVS)** is the gold standard for determining the *laterality* of aldosterone excess (unilateral vs. bilateral) and is essential for guiding surgical decisions.- However, AVS is an **invasive procedure** and is typically performed *after* initial non-invasive imaging (like CT adrenals) and often reserved for cases where CT is inconclusive or in older patients, making it not the initial investigation.

Question 68: A 29-year-old woman presents with amenorrhea, galactorrhea, and visual field defects. MRI shows a 2.5 cm pituitary mass compressing the optic chiasm. Prolactin is 12000 mU/L. What is the most appropriate initial treatment?

A. Transsphenoidal surgery
B. Cabergoline (Correct Answer)
C. Bromocriptine
D. Radiotherapy
E. Observation

Explanation: ***Cabergoline***- This is a **dopamine agonist** and the preferred first-line treatment for most prolactinomas, including macroadenomas causing **visual impairment**.- It is highly effective in normalizing prolactin levels (12000 mU/L) and causing significant tumor shrinkage, thus relieving the **optic chiasm compression**.*Transsphenoidal surgery*- Surgery is generally reserved for prolactinomas that are resistant or intolerant to **dopamine agonist therapy**.- While the tumor is large (2.5 cm) and symptomatic, **Cabergoline** is superior for tumor shrinkage and often makes surgery unnecessary or easier if needed later.*Bromocriptine*- This is also a **dopamine agonist** effective for prolactinomas but is less preferred than cabergoline due to a shorter half-life and significantly higher incidence of **gastrointestinal side effects**.- It is typically considered an an alternative for patients who cannot tolerate cabergoline or during pregnancy due to more established safety data.*Radiotherapy*- This is a tertiary treatment option reserved for cases where medical therapy and surgery have failed to achieve disease control, or if there is rapid tumor growth despite other interventions.- Radiotherapy carries risks, most notably the high possibility of causing **hypopituitarism** years after treatment.*Observation*- Observation is inappropriate because the patient is symptomatic, exhibiting **amenorrhea**, **galactorrhea**, and critically, **visual field defects** due to mass effect.- The mass is a **macroadenoma** (2.5 cm) and requires active treatment to prevent further neurologic damage and resolve hormonal disturbances.

Question 69: A 45-year-old woman presents with recurrent episodes of severe headache, sweating, and palpitations. Episodes last 15-20 minutes and her BP during attacks reaches 200/120 mmHg. 24-hour urine metanephrines are elevated. What is the most appropriate preoperative management?

A. Beta-blockers alone
B. Alpha-blockers followed by beta-blockers (Correct Answer)
C. ACE inhibitor
D. Calcium channel blockers
E. No preoperative medication

Explanation: ***Alpha-blockers followed by beta-blockers***- Preoperative preparation for **pheochromocytoma** always begins with **alpha-adrenergic blockade** (e.g., *phenoxybenzamine*) to control blood pressure and allow for plasma volume expansion, which is essential to prevent severe hypotension after tumor removal.- **Beta-blockers** (e.g., *propranolol*) are only added *after* adequate alpha-blockade has been established, typically to manage catecholamine-induced tachycardia or arrhythmias.*Beta-blockers alone*- Using a beta-blocker before achieving adequate alpha-blockade is **contraindicated** because unopposed stimulation of **alpha-1 receptors** leads to severe vasoconstriction and a potentially fatal hypertensive crisis.- Beta-blockade controls heart rate but fails to manage the critical systemic peripheral resistance caused by excess **norepinephrine** and **epinephrine** acting on alpha-receptors.*ACE inhibitor*- **ACE inhibitors** are typically ineffective in managing the severe catecholamine-driven hypertension seen in a pheochromocytoma crisis because they do not directly block **alpha-adrenergic receptors**.- While they are used for essential hypertension, their mechanism (blocking *angiotensin II* production) is insufficiently potent or targeted for necessary preoperative control in this setting.*Calcium channel blockers*- **Calcium channel blockers** (CCBs) can be used as adjuvant therapy to control blood pressure or coronary vasospasm, but they are not the primary initial strategy for comprehensive **adrenergic blockade**.- The standard of care demands initial use of non-selective **alpha-blockers** (like phenoxybenzamine) to ensure both pressure control and necessary volume expansion.*No preoperative medication*- The surgical manipulation of a pheochromocytoma tumor triggers massive, life-threatening release of catecholamines, requiring mandatory preoperative medication to prevent a **hypertensive crisis** and arrhythmias.- This approach would result in extreme, uncontrolled hypertension (often >300/150 mmHg) and high risk of myocardial infarction, stroke, pulmonary edema, or death during surgery.

Question 70: A 52-year-old woman presents with recurrent episodes of severe flushing and diarrhea. CT shows multiple liver lesions and a small bowel mass. 24-hour urine 5-HIAA is elevated. What is the most appropriate initial treatment?

A. Octreotide (Correct Answer)
B. Surgical resection
C. Chemotherapy
D. Radiotherapy
E. Liver transplantation

Explanation: ***Octreotide*** - The patient's presentation with **recurrent flushing**, **diarrhea**, **multiple liver lesions**, a **small bowel mass**, and **elevated 24-hour urine 5-HIAA** strongly suggests **carcinoid syndrome**. - **Somatostatin analogs** like **octreotide** are the **first-line medical treatment** for symptomatic carcinoid syndrome, effectively controlling hormone release (e.g., serotonin) and alleviating symptoms. *Surgical resection* - While **surgical debulking** of the primary tumor and liver metastases can be considered, particularly for symptom control or local complications, it is often not the initial treatment for symptomatic, metastatic carcinoid syndrome due to its invasiveness. - The immediate priority is typically symptom management with medical therapy, especially in the presence of widespread disease indicated by multiple liver lesions. *Chemotherapy* - **Chemotherapy** is generally reserved for **poorly differentiated neuroendocrine tumors** or those with rapid progression and high tumor burden. - Well-differentiated neuroendocrine tumors causing carcinoid syndrome often respond poorly to conventional chemotherapy, making it a less preferred initial approach compared to somatostatin analogs. *Radiotherapy* - **Radiotherapy** is primarily used for **localized disease control**, such as managing bone metastases or specific painful lesions, and is not a systemic treatment for carcinoid syndrome or its endocrine symptoms. - It does not effectively address the systemic release of hormones responsible for flushing and diarrhea. *Liver transplantation* - **Liver transplantation** is an aggressive and highly selective option considered only for patients with **limited liver metastatic disease** and no other extrahepatic spread, aiming for potential cure in very specific cases. - It is not an initial treatment for symptom control in a patient presenting with symptomatic metastatic carcinoid syndrome.

Question 71: A 43-year-old woman presents with fatigue, muscle weakness, and hypertension. Blood tests show hypokalemia and metabolic alkalosis. Plasma aldosterone is elevated with suppressed renin. What is the most likely diagnosis?

A. Primary hyperaldosteronism (Correct Answer)
B. Secondary hyperaldosteronism
C. Cushing's syndrome
D. Renal artery stenosis
E. Pheochromocytoma

Explanation: ***Primary hyperaldosteronism***- The combination of **hypertension**, **hypokalemia**, and **metabolic alkalosis** with **elevated plasma aldosterone** and **suppressed renin** is pathognomonic for primary hyperaldosteronism. This condition is due to autonomous aldosterone production, often from an adrenal adenoma or bilateral adrenal hyperplasia.- **Aldosterone** causes increased sodium reabsorption (leading to hypertension) and increased potassium and hydrogen ion excretion (leading to hypokalemia and metabolic alkalosis).*Secondary hyperaldosteronism*- While secondary hyperaldosteronism also presents with **elevated aldosterone**, it is characterized by **elevated plasma renin activity** due to an underlying cause stimulating the renin-angiotensin-aldosterone system (e.g., renal artery stenosis, heart failure).- The patient's **suppressed renin** clearly differentiates this from a primary cause of hyperaldosteronism.*Cushing's syndrome*- Cushing's syndrome involves excessive **cortisol**, not primarily aldosterone, and typically presents with signs like **central obesity**, **moon facies**, **striae**, and **hyperglycemia**.- While hypertension can occur, the characteristic electrolyte disturbances of **hypokalemia** and **metabolic alkalosis** with elevated aldosterone and suppressed renin are not primary features of Cushing's syndrome.*Renal artery stenosis*- Renal artery stenosis is a cause of **secondary hypertension** due to activation of the **renin-angiotensin-aldosterone system** (RAAS).- This would lead to **elevated renin** and subsequently elevated aldosterone, which contradicts the patient's finding of **suppressed renin**.*Pheochromocytoma*- Pheochromocytoma is a tumor producing **catecholamines** (epinephrine, norepinephrine), leading to symptoms like **paroxysmal hypertension**, **tachycardia**, **palpitations**, and **sweating**.- It does not typically cause **hypokalemia** and **metabolic alkalosis** due to aldosterone excess; its hypertension is mediated by catecholamines.

Question 72: A 35-year-old man presents with recurrent peptic ulcers and diarrhea. Serum gastrin is markedly elevated. CT shows a pancreatic mass. What is the most likely diagnosis?

A. Insulinoma
B. Gastrinoma (Correct Answer)
C. Glucagonoma
D. VIPoma
E. Pancreatic adenocarcinoma

Explanation: ***Gastrinoma***- This presentation is pathognomonic for **Zollinger-Ellison syndrome (ZEs)**, which results from a gastrin-producing tumor (gastrinoma) usually found in the pancreas or duodenum.- The excessive secretion of **gastrin** leads to profound gastric acid hypersecretion, resulting in severe, recurrent, and often refractory peptic ulcers and secretory diarrhea.*Insulinoma*- Insulinomas secrete excess **insulin**, which typically results in severe fasting **hypoglycemia** and neuroglycopenic symptoms (Whipple's triad), not peptic ulcers or chronic diarrhea.- Diagnostic findings are characterized by inappropriately elevated **insulin** and C-peptide levels during periods of hypoglycemia, without high gastrin.*Glucagonoma*- Glucagonomas secrete excess **glucagon** and typically present with the classic triad of **necrolytic migratory erythema** (a characteristic skin rash), diabetes mellitus, and weight loss.- The key laboratory finding is markedly elevated serum **glucagon**, and these tumors are not associated with intractable peptic ulcer disease.*VIPoma*- VIPomas secrete **Vasoactive Intestinal Peptide (VIP)**, causing the syndrome of watery diarrhea, hypokalemia, and achlorhydria (WDHA syndrome).- While it causes profuse watery diarrhea, it is characterized by **achlorhydria** and low gastrin levels, contradicting the findings of recurrent ulcers and high serum gastrin.*Pancreatic adenocarcinoma*- This is a malignant tumor typically presenting with signs of obstruction (painless **jaundice**), abdominal pain, and significant weight loss.- It is not an endocrine tumor and does not cause primary **hypergastrinemia** or the severe peptic ulceration seen in this patient.

Question 73: A 41-year-old woman presents with recurrent kidney stones and bone pain. Serum calcium is 2.9 mmol/L, phosphate 0.7 mmol/L, PTH 85 pg/mL (elevated). What is the most likely diagnosis?

A. Primary hyperparathyroidism (Correct Answer)
B. Secondary hyperparathyroidism
C. Tertiary hyperparathyroidism
D. Sarcoidosis
E. Malignancy

Explanation: ***Primary hyperparathyroidism***- High serum **calcium** (2.9 mmol/L) and an inappropriately high **parathyroid hormone (PTH)** (85 pg/mL) confirm this diagnosis, as PTH should be suppressed in response to hypercalcemia.- Clinical features like recurrent **kidney stones** (due to hypercalciuria) and **bone pain** are classic manifestations, supporting this diagnosis.*Secondary hyperparathyroidism*- This condition is characterized by high PTH levels occurring as a physiological response to long-standing **hypocalcemia**, typically due to **Vitamin D deficiency** or **Chronic Kidney Disease**.- The patient exhibits significant **hypercalcemia**, which inherently rules out secondary hyperparathyroidism as an initial diagnosis.*Tertiary hyperparathyroidism*- This occurs when parathyroid glands become autonomous after prolonged **secondary hyperparathyroidism**, usually in the setting of **end-stage renal disease**.- While tertiary hyperparathyroidism can present with high PTH and hypercalcemia, in a patient without a clear history of chronic kidney disease, primary hyperparathyroidism is the more likely initial cause.*Sarcoidosis*- Sarcoidosis causes hypercalcemia due to the ectopic production of **1,25-dihydroxyvitamin D** by activated macrophages.- This excess vitamin D promotes intestinal calcium absorption which leads to suppression of the normal **PTH** levels (PTH would be low or undetectable).*Malignancy*- Malignancy-induced hypercalcemia (often due to **PTH-related peptide [PTHrP]**) acts like PTH but causes suppression of the true intrinsic **PTH** level.- Hypercalcemia due to bone metastases also suppresses PTH, which is contradictory to this patient's elevated PTH level.

Question 74: A 42-year-old woman presents with fatigue, muscle weakness, and hyperpigmentation of her palmar creases and buccal mucosa. Blood pressure is 95/60 mmHg. Na+ 128 mmol/L, K+ 5.2 mmol/L. What is the most likely diagnosis?

A. Addison's disease (Correct Answer)
B. Cushing's syndrome
C. Conn's syndrome
D. Hypothyroidism
E. Chronic kidney disease

Explanation: ***Addison's disease*** - The constellation of **hyperpigmentation** (due to high **ACTH** stimulating melanocytes), profound fatigue, muscle weakness, and **hypotension** is classic for primary adrenal insufficiency. - The electrolyte imbalances—**hyponatremia** (salt wasting due to mineralocorticoid deficiency) and **hyperkalemia** (lack of aldosterone action)—further confirm this diagnosis. *Cushing's syndrome* - This condition involves **glucocorticoid excess** and typically presents with centripetal obesity, striae, and **hypertension**, not hypotension. - Electrolytes often show **hypokalemia** (due to cortisol's weak mineralocorticoid effects) and normal or elevated sodium, not hyperkalemia or severe hyponatremia. *Conn's syndrome* - This is **primary hyperaldosteronism**, characterized by excessive mineralocorticoid activity. - Features include **severe hypertension** and **hypokalemia** (due to potassium wasting), which are the opposite of this patient's electrolytes and blood pressure. *Hypothyroidism* - While causing fatigue, typical signs include **weight gain**, cold intolerance, and **bradycardia**. - It does not cause the specific pattern of profound hypotension, hyperkalemia, or **ACTH-driven hyperpigmentation**. *Chronic kidney disease* - CKD can cause fatigue, hyperkalemia, and hyponatremia, but usually presents with signs of uremia and requires elevated creatinine/BUN. - The prominent **hyperpigmentation** in the palmar creases is a specific sign of primary adrenal failure due to high ACTH, which is not a defining feature of isolated CKD.

Question 75: A 35-year-old man presents with recurrent episodes of severe sweating, palpitations, and headache lasting 15-20 minutes. His BP during an episode is 220/130 mmHg. 24-hour urine catecholamines are elevated. What is the most likely diagnosis?

A. Essential hypertension
B. Pheochromocytoma (Correct Answer)
C. Panic disorder
D. Hyperthyroidism
E. Renal artery stenosis

Explanation: ***Pheochromocytoma***- The classic triad of **paroxysmal headache**, **sweating**, and **palpitations** along with severe **hypertension** (220/130 mmHg) are hallmark clinical features.- The diagnosis is confirmed by significantly elevated **24-hour urine catecholamines**, indicating excessive secretion from this adrenal medullary tumor.*Essential hypertension*- This condition typically presents with a **sustained, stable elevation** in blood pressure, not severe, short-lived **paroxysmal hypertensive crises**.- Essential hypertension is a diagnosis of exclusion and would not be associated with a classic symptom triad or markedly elevated **catecholamine** levels.*Panic disorder*- While panic attacks can cause palpitations and sweating, they rarely induce blood pressure readings as dramatically high as **220/130 mmHg**.- Panic disorder is a psychiatric condition and would not lead to significantly increased **24-hour urinary catecholamine** levels.*Hyperthyroidism*- This condition causes **sustained symptoms** (e.g., tachycardia, weight loss, heat intolerance), not acute paroxysmal crises.- While it can cause sympathetic hyperactivity, it would not result in the marked, episodic surges of **catecholamines** diagnostic of a pheochromocytoma, and hypertension is often predominantly **systolic**.*Renal artery stenosis*- This causes sustained secondary hypertension due to activation of the **renin-angiotensin-aldosterone system** (RAAS).- It is not associated with the paroxysmal triad (sweating, palpitations, headache) and would not result in elevated urinary **catecholamines**.

Question 76: A 24-year-old woman presents with amenorrhea, galactorrhea, and bitemporal visual field defects. MRI shows a 2cm pituitary mass. Prolactin level is 8000 mU/L. What is the most appropriate initial treatment?

A. Transsphenoidal surgery
B. Radiotherapy
C. Cabergoline (Correct Answer)
D. Bromocriptine
E. Octreotide

Explanation: ***Cabergoline***- **Cabergoline** is the preferred first-line medical treatment for **prolactinomas** (both micro- and macroprolactinomas) due to its high efficacy in normalizing prolactin levels and shrinking tumor size.- It is a long-acting **dopamine agonist** that effectively treats the symptoms (amenorrhea, galactorrhea) and reverses mass effects (**bitemporal visual field defects**) by causing significant tumor shrinkage.*Transsphenoidal surgery*- Surgery is typically reserved for tumors resistant to the maximal dose of **dopamine agonists** or for patients who cannot tolerate medical therapy.- Surgical intervention is also considered for patients presenting with **acute apoplexy** or significant visual loss that is unresponsive to a short trial of high-dose dopamine agonists.*Radiotherapy*- This is a tertiary modality, generally considered only for **aggressive** or **non-resectable tumors** that fail to respond to maximal doses of dopamine agonists and surgical intervention.- It carries risks of delayed effects, including **hypopituitarism**, and is rarely used as primary treatment for prolactinomas.*Bromocriptine*- While also a **dopamine agonist** effective for prolactinomas, **Cabergoline** is superior as a true first-line treatment due to its twice-weekly dosing (better compliance) and lower incidence of **gastrointestinal side effects**.- **Bromocriptine** is usually reserved for patients who do not tolerate or who cannot access cabergoline.*Octreotide*- **Octreotide** is a **somatostatin analog** used primarily in the treatment of **acromegaly** (growth hormone-secreting tumors) and **TSH-secreting tumors**.- It does not effectively reduce prolactin levels, making it ineffective for the primary management of a **prolactinoma**.

Question 77: A 43-year-old woman presents with a 6-month history of weight gain, purple striae, and proximal muscle weakness. Her blood glucose is elevated and she has developed hypertension. 24-hour urine cortisol is raised. What is the most appropriate initial investigation?

A. MRI pituitary
B. Dexamethasone suppression test (Correct Answer)
C. ACTH levels
D. Adrenal CT
E. Midnight salivary cortisol

Explanation: ***Dexamethasone suppression test***- The constellation of symptoms (**weight gain**, **purple striae**, **proximal muscle weakness**, **hypertension**, **elevated glucose**), along with a raised 24-hour urine cortisol (UFC), strongly suggests **hypercortisolism** (Cushing's syndrome).- The **Low-Dose Dexamethasone Suppression Test** (LDDST) is the gold standard for biochemically confirming Cushing's syndrome, demonstrating the loss of normal cortisol feedback regulation.*MRI pituitary*- This test is a **localization study** used to identify a pituitary adenoma (Cushing's disease) and is only warranted after the biochemical diagnosis of Cushing's syndrome is confirmed and categorized as **ACTH-dependent**.- Performing an MRI before confirming the diagnosis and ACTH dependency can lead to unnecessary imaging or misinterpretation of incidental findings.*ACTH levels*- Measuring **ACTH levels** is the crucial next step *after* confirming hypercortisolism to differentiate between **ACTH-dependent** and **ACTH-independent** causes of Cushing's syndrome.- However, the initial step following screening (raised 24-hour UFC) is to confirm true pathological hypercortisolism with a dynamic test like the LDDST.*Adrenal CT*- A CT of the adrenals is a **localization study** indicated when ACTH levels are low, suggesting an **ACTH-independent** cause (e.g., primary adrenal adenoma or carcinoma).- It is inappropriate to proceed directly to imaging without biochemical confirmation and etiological classification, as this risks missing the true cause or performing unnecessary tests.*Midnight salivary cortisol*- This test is primarily used as a **screening test** for endogenous hypercortisolism, often in conjunction with 24-hour UFC and LDDST.- Since the 24-hour UFC is already raised, indicating probable hypercortisolism, a further screening test is less informative than the LDDST, which directly assesses the feedback mechanism essential for diagnosis.

Question 78: A 26-year-old woman with type 1 diabetes is planning pregnancy. She currently uses insulin degludec 28 units at night and insulin aspart with meals. Her HbA1c is 58 mmol/mol (7.5%). She takes no other regular medications. What additional medication should be commenced before conception and continued until at least 12 weeks gestation?

A. Folic acid 400 micrograms daily
B. Folic acid 5mg daily (Correct Answer)
C. Aspirin 75mg daily
D. Aspirin 150mg daily
E. Vitamin D 400 units daily

Explanation: ***Folic acid 5mg daily*** - Women with **diabetes mellitus** (Type 1 or Type 2) are at a higher risk of **neural tube defects** and require a high-dose supplementation of **5mg folic acid**. - This dose should be started **pre-conception** and continued until **12 weeks gestation** to optimize fetal spinal cord development.*Folic acid 400 micrograms daily* - This is the standard dose for the **general population** but is insufficient for high-risk groups like those with diabetes or a high BMI. - Using this lower dose in a diabetic patient increases the relative risk of **congenital malformations** compared to the high-dose regimen.*Aspirin 75mg daily* - Low-dose aspirin is used to reduce the risk of **pre-eclampsia**, but the standard recommended dose for high-risk patients has shifted toward **150mg**. - Crucially, aspirin is initiated from **12 weeks gestation** until birth, rather than during the pre-conception period.*Aspirin 150mg daily* - While **150mg aspirin** is indicated for diabetic pregnant women to prevent **pre-eclampsia**, it is not the medication started pre-conception. - The protocol specifies starting this medication in the **second trimester** (from 12 weeks), not before pregnancy.*Vitamin D 400 units daily* - General supplementation of **Vitamin D** is recommended for all pregnant and breastfeeding women to support **bone health**. - While beneficial, it is not the priority medication specifically indicated to mitigate the high risk of **neural tube defects** associated with diabetes.

Question 79: A 55-year-old woman undergoes total thyroidectomy for a 4.5cm papillary thyroid carcinoma with lymph node involvement. Histology confirms papillary carcinoma with extrathyroidal extension and 3 out of 8 lymph nodes positive. Post-operatively, she is started on levothyroxine 100 micrograms once daily. What is the target TSH level for this patient in the first year following surgery?

A. 0.5-2.0 mU/L (within reference range)
B. 2.0-5.0 mU/L (upper reference range)
C. <0.1 mU/L (suppressed below reference range) (Correct Answer)
D. 5.0-10.0 mU/L (above reference range)
E. Undetectable (<0.01 mU/L)

Explanation: ***<0.1 mU/L (suppressed below reference range)*** - This patient is classified as **high-risk** due to a large primary tumor (> 4cm), **extrathyroidal extension**, and **positive lymph nodes**. - Target **TSH suppression** to <0.1 mU/L is indicated in high-risk patients to minimize the risk of recurrence and inhibit the growth of potential residual microscopic disease. *0.5-2.0 mU/L (within reference range)* - This target is typically reserved for **low-risk** patients who have a maintained excellent response to treatment and are in **remission**. - It is inappropriate for this patient's initial post-operative phase given the aggressive histopathological features markers. *2.0-5.0 mU/L (upper reference range)* - Maintaining TSH in the upper normal range is generally avoided in thyroid cancer patients as it provides insufficient **TSH suppression**. - Higher TSH levels may theoretically stimulate the growth of remaining **follicular-cell-derived** cancer cells via TSH receptors. *5.0-10.0 mU/L (above reference range)* - These levels indicate **hypothyroidism**, which is contraindicated following surgery for differentiated thyroid carcinoma. - Elevated TSH levels increase the risk of disease progression and stimulate **thyroglobulin** production from residual tissue. *Undetectable (<0.01 mU/L)* - While profound suppression is the goal, an **undetectable TSH** is not routinely required and poses significant risks of **atrial fibrillation** and **osteoporosis**. - Guidelines generally recommend suppression to <0.1 mU/L rather than aiming for an absolutely undetectable level to balance oncological benefit and metabolic side effects.

Question 80: A 65-year-old man with type 2 diabetes for 12 years on metformin and empagliflozin presents for annual review. His eGFR has declined from 54 mL/min/1.73m² one year ago to 28 mL/min/1.73m² currently. Urine albumin:creatinine ratio is 42 mg/mmol. Blood pressure is 142/88 mmHg. He is taking ramipril 10mg once daily. HbA1c is 64 mmol/mol (8.0%). What is the most appropriate modification to his diabetes management?

A. Continue current medication and review in 3 months
B. Stop empagliflozin and continue metformin (Correct Answer)
C. Stop metformin and continue empagliflozin
D. Stop both medications and start insulin
E. Stop both medications and start gliclazide

Explanation: ***Stop empagliflozin and continue metformin*** - **Empagliflozin** (an SGLT2 inhibitor) loses significant **glucose-lowering efficacy** when the **eGFR falls below 30 mL/min/1.73m²**, necessitating its discontinuation for glycemic control, especially with an HbA1c of 8.0%. - While metformin typically requires **dose reduction** below an eGFR of 45 and is often stopped below 30, continuing it cautiously (likely with a reduced dose) while removing an ineffective agent is a reasonable initial step. *Continue current medication and review in 3 months* - The significant decline in **eGFR to 28 mL/min/1.73m²** indicates **CKD Stage 4** and warrants immediate medication review and adjustment, not just continued observation. - An **HbA1c of 8.0%** alongside worsening renal function demonstrates inadequate glycemic control, which current medications are failing to address effectively. *Stop metformin and continue empagliflozin* - Although metformin's use is often limited below **eGFR 30** due to the risk of **lactic acidosis**, continuing empagliflozin for glycemic control at an eGFR of 28 mL/min/1.73m² is not advisable due to its reduced efficacy. - This approach would leave the patient with a suboptimal and likely ineffective glucose-lowering regimen, given the high HbA1c. *Stop both medications and start insulin* - Starting **insulin** is a major escalation, and while it's safe in renal impairment, it's often considered after optimizing oral regimens or when oral agents are no longer sufficient or safe. - It is premature to stop both medications and jump directly to insulin without first adjusting existing oral therapy or considering other renal-safe oral alternatives like **DPP-4 inhibitors**. *Stop both medications and start gliclazide* - **Gliclazide**, a sulfonylurea, carries a significantly increased risk of **prolonged hypoglycemia** in patients with **severe renal impairment** like an eGFR of 28 mL/min/1.73m² because its active metabolites are renally cleared. - This medication switch would be dangerous given the patient's renal status and would heighten the risk of severe adverse events.

Question 81: A 37-year-old woman presents with anxiety, palpitations, and heat intolerance. Examination reveals a smooth, non-tender goitre and a resting tremor. Thyroid function shows TSH <0.01 mU/L, free T4 38 pmol/L, free T3 16.4 pmol/L. TSH receptor antibodies are strongly positive. She is started on carbimazole 40mg once daily. After 6 weeks, she develops a sore throat and fever. Blood tests show: Hb 118 g/L, WCC 1.8 × 10⁹/L, neutrophils 0.4 × 10⁹/L, platelets 242 × 10⁹/L. What is the most appropriate immediate management?

A. Reduce carbimazole dose to 20mg daily
B. Stop carbimazole temporarily until infection resolves
C. Continue carbimazole and prescribe antibiotics
D. Stop carbimazole and arrange urgent haematology review (Correct Answer)
E. Stop carbimazole and start propylthiouracil

Explanation: ***Stop carbimazole and arrange urgent haematology review*** - The patient has **agranulocytosis** (neutrophils < 0.5 × 10⁹/L), a rare but life-threatening complication of **carbimazole**, which mandates immediate and **permanent cessation** of the drug. - Urgent clinical management includes hospitalization for **broad-spectrum antibiotics** and a specialist review for potential treatment with **granulocyte colony-stimulating factor (G-CSF)**. *Reduce carbimazole dose to 20mg daily* - Agranulocytosis is an **idiosyncratic reaction**, not a dose-dependent one, so lowering the dose provides no protection against sepsis. - Continuing the drug at any dose in the presence of severe **neutropenia** is unsafe and delays essential recovery of the bone marrow. *Stop carbimazole temporarily until infection resolves* - Because of the high risk of **cross-reactivity** and recurrence, carbimazole must be stopped **permanently**, not just temporarily. - Re-challenging the patient with the drug later would likely trigger another episode of severe **bone marrow suppression**. *Continue carbimazole and prescribe antibiotics* - Antibiotics alone cannot resolve the underlying **drug-induced neutropenia**, and continuing the offending agent is life-threatening. - The primary cause of the **sore throat and fever** is the lack of clinical immune response due to the medication; the trigger must be removed first. *Stop carbimazole and start propylthiouracil* - **Propylthiouracil (PTU)** also carries a significant risk of **agranulocytosis** and exhibits high cross-reactivity with carbimazole. - If a patient develops agranulocytosis on one thionamide, neither should be used; alternative treatments like **radioactive iodine** or **surgery** must be considered.

Question 82: A 46-year-old woman with type 2 diabetes on metformin 1g twice daily and gliclazide 160mg twice daily has an HbA1c of 69 mmol/mol (8.5%). Her BMI is 34 kg/m². She works as a heavy goods vehicle (HGV) driver. What is the most appropriate addition to her treatment?

A. Add sitagliptin 100mg once daily (Correct Answer)
B. Add pioglitazone 30mg once daily
C. Add dapagliflozin 10mg once daily
D. Add insulin glargine at bedtime
E. Add exenatide twice daily before meals

Explanation: ***Add sitagliptin 100mg once daily*** - **Sitagliptin**, a **DPP-4 inhibitor**, has a **low risk of hypoglycemia**, which is crucial for an **HGV driver** as severe hypoglycemic episodes can be dangerous and impact their driving license. - It is **weight neutral**, making it a suitable choice for a patient with a **BMI of 34 kg/m²**, avoiding further weight gain, and can be easily added to existing dual therapy. *Add pioglitazone 30mg once daily* - **Pioglitazone** is known to cause **significant weight gain**, which would be detrimental for a patient with a **BMI of 34 kg/m²**. - It is also associated with a risk of **fluid retention** and **heart failure exacerbation**, as well as a potential increased risk of **bladder cancer**, making it a less favorable option. *Add dapagliflozin 10mg once daily* - While **SGLT2 inhibitors** like **dapagliflozin** can promote **weight loss** and have cardiovascular/renal benefits, they can increase the risk of **genital candidiasis**, **urinary tract infections**, and **volume depletion**. - Given the patient's occupation, agents that could cause **dehydration** or electrolyte imbalances, potentially affecting alertness, might be less desirable compared to a safer option for a third line agent. *Add insulin glargine at bedtime* - Initiating **insulin therapy** typically carries a higher risk of **hypoglycemia**, which would pose significant safety concerns and potential licensing issues for an **HGV driver** according to **DVLA regulations**. - Insulin also commonly causes **weight gain**, which is undesirable in a patient with a **high BMI**. *Add exenatide twice daily before meals* - **GLP-1 receptor agonists** like **exenatide** are effective for weight loss and glycemic control, but they are administered via **injection**, which can be less convenient than an oral medication. - They are also associated with **gastrointestinal side effects** like nausea and vomiting, which could impact the patient's quality of life and adherence, making a well-tolerated oral agent a better initial choice for triple therapy.

Question 83: A 73-year-old man with type 2 diabetes for 19 years presents with confusion. He has a background of hypertension and ischaemic heart disease. His wife reports he has been increasingly drowsy over 5 days with reduced oral intake. On examination: temperature 36.8°C, pulse 110/min, BP 95/60 mmHg, GCS 13/15. Blood tests show: glucose 62.4 mmol/L, sodium 158 mmol/L, potassium 4.8 mmol/L, urea 28.4 mmol/L, creatinine 198 μmol/L, osmolality 392 mOsm/kg. Venous blood gas: pH 7.38, bicarbonate 22 mmol/L. Urinalysis: glucose 4+, ketones negative. What is the most appropriate initial fluid resuscitation?

A. 0.9% sodium chloride 1000 mL over 1 hour (Correct Answer)
B. Hartmann's solution 1000 mL over 1 hour
C. 0.45% sodium chloride 1000 mL over 1 hour
D. 5% dextrose 1000 mL over 1 hour
E. 0.9% sodium chloride with 40 mmol/L potassium chloride 1000 mL over 1 hour

Explanation: ***0.9% sodium chloride 1000 mL over 1 hour*** - The patient presents with **Hyperosmolar Hyperglycaemic State (HHS)**, evidenced by severe **hyperglycaemia** (>30 mmol/L), **hyperosmolality** (>320 mOsm/kg), and lack of ketosis; the primary goal is restoration of circulating volume. - **0.9% sodium chloride** is the recommended initial fluid for resuscitation in HHS, even in the presence of hypernatraemia, as it is relatively hypotonic to the patient's serum and prevents a rapid drop in osmolality. *Hartmann's solution 1000 mL over 1 hour* - While used in some resuscitation scenarios, it is not the standard recommendation for **HHS management** guidelines, which prioritize isotonic saline to stabilize intravascular volume. - It contains **potassium and lactate**, which may complicate the fine-tuning of electrolyte balance required in the prolonged recovery phase of HHS. *0.45% sodium chloride 1000 mL over 1 hour* - **Hypotonic saline (0.45%)** is only considered if the serum osmolality is not declining despite an adequate positive fluid balance with 0.9% saline. - Administering hypotonic fluids too early or too rapidly increases the risk of **cerebral oedema** and a precipitous drop in serum sodium. *5% dextrose 1000 mL over 1 hour* - Giving **5% dextrose** initially would worsen the existing severe **hyperglycaemia** and exacerbate the hyperosmolar state. - Dextrose is only introduced in later stages of management once blood glucose levels have dropped to a specific threshold (e.g., 10-15 mmol/L). *0.9% sodium chloride with 40 mmol/L potassium chloride 1000 mL over 1 hour* - Aggressive **potassium replacement** is not indicated in the first hour of resuscitation when the serum potassium is within the normal range (4.8 mmol/L). - Initial management focuses purely on **volume expansion**; potassium is usually added in subsequent bags once the patient is producing urine and levels begin to fall due to dilution or insulin.

Question 84: A 51-year-old woman presents with fatigue and is found to have TSH 74 mU/L (0.5-5.0) and free T4 6 pmol/L (10-22). She is started on levothyroxine 50 micrograms once daily. When should thyroid function tests be rechecked to guide dose adjustment?

A. After 2 weeks
B. After 1 week
C. After 4 weeks
D. After 8-12 weeks (Correct Answer)
E. After 6 months

Explanation: ***After 8-12 weeks*** - It takes approximately **6-8 weeks** for **TSH levels** to reach a new steady state and equilibrate after starting or changing the dose of **levothyroxine**. - Testing within this window (8-12 weeks) provides the most accurate reflection of the patient's long-term thyroid status due to the long **seven-day half-life** of T4. *After 2 weeks* - This is too early for monitoring because the full therapeutic effect on the **pituitary-thyroid axis** will not have manifested yet. - The **serum T4** levels may fluctuate, but the **TSH** will not yet have decreased significantly from its baseline high of 74 mU/L. *After 1 week* - At one week, the patient may feel slight symptomatic improvement, but the **steady-state concentration** of the drug is far from being achieved. - Rechecking at this stage would likely lead to inappropriate **dose escalations** based on misleadingly high TSH results. *After 4 weeks* - Although some clinical guidelines may monitor at 6 weeks, 4 weeks is generally considered insufficient for full **TSH stabilization**. - Adjusting doses at this point risks **over-titration** as the TSH is often still in a downward trend and has not bottomed out. *After 6 months* - This interval is too long for the initial titration phase where the patient remains profoundly **hypothyroid** (TSH 74 mU/L). - Six-month or **annual monitoring** is reserved for stable patients who have already achieved a **euthyroid state** on a consistent dose.

Question 85: A 29-year-old man with type 1 diabetes for 14 years is reviewed in clinic. He uses a basal-bolus insulin regimen with insulin degludec at night and insulin aspart before meals. His HbA1c is 82 mmol/mol (9.6%). He reports frequent episodes of hypoglycaemia, occurring 4-5 times per week, usually before lunch. His pre-breakfast glucose readings average 14-16 mmol/L. What is the most likely explanation for his elevated morning glucose levels?

A. Insufficient basal insulin dose
B. Dawn phenomenon
C. Somogyi effect (Correct Answer)
D. Excessive carbohydrate intake at breakfast
E. Impaired insulin absorption

Explanation: ***Somogyi effect*** - This occurs when **nocturnal hypoglycaemia** triggers a surge in counter-regulatory hormones (glucagon, epinephrine, cortisol), leading to **rebound hyperglycaemia** in the morning. - The combination of **frequent hypoglycaemia** and high pre-breakfast glucose readings (14-16 mmol/L) is classic for this rebound mechanism. *Insufficient basal insulin dose* - Insufficient basal insulin would typically cause high glucose readings throughout the entire day and night without causing **frequent hypoglycaemia**. - It does not explain why the patient would experience hypoglycaemic episodes 4-5 times per week. *Dawn phenomenon* - This refers to a rise in early morning glucose due to the physiological release of **growth hormone** and **cortisol** that antagonize insulin, without preceding hypoglycaemia. - Unlike the Somogyi effect, it is not preceded by **nocturnal hypoglycaemia**, which is likely present here given the patient's symptomatic history. *Excessive carbohydrate intake at breakfast* - High carbohydrate intake at breakfast would primarily affect **post-prandial glucose** readings rather than pre-breakfast (fasting) values. - This does not account for the **high morning basal readings** or the frequent hypoglycaemia occurring before lunch. *Impaired insulin absorption* - **Lipohypertrophy** or impaired absorption would cause unpredictable and generally **elevated glucose levels** due to reduced insulin efficacy. - It would not characteristically lead to this specific pattern of **recurrent hypoglycaemia** followed by morning spikes.

Question 86: What is the threshold HbA1c level (in mmol/mol) for diagnosing diabetes mellitus in an asymptomatic patient according to WHO and Diabetes UK criteria?

A. 58 mmol/mol (7.5%)
B. 64 mmol/mol (8.0%)
C. 42 mmol/mol (6.0%)
D. 48 mmol/mol (6.5%) (Correct Answer)
E. 53 mmol/mol (7.0%)

Explanation: ***48 mmol/mol (6.5%)***- According to **WHO** and **Diabetes UK** criteria, an HbA1c of **48 mmol/mol (6.5%)** or above is the standard threshold for diagnosing diabetes mellitus.- For **asymptomatic patients**, this result must be **confirmed with a repeat test** on a separate occasion to establish the diagnosis.*58 mmol/mol (7.5%)*- This level is significantly higher than the diagnostic threshold and is often used as a **target level** for intensifying therapy in patients already diagnosed.- It is not used as a threshold for initial diagnosis in clinical guidelines.*64 mmol/mol (8.0%)*- This value represents poorly controlled diabetes or a **higher glycemic target** for elderly patients or those with multiple comorbidities.- Using this as a diagnostic cutoff would result in a massive failure to diagnose **early-stage diabetes**.*42 mmol/mol (6.0%)*- An HbA1c between **42-47 mmol/mol (6.0-6.4%)** is classified as the **prediabetes** range or high risk for developing diabetes.- Levels below 42 mmol/mol are generally considered within the **normal/healthy range** for the general population.*53 mmol/mol (7.0%)*- This is a common **therapeutic target** for many adults with established type 2 diabetes managed with medication.- While it exceeds the diagnostic threshold, the actual **cutoff point** for diagnosis remains lower at 48 mmol/mol.

Question 87: A 33-year-old woman is diagnosed with Graves' disease. Thyroid function shows TSH <0.01 mU/L, free T4 42 pmol/L, free T3 18.2 pmol/L. She is planning to conceive within the next 6 months. What is the most appropriate initial management?

A. Carbimazole titration regimen
B. Carbimazole block-and-replace regimen
C. Propylthiouracil (Correct Answer)
D. Radioactive iodine therapy
E. Total thyroidectomy

Explanation: ***Propylthiouracil*** - **Propylthiouracil (PTU)** is the preferred antithyroid drug for women planning pregnancy or in the **first trimester** because it has a lower risk of causing major congenital malformations compared to carbimazole. - The switch to PTU is critical for patients planning to conceive within **6 months** to avoid the risk of **carbimazole embryopathy**, which includes defects like aplasia cutis and esophageal atresia. *Carbimazole titration regimen* - **Carbimazole** is usually the first-line treatment for Graves' disease, but it is associated with a risk of **congenital abnormalities** during early fetal development. - It is generally avoided in patients actively planning a pregnancy to minimize the risk of **teratogenicity** during the organogenesis phase. *Carbimazole block-and-replace regimen* - This regimen involves high-dose antithyroid drugs combined with **levothyroxine**, which is contraindicated during pregnancy as it requires higher doses of medications that can cross the placenta. - Using **carbimazole** in this regimen still poses a significant risk of **embryopathy** for a patient planning to conceive soon. *Radioactive iodine therapy* - **Radioactive iodine (RAI)** is absolutely contraindicated in pregnancy and carries a strict recommendation to avoid conception for at least **6 months** following treatment. - While it provides a permanent cure for **hyperthyroidism**, it would significantly delay the patient's goal of conceiving within the specified 6-month window. *Total thyroidectomy* - **Total thyroidectomy** is an invasive surgical option usually reserved for patients with large goiters, compressive symptoms, or those who fail medical therapy. - While it allows for rapid stabilization of thyroid levels before pregnancy, it is not the **initial management** of choice for a newly diagnosed patient when medical options are available.

Question 88: A 68-year-old woman with type 2 diabetes for 16 years attends for diabetic foot screening. She has longstanding hypertension and stage 3 chronic kidney disease. On examination, both feet are warm with palpable pulses. Monofilament testing shows absent sensation bilaterally on the plantar surface. Ankle reflexes are absent. Vibration sense is reduced to the knees bilaterally. What is her foot risk classification according to NICE guidelines?

A. Acute diabetic foot emergency - immediate admission
B. Low risk - annual review indicated
C. Moderate risk - review every 3-6 months
D. High risk - review every 1-3 months (Correct Answer)
E. Active diabetic foot problem - specialist referral

Explanation: ***High risk - review every 1-3 months*** - According to **NICE guidelines (NG19)**, a patient is classified as high risk if they have **loss of protective sensation** (absent monofilament test) plus another risk factor such as **chronic kidney disease** (stage 4 or 5) or deformity. - While her pulses are palpable, her combination of **sensory neuropathy** and **CKD** (medical risk factor) warrants frequent monitoring every **1-3 months** to prevent ulceration. *Acute diabetic foot emergency - immediate admission* - This category is reserved for patients with life-threatening complications like **gas gangrene**, **necrotising fasciitis**, or systemic sepsis. - This patient is clinically stable with **warm feet** and no evidence of acute infection or critical ischemia. *Low risk - annual review indicated* - Low risk classification requires the **absence of any risk factors**, such as normal sensation and intact peripheral pulses. - This patient has significant **neuropathy** and **CKD**, making an annual review insufficient for her safety. *Moderate risk - review every 3-6 months* - Moderate risk is assigned when there is only **one risk factor** present, such as isolated loss of sensation or isolated peripheral arterial disease. - Because this patient has **multiple risk factors** (neuropathy and long-standing CKD/diabetes duration), she exceeds the criteria for moderate risk. *Active diabetic foot problem - specialist referral* - This classification applies to patients with an **active ulcer**, infection, suspected **Charcot arthropathy**, or gangrene. - Although she is at high risk for these issues, her skin is currently intact with no **active ulceration** mentioned in the examination.

Question 89: A 19-year-old woman with type 1 diabetes for 5 years presents to the emergency department with vomiting and abdominal pain. Blood tests show: glucose 28.4 mmol/L, pH 7.18, bicarbonate 11 mmol/L, ketones 5.2 mmol/L, sodium 131 mmol/L, potassium 5.8 mmol/L, urea 8.2 mmol/L, creatinine 98 μmol/L. She is started on fixed-rate insulin infusion and intravenous fluids. After 4 hours, repeat blood shows: glucose 18.2 mmol/L, pH 7.24, bicarbonate 13 mmol/L, potassium 3.6 mmol/L. What is the most appropriate next step?

A. Continue current management and recheck in 2 hours
B. Add 10% glucose infusion and continue fixed-rate insulin (Correct Answer)
C. Reduce the fixed-rate insulin infusion rate by half
D. Stop fixed-rate insulin and start subcutaneous insulin
E. Increase the fixed-rate insulin infusion rate

Explanation: ***Add 10% glucose infusion and continue fixed-rate insulin*** - According to **DKA management guidelines**, 10% glucose should be added once blood glucose falls below **14 mmol/L** to prevent hypoglycemia while maintaining the insulin infusion needed to suppress **ketogenesis**. - Although the glucose is currently 18.2 mmol/L, the rapid drop and the ongoing need for **fixed-rate intravenous insulin infusion (FRIII)** to clear ketones (acidosis is still present with pH 7.24) necessitate the addition of glucose soon to ensure the insulin rate is not decreased prematurely. *Continue current management and recheck in 2 hours* - Waiting 2 hours without intervention risks a further precipitous drop in glucose, as the **insulin infusion** remains at a fixed rate regardless of blood sugar levels. - Active management of **potassium** and preparation for glucose administration are required as the patient approaches target glucose levels while still in **acidosis**. *Reduce the fixed-rate insulin infusion rate by half* - The **fixed-rate insulin** must remain constant (usually 0.1 units/kg/hr) to effectively switch off **ketone production** and resolve the metabolic acidosis. - Reducing the insulin rate prematurely will delay the resolution of **ketoacidosis**, even if the blood glucose is improving. *Stop fixed-rate insulin and start subcutaneous insulin* - Transition to **subcutaneous insulin** is only appropriate when the DKA has resolved, defined by a **pH >7.3**, bicarbonate >15 mmol/L, and ketones <0.6 mmol/L. - This patient is still **acidotic** (pH 7.24, bicarbonate 13 mmol/L), so stopping the IV infusion would lead to a rebound in **ketosis**. *Increase the fixed-rate insulin infusion rate* - The **biochemical markers** (pH and bicarbonate) are already improving, indicating that the current insulin dose is sufficient to treat the **ketoacidosis**. - Increasing the rate would unnecessarily increase the risk of **hypoglycemia** and rapid electrolyte shifts, such as life-threatening **hypokalemia**.

Question 90: A 57-year-old man with type 2 diabetes for 10 years presents with a 4-month history of progressive weakness, particularly when climbing stairs. He also reports erectile dysfunction and reduced libido. Examination shows proximal muscle weakness and reduced reflexes. HbA1c is 76 mmol/mol (9.1%). Thyroid function tests show TSH 0.2 mU/L (0.5-5.0), free T4 18 pmol/L (10-22), free T3 3.8 pmol/L (3.5-6.5). What is the most likely diagnosis?

A. Subclinical hyperthyroidism
B. Diabetic amyotrophy
C. Primary hypothyroidism
D. Secondary hypothyroidism (Correct Answer)
E. Sick euthyroid syndrome

Explanation: ***Secondary hypothyroidism*** - The biochemical pattern of a **low TSH** (0.2 mU/L) alongside a **low-normal free T3** (3.8 pmol/L) and normal free T4 is diagnostic of **central (secondary) hypothyroidism**, indicating a failure of the pituitary gland to produce adequate TSH. - The combination of **proximal muscle weakness**, **reduced reflexes**, **erectile dysfunction**, and **reduced libido** suggests multiple pituitary hormone deficiencies (**hypopituitarism**) affecting both thyroid and gonadal axes. *Subclinical hyperthyroidism* - This condition is defined by a **low TSH** with **normal free T3 and T4** levels but usually presents with subtle or no symptoms, or mild symptoms of thyroid hormone excess. - It does not explain the presence of **proximal muscle weakness** (more typical of hypothyroidism) or symptoms of **hypogonadism** like reduced libido and erectile dysfunction. *Diabetic amyotrophy* - While it causes **proximal muscle weakness** in patients with diabetes, it typically presents with **severe thigh pain** and is often **asymmetric** in the early stages. - It is a neurogenic complication of diabetes and would not account for the **low TSH** or the patient's **sexual dysfunction** symptoms, which point to an endocrine etiology. *Primary hypothyroidism* - In **primary hypothyroidism**, the TSH would be **elevated** as the pituitary attempts to compensate for a failing thyroid gland by increasing TSH secretion. - The patient’s biochemical profile shows an **inappropriately low TSH**, which localizes the pathology to the **hypothalamus or pituitary** rather than the thyroid gland itself. *Sick euthyroid syndrome* - This is typically seen in patients with **severe acute illness** and usually features a **low T3** with a normal or low T4 and TSH. - The **chronic presentation** (4-month history) of this patient’s symptoms and the associated features of **hypogonadism** make a primary pituitary lesion much more likely than a transient illness-related thyroid axis dysfunction.

Question 91: A 42-year-old woman with type 2 diabetes is started on empagliflozin. She returns 2 weeks later with a 3-day history of urinary frequency, dysuria, and lower abdominal pain. Urine dipstick shows blood 2+, protein 1+, leucocytes 3+, and nitrites positive. Temperature is 38.2°C. She is haemodynamically stable. Blood glucose is 18.2 mmol/L. What is the most appropriate initial management?

A. Continue empagliflozin and prescribe oral antibiotics
B. Stop empagliflozin temporarily and prescribe oral antibiotics (Correct Answer)
C. Stop empagliflozin permanently and prescribe oral antibiotics
D. Continue empagliflozin and admit for intravenous antibiotics
E. Stop empagliflozin temporarily and admit for intravenous antibiotics

Explanation: ***Stop empagliflozin temporarily and prescribe oral antibiotics***- SGLT2 inhibitors like **empagliflozin** promote **glycosuria**, which increases the risk of **urinary tract infections (UTIs)** and should be paused during acute illness to prevent dehydration and **euglycemic ketoacidosis**.- Since the patient is **haemodynamically stable** and lacks signs of systemic sepsis or pyelonephritis (e.g., flank pain, significant constitutional symptoms), **oral antibiotics** are the preferred first-line treatment for a symptomatic UTI.*Continue empagliflozin and prescribe oral antibiotics*- Continuing the drug during an active infection provides a **glucose-rich environment** in the urinary tract that may delay recovery or exacerbate the infection.- Failure to pause the medication increases the risk of **SGLT2-induced dehydration** and metabolic complications during an acute inflammatory state, such as **euglycemic DKA**.*Stop empagliflozin permanently and prescribe oral antibiotics*- **Permanent discontinuation** is generally not required for a single episode of UTI, as this is a manageable and known potential side effect of the drug class.- If infections become **recurrent** or severe (e.g., urosepsis), then a permanent switch to a different class of antidiabetic medication may be considered.*Continue empagliflozin and admit for intravenous antibiotics*- **Intravenous antibiotics** and admission are unnecessary because the patient is stable and does not present with **flank pain**, vomiting, or signs of **urosepsis**.- Continuing the SGLT2 inhibitor while the patient has a high fever and active infection is contraindicated due to the risk of **hypovolemia** and metabolic derangement.*Stop empagliflozin temporarily and admit for intravenous antibiotics*- Although stopping the medication is correct, admission is reserved for patients with **upper UTI (pyelonephritis)**, urinary obstruction, or those unable to tolerate oral intake.- Her symptoms of **dysuria** and **lower abdominal pain** suggest a lower UTI (cystitis), which can be managed safely in the outpatient setting with **oral therapy**.

Question 92: A 50-year-old woman presents to the emergency department with sudden-onset severe headache, photophobia, and neck stiffness. She was recently started on carbimazole 40mg once daily for newly diagnosed Graves' disease 3 weeks ago. Temperature is 38.7°C, HR 116/min, BP 108/68 mmHg. She appears unwell. Full blood count shows: Hb 118 g/L, WCC 1.2 × 10⁹/L (neutrophils 0.2 × 10⁹/L), platelets 245 × 10⁹/L. What is the most critical immediate action?

A. Arrange urgent CT head and lumbar puncture to exclude meningitis
B. Stop carbimazole immediately and start broad-spectrum IV antibiotics after blood cultures (Correct Answer)
C. Give IV hydrocortisone 100mg and propranolol 40mg for impending thyroid storm
D. Arrange urgent haematology review for possible aplastic anaemia
E. Start G-CSF (granulocyte colony-stimulating factor) immediately

Explanation: ***Stop carbimazole immediately and start broad-spectrum IV antibiotics after blood cultures***- The patient presents with **fever**, **meningism**, and profound **agranulocytosis** (neutrophils 0.2 × 10⁹/L), a life-threatening side effect of **carbimazole**. This clinical picture is consistent with **neutropenic sepsis**.- The most critical immediate action is to **stop the causative drug** (carbimazole) and initiate **broad-spectrum IV antibiotics** promptly (within 1 hour) after obtaining blood cultures to treat the severe infection.*Arrange urgent CT head and lumbar puncture to exclude meningitis*- While the patient's symptoms suggest **meningism**, performing these investigations would significantly delay the administration of **life-saving antibiotics** in a critically unwell, neutropenic patient.- In suspected **neutropenic sepsis**, empirical broad-spectrum antibiotics are paramount; imaging/LP should only be considered if the patient is stable enough and if it won't delay critical treatment.*Give IV hydrocortisone 100mg and propranolol 40mg for impending thyroid storm*- Although the patient has Graves' disease and some hyperthyroid symptoms like tachycardia, the severe **neutropenia** and fever make **neutropenic sepsis** the immediate life-threatening concern, not thyroid storm.- Managing acute sepsis takes precedence; treating a potential thyroid storm without immediately addressing the profound infection risk would be inappropriate.*Arrange urgent haematology review for possible aplastic anaemia*- The blood count primarily shows severe **neutropenia** (agranulocytosis) with normal Hb and platelets, making **aplastic anaemia** (which typically involves pancytopenia) less likely than drug-induced agranulocytosis.- While a haematology review will be necessary for definitive diagnosis and management, it is not the *immediate* critical action; stabilizing the patient from sepsis is the priority.*Start G-CSF (granulocyte colony-stimulating factor) immediately*- **G-CSF** helps stimulate granulocyte production and can shorten the duration of neutropenia, but it is not a first-line emergency treatment for acute **neutropenic sepsis**.- The immediate priorities are cessation of the causative drug and aggressive **antibiotic therapy** to combat the active infection, not just to raise neutrophil counts.

Question 93: A 63-year-old woman with type 2 diabetes for 11 years on metformin, gliclazide, and empagliflozin presents with recurrent genital candidiasis (4 episodes in 8 months) despite good glycaemic control (HbA1c 52 mmol/mol). She has had multiple courses of topical antifungals with temporary improvement. She has no other urogenital symptoms. BMI is 29 kg/m², blood pressure 136/82 mmHg, eGFR 72 ml/min/1.73m². Past medical history includes hypertension and previous transient ischaemic attack 3 years ago. What is the most appropriate modification to her diabetes medication regimen?

A. Stop empagliflozin and add dulaglutide 0.75mg once weekly (Correct Answer)
B. Stop empagliflozin and increase gliclazide dose
C. Stop gliclazide and increase empagliflozin to 25mg
D. Continue all medications and add long-term prophylactic fluconazole
E. Stop empagliflozin and add pioglitazone 15mg once daily

Explanation: ***Stop empagliflozin and add dulaglutide 0.75mg once weekly*** - **SGLT2 inhibitors** like empagliflozin cause **glucosuria**, which directly promotes recurrent **genital candidiasis**; switching to a **GLP-1 receptor agonist** removes this trigger. - **Dulaglutide** is preferred here because it provides **cardiovascular protection** (essential given her history of **TIA**) and assists with weight management without the infection risk. *Stop empagliflozin and increase gliclazide dose* - While stopping the SGLT2 inhibitor resolves the infection, increasing **gliclazide (a sulfonylurea)** significantly increases the risk of **hypoglycaemia**. - This approach fails to provide the **cardiovascular benefits** required for a patient with a previous **Transient Ischaemic Attack (TIA)**. *Stop gliclazide and increase empagliflozin to 25mg* - Increasing the dose of **empagliflozin** would increase **urinary glucose excretion**, likely worsening the frequency and severity of the **genital candidiasis**. - This does not address the patient's primary complaint of recurrent infections and would be clinically counterproductive. *Continue all medications and add long-term prophylactic fluconazole* - Prophylactic **fluconazole** is not recommended as a primary strategy to manage medication-induced infections when an effective **alternative glucose-lowering therapy** is available. - This approach exposes the patient to unnecessary long-term drug side effects and potential **antifungal resistance** while leaving the underlying cause untreated. *Stop empagliflozin and add pioglitazone 15mg once daily* - **Pioglitazone** is generally avoided or used with caution in patients with a history of **stroke or TIA** due to potential concerns regarding cardiovascular complications. - It is also associated with **weight gain** and **fluid retention**, which are undesirable given the patient's **BMI of 29 kg/m²**.

Question 94: A 28-year-old woman with type 1 diabetes for 15 years is admitted with diabetic ketoacidosis. Initial results: pH 7.08, glucose 32.6 mmol/L, ketones 6.2 mmol/L, potassium 5.8 mmol/L. Standard DKA protocol is commenced with fixed-rate IV insulin infusion (FRIII) at 0.1 units/kg/hour and IV fluid resuscitation. After 6 hours, repeat blood gas shows: pH 7.28, glucose 14.2 mmol/L, ketones 2.4 mmol/L, bicarbonate 16 mmol/L, potassium 3.8 mmol/L. What represents appropriate adjustment to her insulin regimen at this point?

A. Continue FRIII at current rate and add 10% dextrose infusion at 125ml/hour (Correct Answer)
B. Reduce FRIII to 0.05 units/kg/hour and continue 0.9% sodium chloride
C. Continue FRIII at current rate and switch to 5% dextrose instead of 0.9% saline
D. Stop FRIII and commence variable-rate IV insulin infusion targeting glucose 6-10 mmol/L
E. Increase FRIII to 0.15 units/kg/hour until ketones are <0.6 mmol/L

Explanation: ***Continue FRIII at current rate and add 10% dextrose infusion at 125ml/hour*** - The patient's **pH (7.28)** and **ketone levels (2.4 mmol/L)** indicate that **ketoacidosis** has not fully resolved, requiring the **Fixed-Rate Intravenous Insulin Infusion (FRIII)** to continue at its current rate to suppress ketogenesis. - Her blood **glucose (14.2 mmol/L)** has fallen to a level where **10% dextrose** must be added to the IV fluids to prevent **hypoglycemia** while the therapeutic insulin dose continues to clear ketones. *Reduce FRIII to 0.05 units/kg/hour and continue 0.9% sodium chloride* - Reducing the **insulin rate** prematurely, before resolution of ketoacidosis (ketones <0.6 mmol/L and pH >7.3), would impede the necessary **suppression of ketone production**. - Continuing only **0.9% sodium chloride** without adding dextrose when glucose is falling would put the patient at high risk of **hypoglycemia**. *Continue FRIII at current rate and switch to 5% dextrose instead of 0.9% saline* - In DKA, when blood glucose falls, **10% dextrose** is generally preferred over 5% dextrose to provide adequate glucose replacement to counteract the high insulin dose and prevent **hypoglycemia**. - Often, dextrose is *added* to the existing fluid regimen, rather than completely replacing **0.9% saline**, which may still be required for ongoing volume resuscitation. *Stop FRIII and commence variable-rate IV insulin infusion targeting glucose 6-10 mmol/L* - Stopping **FRIII** is inappropriate as the patient's **ketoacidosis** is still active (ketones 2.4 mmol/L, pH 7.28), and premature cessation risks a rebound of DKA. - A **variable-rate insulin infusion (VRIII)** is not used for acute DKA management; it is typically reserved for glucose control in stable, but nil-by-mouth, diabetic patients. *Increase FRIII to 0.15 units/kg/hour until ketones are <0.6 mmol/L* - The patient is responding appropriately to the current **FRIII** rate, with a significant reduction in **ketones** (from 6.2 to 2.4 mmol/L, a drop of 3.8 mmol/L over 6 hours, or ~0.63 mmol/L/hr). - An increase in the insulin rate is only indicated if there is an inadequate response, such as a failure of ketones to fall by at least **0.5 mmol/L/hr** or glucose by **3 mmol/L/hr**.

Question 95: A 39-year-old woman is referred by her GP with suspected Graves' disease. She has palpitations, tremor, and weight loss. Examination reveals a diffuse, non-tender goitre, exophthalmos with lid retraction, and lid lag. Thyroid function shows: TSH <0.05 mU/L, free T4 42 pmol/L (10-22), free T3 18.4 pmol/L (3.5-6.5). TSH receptor antibodies are positive. She works as a primary school teacher. What is the most appropriate initial management strategy?

A. Carbimazole 40mg once daily with block and replace regimen after 4 weeks
B. Propylthiouracil 100mg three times daily
C. Carbimazole 20mg once daily with dose titration according to thyroid function (Correct Answer)
D. Radioactive iodine therapy
E. Propranolol 40mg three times daily alone, then reassess in 4 weeks

Explanation: ***Carbimazole 20mg once daily with dose titration according to thyroid function*** - **Carbimazole** is the first-line antithyroid drug for Graves' disease, and a **titration regimen** is generally preferred as it involves a lower cumulative drug dose and minimizes side effects. - The initial dose of **Carbimazole** is adjusted every 4-8 weeks based on **thyroid function tests (TFTs)** until the patient is euthyroid. *Carbimazole 40mg once daily with block and replace regimen after 4 weeks* - A **block and replace** regimen involves higher doses of carbimazole followed by levothyroxine, typically reserved for patients with **unstable thyroid levels** or difficulty with frequent monitoring. - This regimen is associated with a higher risk of **side effects** compared to the titration regimen and is not the standard first-line approach for initial management. *Propylthiouracil 100mg three times daily* - **Propylthiouracil (PTU)** is usually considered a second-line treatment due to the risk of severe **hepatotoxicity**, which can be fatal. - It is primarily preferred in the **first trimester of pregnancy**, during **thyroid storm**, or if the patient is intolerant to carbimazole. *Radioactive iodine therapy* - Radioactive iodine is a definitive treatment but is relatively contraindicated in this patient due to active **thyroid eye disease** (exophthalmos, lid retraction, lid lag), which can be worsened by the treatment. - As a primary school teacher, the patient's constant **contact with children** would make adherence to post-treatment radiation precautions challenging. *Propranolol 40mg three times daily alone, then reassess in 4 weeks* - **Propranolol** provides symptomatic relief for manifestations like **palpitations** and **tremors** by blocking beta-adrenergic receptors. - It does not address the underlying overproduction of **thyroid hormones** and should be used as an **adjunct therapy** alongside antithyroid drugs, not as monotherapy for overt hyperthyroidism.

Question 96: A 66-year-old man with type 2 diabetes for 14 years presents with progressive bilateral lower limb pain, worse at night and partially relieved by hanging legs over the bed edge. He has a 40 pack-year smoking history. Examination reveals absent foot pulses bilaterally, prolonged capillary refill time >5 seconds, reduced temperature in both feet, and a shallow ulcer on the lateral aspect of the right foot measuring 1.5cm. Ankle-brachial pressure index (ABPI) is 0.52 on the right and 0.58 on the left. What is the most appropriate next step in management?

A. Arrange urgent vascular surgery assessment within 2 weeks
B. Start high-dose statin and antiplatelet therapy, routine podiatry referral
C. Apply compression bandaging to the ulcer and arrange outpatient vascular review
D. Request urgent CT angiography and refer to vascular multidisciplinary team within 1 week (Correct Answer)
E. Admit for IV antibiotics and surgical debridement

Explanation: ***Request urgent CT angiography and refer to vascular multidisciplinary team within 1 week*** - This patient presents with classic signs and symptoms of **critical limb ischemia (CLI)**, including **rest pain**, a non-healing **ischemic ulcer**, and severely reduced **Ankle-Brachial Pressure Index (ABPI < 0.6)**. - According to national guidelines (e.g., **NICE**), patients with suspected CLI require **urgent assessment** by a **vascular multidisciplinary team (MDT)** within **1 week**, along with urgent **imaging (CT or MR angiography)** to identify suitable targets for revascularization. *Arrange urgent vascular surgery assessment within 2 weeks* - A **2-week referral timeframe** is typically appropriate for patients with **stable claudication** or less severe, non-limb-threatening peripheral arterial disease. - However, the presence of **rest pain** and **tissue loss (ulceration)** signifies **critical limb ischemia**, which is a limb-threatening condition requiring **immediate attention** and a significantly shorter referral window (within 1 week). *Start high-dose statin and antiplatelet therapy, routine podiatry referral* - While **high-dose statins** and **antiplatelet therapy** are crucial for **secondary prevention** in patients with PAD and for overall cardiovascular risk reduction, they do not address the acute need for **revascularization** in CLI. - A **routine podiatry referral** is insufficient for an active **ischemic ulcer** associated with CLI, as the priority is to restore blood flow to promote healing. *Apply compression bandaging to the ulcer and arrange outpatient vascular review* - **Compression bandaging** is **contraindicated** in patients with significant arterial insufficiency, especially when the **ABPI is less than 0.8** (and certainly <0.6), as it can further impair blood flow and worsen ischemia. - This measure is typically used for **venous ulcers**, not the **arterial/ischemic ulcer** presented here. An outpatient review is too slow for CLI. *Admit for IV antibiotics and surgical debridement* - While infection can complicate ischemic ulcers, there is no explicit mention of systemic signs of infection (fever, spreading cellulitis, purulent discharge) requiring **immediate IV antibiotics** as the *most appropriate next step* before assessing revascularization needs. - **Surgical debridement** of an ischemic ulcer without first ensuring adequate blood supply (**revascularization**) is ill-advised, as it can worsen tissue loss and prevent healing. Revascularization is the priority.

Question 97: A 31-year-old woman presents with a 3-month history of fatigue, weight gain of 6 kg, constipation, and dry skin. She is planning pregnancy. Blood tests show: TSH 14.8 mU/L (0.5-5.0), free T4 8.2 pmol/L (10-22), anti-thyroid peroxidase antibodies strongly positive. She has no previous thyroid history. What is the most appropriate initial levothyroxine dose considering her circumstances?

A. 25 micrograms once daily
B. 50 micrograms once daily
C. 100 micrograms once daily
D. 1.6 micrograms per kilogram body weight once daily (Correct Answer)
E. 75 micrograms once daily

Explanation: ***1.6 micrograms per kilogram body weight once daily*** - In young, healthy patients with **primary hypothyroidism**, especially those **planning pregnancy**, the goal is to achieve rapid euthyroidism using a **full replacement dose**. - A weight-based calculation ensures the TSH is brought within the narrow target range (<2.5 mU/L) quickly to prevent **fetal neurodevelopmental** complications. *25 micrograms once daily* - This low starting dose is reserved for the **elderly** or patients with known **ischemic heart disease** to avoid precipitating an arrhythmia or angina. - Using this dose in a young woman planning pregnancy would result in a dangerously slow correction of her **hypothyroid state**. *50 micrograms once daily* - This is a common starting dose for middle-aged adults without cardiac disease, but it is effectively a **partial replacement dose**. - It is insufficient for a patient needing rapid normalization of thyroid function for **conception and early pregnancy**. *100 micrograms once daily* - While 100 mcg might be close to the final requirement for some, a **fixed dose** does not account for the patient's specific body mass and weight gain. - Guidelines prioritize **weight-based dosing** (1.6 mcg/kg) to reach euthyroid status more accurately than generic fixed doses. *75 micrograms once daily* - This represents a moderate starting dose but remains an **under-replacement** for most healthy young adults with a TSH as high as 14.8 mU/L. - It fails to meet the clinical urgency required for a patient **actively planning pregnancy** where metabolic demands will soon increase.

Question 98: A 43-year-old woman with type 1 diabetes for 22 years attends for diabetic eye screening. She is asymptomatic with no visual complaints. Retinal photography shows scattered dot and blot haemorrhages, multiple cotton wool spots, venous beading in 2 quadrants, and intraretinal microvascular abnormalities (IRMA) in 1 quadrant bilaterally. There is no evidence of new vessels or macular oedema. What is the diagnosis and most appropriate management?

A. Severe non-proliferative diabetic retinopathy - refer urgent ophthalmology within 2 weeks (Correct Answer)
B. Diabetic maculopathy - refer urgent ophthalmology within 1 week
C. Mild non-proliferative diabetic retinopathy - continue annual screening
D. Moderate non-proliferative diabetic retinopathy - refer routine ophthalmology
E. Proliferative diabetic retinopathy - refer emergency ophthalmology within 24 hours

Explanation: ***Severe non-proliferative diabetic retinopathy - refer urgent ophthalmology within 2 weeks***- This diagnosis is confirmed by the presence of **venous beading** in 2 quadrants and **intraretinal microvascular abnormalities (IRMA)** in 1 quadrant, meeting the criteria for **severe non-proliferative diabetic retinopathy (NPDR)** based on the 4-2-1 rule.- Patients with severe NPDR are at high risk of progressing to proliferative disease and require **urgent ophthalmology referral within 2 weeks** for close monitoring and consideration of treatment. *Diabetic maculopathy - refer urgent ophthalmology within 1 week*- This diagnosis requires signs like **macular oedema**, **hard exudates**, or **retinal thickening** affecting the macula, which are explicitly stated as absent in this case.- The findings of venous beading and IRMA indicate diffuse retinal ischemia and vascular changes rather than localized macular pathology.*Mild non-proliferative diabetic retinopathy - continue annual screening*- Mild NPDR is characterized by only a few **microaneurysms** and possibly some dot/blot hemorrhages, which is far less severe than the features observed.- Continuing **annual screening** would be inadequate for a patient with multiple cotton wool spots, venous beading, and IRMA, as these indicate advanced retinopathy requiring prompt intervention.*Moderate non-proliferative diabetic retinopathy - refer routine ophthalmology*- Moderate NPDR involves more extensive microaneurysms and dot/blot hemorrhages but does not meet the specific criteria of the **4-2-1 rule** for severe disease.- The presence of **venous beading** in two quadrants and **IRMA** in one quadrant places this case firmly in the severe NPDR category, making routine referral inappropriate.*Proliferative diabetic retinopathy - refer emergency ophthalmology within 24 hours*- Proliferative diabetic retinopathy (PDR) is defined by the presence of **neovascularization** (new vessels) or **vitreous hemorrhage**, which were explicitly noted as absent.- Although severe NPDR is a precursor to PDR, it does not warrant an **emergency 24-hour referral** unless there is active neovascularization or acute vision-threatening complications.

Question 99: A 52-year-old man with type 2 diabetes for 7 years attends for his annual diabetic foot screening. He has no foot symptoms. Examination reveals normal foot structure, warm feet with palpable pulses bilaterally. 10g monofilament testing shows absent sensation at 4 out of 10 sites on the right foot and 3 out of 10 sites on the left foot. Vibration perception threshold using a neurothesiometer is 32 volts on the right and 28 volts on the left hallux. Ankle reflexes are absent bilaterally. What is his current diabetic foot risk status and appropriate management interval?

A. Low risk - annual screening
B. Moderate risk - review every 3-6 months (Correct Answer)
C. High risk - review every 2-3 months
D. Active problem - weekly podiatry review
E. Low risk - screening every 2 years

Explanation: ***Moderate risk - review every 3-6 months*** - The patient exhibits clear evidence of **peripheral neuropathy**, including **absent sensation on 10g monofilament** testing at multiple sites and an elevated **vibration perception threshold (VPT >25V)**, along with absent ankle reflexes. - The presence of neuropathy as a single risk factor, without concurrent ischemia or deformity, places the patient in the **moderate risk** category, necessitating a review every **3 to 6 months** as per diabetic foot care guidelines (e.g., NICE NG19). *Low risk - annual screening* - **Low risk** status is appropriate for individuals with **no clinical evidence of loss of protective sensation**, normal peripheral pulses, and absence of foot deformity. - This patient clearly has **sensory deficits** (monofilament, VPT) and **absent ankle reflexes**, ruling out a low-risk classification. *High risk - review every 2-3 months* - **High risk** designation typically applies to patients with a combination of risk factors, such as **neuropathy and ischemia**, or neuropathy/ischemia with **foot deformity**, or a history of ulceration or Charcot arthropathy. - While the patient has neuropathy, he has **palpable pulses** (no ischemia) and a **normal foot structure** (no deformity), therefore not meeting the criteria for high risk. *Active problem - weekly podiatry review* - An **active problem** refers to acute conditions requiring urgent intervention, such as a **diabetic foot ulcer**, **spreading infection**, or **acute Charcot neuroarthropathy**. - This patient is asymptomatic with no visible acute issues or skin breakdown, thus an **active problem** status and weekly podiatry review are not indicated. *Low risk - screening every 2 years* - This option is incorrect as the patient's established **neuropathy** places him at **moderate risk**, not low risk. - Furthermore, a **2-year screening interval** is not recommended for any diabetic foot risk category; even low-risk patients require annual screening.

Question 100: A 77-year-old woman with type 2 diabetes is admitted from a nursing home with pneumonia. She has been increasingly confused over 5 days with reduced oral intake. Observations: BP 96/54 mmHg, HR 108/min, temperature 38.2°C, GCS 13. Blood results: glucose 44.2 mmol/L, sodium 156 mmol/L, urea 28.4 mmol/L, creatinine 242 μmol/L, osmolality 368 mOsm/kg. Urine ketones negative. Which fluid regimen is most appropriate for the first 12 hours?

A. 0.9% sodium chloride 1L over 1 hour, then 1L over 2 hours, then 1L over 4 hours, then 1L over 6 hours
B. 0.45% sodium chloride 1L over 1 hour, then 1L over 2 hours, then 1L over 2 hours, then 1L over 4 hours (Correct Answer)
C. 0.9% sodium chloride 500ml over 1 hour, then 500ml over 2 hours, then 500ml over 4 hours, then 500ml over 6 hours
D. 0.45% sodium chloride 500ml over 1 hour, then 1L over 2 hours, then 1L over 4 hours
E. 0.9% sodium chloride 1L over 2 hours, then 1L over 4 hours, then 1L over 6 hours

Explanation: ***0.45% sodium chloride 1L over 1 hour, then 1L over 2 hours, then 1L over 2 hours, then 1L over 4 hours*** - The patient presents with **Hyperosmolar Hyperglycaemic State (HHS)**, evidenced by severe hyperglycaemia (44.2 mmol/L), profound hyperosmolality (368 mOsm/kg), significant dehydration (hypotension, tachycardia, elevated urea/creatinine), and absent ketosis. - Given the severe **hypernatraemia (156 mmol/L)** and hyperosmolality, **0.45% (hypotonic) sodium chloride** is the most appropriate fluid to correct the **free water deficit** and gradually reduce serum osmolality, with an initial rapid bolus for haemodynamic support. *0.9% sodium chloride 1L over 1 hour, then 1L over 2 hours, then 1L over 4 hours, then 1L over 6 hours* - This regimen uses **0.9% sodium chloride**, which is **isotonic** and may exacerbate or fail to correct the patient's severe **hypernatraemia** and hyperosmolality, increasing the risk of complications. - While 0.9% NaCl might be used for initial rapid volume expansion in profound shock, continued use for the bulk of fluid replacement in HHS with significant hypernatremia is suboptimal as it does not address the free water deficit effectively. *0.9% sodium chloride 500ml over 1 hour, then 500ml over 2 hours, then 500ml over 4 hours, then 500ml over 6 hours* - The total fluid volume of **2 litres over 13 hours** is significantly **insufficient** for a patient with severe dehydration and hypovolemic shock, delaying effective resuscitation. - Similar to the previous option, utilizing **0.9% sodium chloride** for primary fluid replacement is inappropriate in the context of severe **hypernatraemia** and hyperosmolality in HHS. *0.45% sodium chloride 500ml over 1 hour, then 1L over 2 hours, then 1L over 4 hours* - Although it correctly specifies **0.45% sodium chloride**, the initial volume of **500ml over 1 hour** may be **too slow** to adequately address the patient's presenting **hypotension** and tachycardia, which require rapid volume expansion. - The total volume provided is also less than what is typically recommended for severe dehydration in HHS over the initial hours. *0.9% sodium chloride 1L over 2 hours, then 1L over 4 hours, then 1L over 6 hours* - This fluid administration schedule is **too slow** for initial resuscitation, with the first litre given over 2 hours, which is inadequate for a patient presenting with **hypotension** and tachycardia. - It also uses **0.9% sodium chloride**, which is not ideal for correcting the **free water deficit** in a patient with significant **hypernatraemia** and hyperosmolality.

Question 101: A 35-year-old man with type 1 diabetes for 18 years presents to the emergency department with a 2-day history of vomiting and abdominal pain. He continued his basal insulin but stopped his mealtime insulin due to poor oral intake. Blood results show: glucose 28.4 mmol/L, pH 7.21, bicarbonate 11 mmol/L, ketones 4.8 mmol/L, sodium 131 mmol/L, potassium 5.2 mmol/L, urea 9.8 mmol/L, creatinine 132 μmol/L. He is started on DKA protocol. After 4 hours of treatment, repeat potassium is 3.1 mmol/L. What is the most appropriate potassium replacement strategy?

A. Add 40 mmol potassium chloride per litre of IV fluid (Correct Answer)
B. Add 20 mmol potassium chloride per litre of IV fluid
C. Give 20 mmol potassium chloride IV bolus over 10 minutes, then add 40 mmol per litre
D. Stop insulin infusion until potassium is above 3.5 mmol/L, then add 40 mmol per litre
E. Add 60 mmol potassium chloride per litre of IV fluid

Explanation: ***Add 40 mmol potassium chloride per litre of IV fluid*** - The patient's potassium level of **3.1 mmol/L** falls within the critical range of **3.0–3.5 mmol/L** during DKA treatment. - According to **DKA management protocols** (e.g., JBDS), when potassium is in this range, **40 mmol/L** of potassium chloride should be added to the intravenous fluids to correct the deficit and prevent further **hypokalaemia** as insulin shifts potassium **intracellularly**. *Add 20 mmol potassium chloride per litre of IV fluid* - This concentration is typically used when serum potassium levels are between **3.5–5.5 mmol/L** to maintain stable potassium during ongoing insulin infusion. - At 3.1 mmol/L, adding only **20 mmol/L** would be insufficient to replenish the potassium deficit and could lead to worsening **hypokalaemia**. *Give 20 mmol potassium chloride IV bolus over 10 minutes, then add 40 mmol per litre* - Administering **potassium as an IV bolus** is extremely dangerous and strictly contraindicated due to the high risk of inducing fatal **cardiac arrhythmias** or **cardiac arrest**. - Potassium must always be given as a **slow, diluted infusion** to allow for gradual cellular uptake and prevent rapid concentration changes in the bloodstream. *Stop insulin infusion until potassium is above 3.5 mmol/L, then add 40 mmol per litre* - Stopping insulin infusion in DKA is inappropriate as it would halt the crucial suppression of **ketogenesis** and prevent the resolution of **acidosis**, thereby worsening the patient's DKA. - The correct approach is to **continue insulin therapy** while aggressively replacing potassium to manage both the DKA and the electrolyte imbalance simultaneously. *Add 60 mmol potassium chloride per litre of IV fluid* - Infusing **60 mmol/L** of potassium chloride through a peripheral intravenous line significantly increases the risk of **severe phlebitis**, local pain, and potential tissue damage. - Most DKA guidelines and safety protocols recommend a maximum potassium concentration of **40 mmol/L** for peripheral infusions; higher concentrations typically require central venous access.

Question 102: A 24-year-old woman with type 1 diabetes for 6 years is brought to the emergency department by ambulance. She was found collapsed at home. Capillary glucose is 1.8 mmol/L. She is unconscious with GCS 6. IV access is difficult due to obesity. Her partner reports she took her usual insulin dose but missed lunch due to gastroenteritis. What is the most appropriate immediate management?

A. Administer 1mg intramuscular glucagon immediately (Correct Answer)
B. Establish IV access and give 100ml 20% dextrose
C. Give 50ml 50% dextrose via intraosseous route
D. Administer 200ml oral glucose solution via nasogastric tube
E. Establish IV access and give 150ml 10% dextrose

Explanation: ***Administer 1mg intramuscular glucagon immediately*** - In this emergency with **severe hypoglycemia** (1.8 mmol/L) and an **unconscious patient (GCS 6)** with **difficult IV access**, intramuscular glucagon is the most appropriate and rapid first-line intervention. - Glucagon works by stimulating **hepatic glycogenolysis**, rapidly raising blood glucose levels, and is effective in Type 1 diabetes where liver glycogen stores are usually sufficient. *Establish IV access and give 100ml 20% dextrose* - Attempting to establish IV access in an **obese patient** with difficult veins will cause a critical **delay in treatment** for a patient with a GCS of 6, where time to glucose elevation is paramount. - **20% dextrose** is highly hypertonic and carries a significant risk of **thrombophlebitis** or extravasation injury if administered via a peripheral vein, especially if IV access is challenging. *Give 50ml 50% dextrose via intraosseous route* - **50% dextrose** is generally not recommended in current guidelines due to the high risk of **tissue necrosis** upon extravasation, even with central or intraosseous administration. - While intraosseous access provides rapid entry, it is typically reserved for **extreme resuscitation** when IV access is impossible and other less invasive rapid options like IM glucagon have failed or are contraindicated. *Administer 200ml oral glucose solution via nasogastric tube* - Administering fluids or glucose orally or via an **NG tube** to an **unconscious patient** with a GCS of 6 poses a very high risk of **aspiration pneumonia**. - This method is also significantly slower in onset compared to parenteral routes and is therefore not suitable for immediate management of severe, symptomatic hypoglycemia. *Establish IV access and give 150ml 10% dextrose* - While **10% dextrose** is a preferred concentration for intravenous glucose to minimize vein irritation, the critical issue remains the **difficult IV access** and the subsequent delay in administering life-saving glucose. - **IM glucagon** offers a quicker, non-IV route to raise blood glucose immediately, allowing IV access to be established for subsequent, more sustained glucose infusion if needed.

Question 103: A 70-year-old man with type 2 diabetes is admitted with acute coronary syndrome. His regular medications include metformin, gliclazide, and atorvastatin. On admission, his HbA1c is 72 mmol/mol. He undergoes successful percutaneous coronary intervention. During his hospital stay, his glucose levels range from 8-14 mmol/L despite withholding gliclazide. Understanding the pathophysiology of hyperglycaemia in acute coronary syndrome, which mechanism primarily explains his elevated glucose levels?

A. Decreased insulin secretion due to beta-cell exhaustion
B. Increased hepatic glucose production from counter-regulatory hormone release (Correct Answer)
C. Reduced peripheral glucose uptake from inflammatory cytokines
D. Impaired incretin effect from acute illness
E. Direct myocardial damage causing insulin resistance

Explanation: ***Increased hepatic glucose production from counter-regulatory hormone release***- In acute stress like **ACS**, the neuroendocrine response triggers the release of **cortisol**, **catecholamines**, and **glucagon**, which stimulate **gluconeogenesis** and **glycogenolysis**.- This surge in **counter-regulatory hormones** is the primary driver for elevated blood glucose levels during acute critical illness, regardless of prior diabetic control.*Decreased insulin secretion due to beta-cell exhaustion*- **Beta-cell exhaustion** is a chronic progressive feature of type 2 diabetes rather than an acute pathophysiology mechanism triggered by a coronary event.- While secretion may be relatively insufficient for the degree of stress, the acute rise is driven by **hormonal antagonism** rather than sudden beta-cell failure.*Reduced peripheral glucose uptake from inflammatory cytokines*- **Inflammatory cytokines** (like TNF-alpha) do contribute to **peripheral insulin resistance**, but they are a secondary mechanism compared to hepatic output.- While cytokines inhibit **GLUT4** translocation in muscle, the dominant factor in acute hyperglycemia is the massive increase in **glucose production** from the liver.*Impaired incretin effect from acute illness*- The **incretin effect** is chronically impaired in patients with **Type 2 Diabetes**, but this deficiency does not fluctuate acutely to explain surge hyperglycemia in ACS.- This mechanism involves **GLP-1** and **GIP** responses to oral glucose, which is less relevant in the context of a systemic **stress response**.*Direct myocardial damage causing insulin resistance*- **Myocardial injury** results in local metabolic shifts, but it does not directly cause systemic **insulin resistance**.- Systemic insulin resistance in this case is a byproduct of high **circulating catecholamines** and **free fatty acids** rather than the damaged heart tissue itself.

Question 104: A 58-year-old woman with type 2 diabetes for 9 years, currently on metformin 1g twice daily and empagliflozin 10mg once daily, attends for review. Her HbA1c is 64 mmol/mol. She has a history of ischaemic heart disease with myocardial infarction 2 years ago and chronic heart failure (LVEF 35%). eGFR is 48 ml/min/1.73m². Blood pressure is 142/86 mmHg. Which is the most appropriate addition to her treatment regimen?

A. Increase empagliflozin to 25mg once daily
B. Add sitagliptin 50mg once daily (Correct Answer)
C. Add gliclazide 40mg once daily
D. Add pioglitazone 15mg once daily
E. Add exenatide 10mcg twice daily

Explanation: ***Add sitagliptin 50mg once daily***- **Sitagliptin** (a **DPP-4 inhibitor**) is a safe and effective option for improving glycemic control. Given her **eGFR of 48 ml/min/1.73m²**, the dose must be reduced to **50mg once daily**.- It is **cardiovascularly neutral** and does not worsen **heart failure**, making it a suitable choice for a patient with a history of **ischaemic heart disease** and **chronic heart failure (LVEF 35%)**, who is already on metformin and empagliflozin.*Increase empagliflozin to 25mg once daily*- While **empagliflozin** provides significant **cardiovascular** and **renal benefits**, increasing the dose from 10mg to 25mg offers minimal additional **HbA1c lowering** when the **eGFR** is below 60 ml/min/1.73m².- The primary **cardioprotective and renoprotective benefits** are largely achieved with the 10mg dose, and the glucose-lowering efficacy of **SGLT2 inhibitors** diminishes with declining renal function.*Add gliclazide 40mg once daily*- **Gliclazide** (a **sulfonylurea**) carries a significant risk of **hypoglycemia** and **weight gain**, which are generally undesirable in patients with established **cardiovascular disease**.- Unlike **SGLT2 inhibitors** or **GLP-1 receptor agonists**, sulfonylureas do not offer additional **cardiovascular or renal protection**, making them a less preferred choice in high-risk patients.*Add pioglitazone 15mg once daily*- **Pioglitazone** (a **thiazolidinedione**) is **contraindicated** in patients with **symptomatic heart failure** or a history of **heart failure (LVEF 35%)** due to its propensity to cause **fluid retention** and exacerbate heart failure.- Despite its benefits in improving insulin sensitivity, the risk of worsening her **cardiac status** outweighs any potential benefits.*Add exenatide 10mcg twice daily*- **Exenatide** (a **GLP-1 receptor agonist**) is generally avoided or used with extreme caution when the **eGFR** is below 50 ml/min/1.73m², and it is **contraindicated** if the eGFR is below 30 ml/min/1.73m². Her **eGFR is 48 ml/min/1.73m²**.- While other GLP-1 receptor agonists have shown cardiovascular benefits, the renal impairment limits the use of **exenatide** and makes **DPP-4 inhibitors** a safer alternative.

Question 105: A 16-year-old boy presents to the emergency department with a 4-week history of polyuria, polydipsia, and 8 kg weight loss. On examination, he is alert with BMI 19 kg/m². Capillary glucose is 22.4 mmol/L. Urine dipstick shows glucose 3+ and ketones 1+. Venous blood gas shows pH 7.38, bicarbonate 22 mmol/L. Random C-peptide is 180 pmol/L (normal 370-1470). Which autoantibody is most specific for the diagnosis?

A. Anti-islet cell antibodies (ICA)
B. Anti-zinc transporter 8 (ZnT8) antibodies (Correct Answer)
C. Anti-glutamic acid decarboxylase (anti-GAD) antibodies
D. Anti-insulin antibodies (IAA)
E. Anti-insulinoma antigen-2 (IA-2) antibodies

Explanation: ***Anti-zinc transporter 8 (ZnT8) antibodies*** - These antibodies are considered the **most specific** marker for **Type 1 Diabetes Mellitus (T1DM)** and are particularly useful in differentiating it from other forms of diabetes, especially when other antibodies are negative. - They are present in approximately 60-80% of newly diagnosed cases and can be predictive of **beta-cell destruction** even in the absence of other autoantibodies. *Anti-islet cell antibodies (ICA)* - ICA were historically the first autoantibodies identified but are now largely replaced by more specific assays due to being **labor-intensive** and less precise. - They reflect a general autoimmune response against various antigens within the **pancreatic islets** rather than a single specific protein. *Anti-glutamic acid decarboxylase (anti-GAD) antibodies* - While **Anti-GAD** antibodies are the **most common** autoantibody in T1DM, present in 70-80% of patients, they are less specific than ZnT8 antibodies. - Anti-GAD antibodies can also be found in other autoimmune conditions, such as **Stiff Person Syndrome** or autoimmune thyroid disease, making them less specific for T1DM alone. *Anti-insulin antibodies (IAA)* - IAA are often the first autoantibodies to appear in very young children with T1DM, especially before insulin therapy, but have **low specificity** if the patient has already received exogenous insulin. - Their diagnostic utility decreases significantly with age and after exposure to insulin, making them less reliable in older adolescents like the patient described. *Anti-insulinoma antigen-2 (IA-2) antibodies* - IA-2 antibodies are present in about 50-70% of newly diagnosed T1DM cases and are associated with **rapid progression** of beta-cell destruction. - While important for diagnosis as part of an autoantibody panel, they do not possess the same level of individual **specificity** for T1DM as Anti-zinc transporter 8 antibodies.

Question 106: A 53-year-old man with type 2 diabetes treated with metformin and sitagliptin has an HbA1c of 69 mmol/mol. His BMI is 32 kg/m² and eGFR is 42 ml/min/1.73m². He has a history of heart failure with reduced ejection fraction diagnosed 2 years ago, currently NYHA class II. Which medication should be added to improve both his glycaemic control and cardiovascular outcomes?

A. Empagliflozin
B. Dapagliflozin (Correct Answer)
C. Canagliflozin
D. Gliclazide
E. Exenatide

Explanation: ***Dapagliflozin*** - **Dapagliflozin** is the most appropriate choice due to its proven **mortality benefit** in patients with **heart failure with reduced ejection fraction (HFrEF)**, as demonstrated in the **DAPA-HF** trial. - It is licensed for glycaemic control and cardiovascular benefits in patients with an **eGFR** as low as 25 ml/min/1.73m², making it suitable for this patient's eGFR of 42 ml/min/1.73m². *Empagliflozin* - **Empagliflozin** generally requires an **eGFR >45 ml/min/1.73m²** for initiation when the primary goal is glycaemic control, making it less suitable for this patient's current renal function. - While it provides significant **cardiovascular protection** and benefits in heart failure, its specific initiation threshold for glucose lowering is more restrictive than dapagliflozin in this eGFR range. *Canagliflozin* - **Canagliflozin** is typically initiated in patients with an **eGFR >60 ml/min/1.73m²**, which excludes it from primary use in this clinical scenario given the patient's eGFR of 42. - Although it demonstrates benefits in **diastolic heart failure** and renal progression, it is not the first-line choice given the current **renal impairment** levels. *Gliclazide* - **Gliclazide**, a sulfonylurea, carries a significant risk of **hypoglycaemia** and does not offer any **cardioprotective** or heart failure benefits. - It may also lead to **weight gain**, which is undesirable in a patient with a **BMI of 32 kg/m²** and existing heart failure. *Exenatide* - **Exenatide** (a GLP-1 receptor agonist) is effective for weight loss and glycaemic control but lacks the specific **mortality benefits** seen with SGLT-2 inhibitors in **HFrEF**. - Per clinical guidelines, **SGLT-2 inhibitors** are prioritized over GLP-1 agonists for patients specifically presenting with **heart failure**.

Question 107: A 36-year-old woman is diagnosed with Graves' disease and started on carbimazole 40mg daily. After 3 weeks, she develops a sore throat and fever. Blood tests show white cell count 1.8 × 10⁹/L with neutrophils 0.4 × 10⁹/L. What is the most appropriate immediate management?

A. Stop carbimazole, admit for IV antibiotics and haematology review (Correct Answer)
B. Continue carbimazole, prescribe antibiotics in the community
C. Stop carbimazole, switch to propylthiouracil, prescribe antibiotics
D. Reduce carbimazole dose to 20mg daily and prescribe antibiotics
E. Stop carbimazole, arrange urgent thyroidectomy

Explanation: ***Stop carbimazole, admit for IV antibiotics and haematology review*** - The patient's symptoms of **sore throat and fever**, combined with a **neutrophil count of 0.4 × 10⁹/L**, indicate **agranulocytosis**, a severe and life-threatening adverse effect of **carbimazole**. Immediate cessation of the drug is crucial to prevent further bone marrow suppression. - Given the high risk of **sepsis** due to severe neutropenia, urgent **hospital admission** for **broad-spectrum intravenous antibiotics** is mandatory, along with **haematology review** for specialized management and monitoring. *Continue carbimazole, prescribe antibiotics in the community* - Continuing **carbimazole** in the presence of **agranulocytosis** would exacerbate the **bone marrow suppression**, leading to a further drop in neutrophil count and an increased risk of overwhelming **sepsis**. - Managing a patient with **febrile neutropenia** and suspected **agranulocytosis** in the community with oral antibiotics is inappropriate and dangerous due to the high mortality risk associated with severe infection. *Stop carbimazole, switch to propylthiouracil, prescribe antibiotics* - While **propylthiouracil (PTU)** is an alternative antithyroid drug, it has a significant risk of **cross-reactivity** for **agranulocytosis** with **carbimazole**, meaning a patient who develops it with one thionamide is likely to develop it with the other. - Switching to another thionamide is therefore contraindicated, and the priority is to manage the acute agranulocytosis and consider non-thionamide options for Graves' disease later. *Reduce carbimazole dose to 20mg daily and prescribe antibiotics* - **Agranulocytosis** is an **idiosyncratic reaction** to carbimazole, meaning it is not dose-dependent. Reducing the dose will not mitigate the risk or severity of the bone marrow suppression. - Any continued exposure to the offending drug will hinder the recovery of **neutrophil production** and maintain the patient's susceptibility to severe infection. *Stop carbimazole, arrange urgent thyroidectomy* - Although **thyroidectomy** is a definitive treatment for **Graves' disease**, performing surgery on a patient with **severe neutropenia** and active infection (fever and sore throat) carries an extremely high risk of **post-operative complications** and **sepsis**. - The immediate priority is to stabilize the patient's haematological status and control the infection; surgical intervention can only be considered once the **agranulocytosis** has resolved and the patient is medically stable.

Question 108: A 61-year-old woman with type 2 diabetes for 13 years presents with numbness in both feet. Examination reveals absent ankle reflexes, reduced vibration sense to the knees bilaterally, and loss of light touch sensation in a stocking distribution. Monofilament testing is abnormal. Foot pulses are palpable. HbA1c is 74 mmol/mol. Which additional investigation is most important to arrange?

A. Nerve conduction studies
B. MRI spine to exclude cauda equina syndrome
C. Serum B12, folate, and thyroid function tests (Correct Answer)
D. Ankle-brachial pressure index measurement
E. Urgent vascular surgery referral

Explanation: ***Serum B12, folate, and thyroid function tests***- In patients with suspected **diabetic peripheral neuropathy**, it is essential to exclude other **reversible causes**; NICE guidelines specifically recommend checking **vitamin B12** and **TSH**.- **Metformin**, commonly used for Type 2 Diabetes, is a known cause of **B12 deficiency**, which can independently cause or exacerbate peripheral neuropathy symptoms.*Nerve conduction studies*- These are generally reserved for **atypical presentations** such as rapid onset, asymmetric symptoms, or when **motor weakness** outweighs sensory loss.- A diagnosis of **diabetic neuropathy** is primarily clinical based on the characteristic **stocking-distribution** and does not require routine electrophysiology.*MRI spine to exclude cauda equina syndrome*- **Cauda equina syndrome** typically presents with acute back pain, **saddle anesthesia**, and bladder/bowel dysfunction, none of which are present here.- The symmetrical, distal sensory loss reaching to the knees is classic for a **length-dependent neuropathy**, not a spinal root compression.*Ankle-brachial pressure index measurement*- ABPI is used to assess for **Peripheral Arterial Disease (PAD)**; however, the patient has **palpable foot pulses**, which makes significant ischemia unlikely.- While PAD often coexists with diabetes, the primary complaint of numbness and the loss of **vibration/monofilament sensation** are neurogenic rather than vascular.*Urgent vascular surgery referral*- Urgent referral is indicated for **limb-threatening ischemia** or acute arterial occlusion, characterized by the '6 Ps' including pulselessness and pallor.- This patient's symptoms are chronic and her **foot pulses are palpable**, indicating that her circulation is currently stable.

Question 109: A 27-year-old woman with type 1 diabetes is admitted with DKA. After 6 hours of treatment with IV fluids and insulin, her glucose falls to 12.4 mmol/L. Venous blood gas shows pH 7.26, bicarbonate 13 mmol/L, ketones 2.8 mmol/L. What is the most appropriate modification to her management?

A. Switch to subcutaneous insulin and stop IV fluids
B. Stop insulin infusion and commence subcutaneous insulin
C. Continue current insulin infusion rate until ketones clear
D. Add 10% glucose infusion and continue fixed-rate insulin (Correct Answer)
E. Reduce insulin infusion rate by half

Explanation: ***Add 10% glucose infusion and continue fixed-rate insulin*** - In **Diabetic Ketoacidosis (DKA)**, the fixed-rate insulin infusion must be maintained to suppress **ketogenesis** until ketones are <0.6 mmol/L and pH >7.3, as the patient's current labs (pH 7.26, ketones 2.8 mmol/L) indicate DKA is not yet resolved. - When blood glucose drops below **14 mmol/L** (or 200 mg/dL), a **10% glucose** infusion should be added to prevent **hypoglycemia** while ensuring the insulin continues to clear the **ketosis**. *Switch to subcutaneous insulin and stop IV fluids* - Transition to **subcutaneous insulin** and stopping IV fluids are only appropriate once DKA is fully resolved, meaning pH >7.3, ketones <0.6 mmol/L, bicarbonate >15 mmol/L, and the patient is able to eat. - Prematurely stopping **IV fluids** and the insulin infusion while the patient is still acidotic and ketotic will lead to worsening **dehydration** and rebound **metabolic acidosis**. *Stop insulin infusion and commence subcutaneous insulin* - The **insulin infusion** must not be stopped until the underlying **ketonemia** and **acidosis** have resolved, as indicated by the DKA resolution criteria. - **Subcutaneous insulin** has a slower onset of action and is not effective for managing the acute metabolic derangements and high insulin requirements in active DKA. *Continue current insulin infusion rate until ketones clear* - While continuing the insulin infusion is crucial for clearing ketones, doing so without adding **glucose** once the blood sugar has fallen below **14 mmol/L** will inevitably lead to **iatrogenic hypoglycemia**. - DKA management protocols emphasize maintaining adequate glucose levels to prevent hypoglycemia while simultaneously treating ketosis with insulin. *Reduce insulin infusion rate by half* - Reducing the **Fixed-Rate Intravenous Insulin Infusion (FRIII)** is generally contraindicated as it would slow down the rate of **ketone clearance** and delay the resolution of **acidosis**. - The strategy is to maintain the insulin dose to treat the **ketosis** and adjust the glucose infusion rate to manage blood sugar levels.

Question 110: A 45-year-old woman with newly diagnosed type 2 diabetes attends for advice. Her HbA1c is 58 mmol/mol, BMI 28 kg/m², and eGFR >90 ml/min/1.73m². She has no other comorbidities. Which additional cardiovascular risk assessment is recommended at diagnosis in all patients with type 2 diabetes?

A. Exercise ECG stress test
B. Coronary artery calcium score CT
C. Lipid profile and 10-year cardiovascular risk calculation (Correct Answer)
D. Echocardiography
E. 24-hour ambulatory blood pressure monitoring

Explanation: ***Lipid profile and 10-year cardiovascular risk calculation*** - In patients newly diagnosed with **type 2 diabetes**, it is standard of care to perform a formal **lipid profile** and calculate the **10-year CV risk** (e.g., QRISK3) to guide primary prevention. - This assessment helps identify those who require **statin therapy** (typically atorvastatin 20mg) if the calculated risk score meets the threshold of **10%** or higher. *Exercise ECG stress test* - This test is not recommended for **asymptomatic** screening in newly diagnosed diabetes and has high rates of false positives in low-risk individuals. - It is reserved for patients presenting with clinical symptoms of **stable angina** or high-risk cardiac features. *Coronary artery calcium score CT* - **CACS** is used primarily as a tie-breaker in specific cases of intermediate risk but is not a routine part of the baseline diabetic workup. - Clinical guidelines prioritize **calculated risk scores** and metabolic parameters over imaging for initial risk stratification. *Echocardiography* - Routine **echocardiography** is not indicated at the time of diagnosis unless there is clinical evidence of **heart failure**, valvular disease, or **structural heart anomalies**. - While diabetes increases the risk of heart failure, it is not a cost-effective screening tool for asymptomatic patients without physical findings. *24-hour ambulatory blood pressure monitoring* - **ABPM** is useful for confirming a diagnosis of **hypertension** if clinic readings are high, but it is not a mandatory screening tool for all patients. - Initial assessment requires standard **clinic blood pressure** measurements; ABPM is reserved for suspected white-coat hypertension or diagnostic uncertainty.

Question 111: A 58-year-old man with type 2 diabetes for 11 years attends for annual review. He takes metformin and empagliflozin. HbA1c is 52 mmol/mol. Fundoscopy shows multiple dot and blot haemorrhages and hard exudates within one disc diameter of the fovea in both eyes, but visual acuity is 6/6 bilaterally. What is the classification of his diabetic retinopathy and appropriate management?

A. Mild non-proliferative retinopathy; continue annual screening
B. Moderate non-proliferative retinopathy; increase screening to 6-monthly
C. Diabetic maculopathy; urgent ophthalmology referral within 1 week (Correct Answer)
D. Severe non-proliferative retinopathy; routine ophthalmology referral
E. Proliferative retinopathy; urgent ophthalmology referral within 1 week

Explanation: ***Diabetic maculopathy; urgent ophthalmology referral within 1 week*** - The presence of **hard exudates** or haemorrhages within **one disc diameter of the fovea** defines diabetic maculopathy, a sight-threatening condition. - Even with preserved **visual acuity** (6/6), the location of these lesions necessitates **urgent ophthalmology referral** to prevent irreversible vision loss. *Mild non-proliferative retinopathy; continue annual screening* - **Mild NPDR** is characterized by microaneurysms only; the presence of **hard exudates** near the fovea signifies a more advanced and urgent condition. - Annual screening is insufficient when lesions are within the macular area, as this risks progression to **macular oedema** and vision impairment. *Moderate non-proliferative retinopathy; increase screening to 6-monthly* - While dot and blot haemorrhages can be seen in **moderate NPDR**, the critical finding here is the proximity of **hard exudates** to the fovea, which defines **maculopathy**. - Increasing screening frequency is inadequate; the patient requires active assessment for **laser therapy** or **anti-VEGF injections** to treat the maculopathy. *Severe non-proliferative retinopathy; routine ophthalmology referral* - **Severe NPDR** is diagnosed by the "4-2-1 rule" (severe haemorrhages in 4 quadrants, venous beading in 2, or intraretinal microvascular abnormalities (IRMA) in 1), which is not fully described. - A routine referral is too slow for potential maculopathy; **urgent intervention** is crucial to prevent foveal involvement and permanent vision loss. *Proliferative retinopathy; urgent ophthalmology referral within 1 week* - **Proliferative retinopathy** is characterized by the presence of **neovascularization** (new vessel formation) on the optic disc or elsewhere in the retina, which is not mentioned in the patient's fundoscopy. - While both conditions warrant urgent referral, the specific fundoscopic findings (hard exudates near the fovea) specifically point to **diabetic maculopathy** rather than proliferative changes.

Question 112: A 32-year-old woman presents with palpitations and anxiety. Examination reveals a fine tremor, warm moist skin, and a smooth, non-tender goitre. Thyroid function tests show TSH <0.05 mU/L (0.5-5.0), free T4 32 pmol/L (9-25), free T3 12.4 pmol/L (3.5-6.5). TSH receptor antibodies are positive. She is planning pregnancy in the next 6 months. What is the most appropriate initial management?

A. Carbimazole titration regime
B. Propylthiouracil (Correct Answer)
C. Carbimazole block and replace regime
D. Radioiodine therapy
E. Propranolol alone

Explanation: ***Propylthiouracil*** - **Propylthiouracil (PTU)** is the initial treatment of choice for hyperthyroidism in women who are **planning pregnancy** or are in the **first trimester**, due to a lower risk of **teratogenesis** compared to Carbimazole. - It is preferred to avoid potential Carbimazole-induced **congenital malformations** such as aplasia cutis or choanal atresia, which are linked to its use in early pregnancy. *Carbimazole titration regime* - Although a standard first-line therapy for **Graves' disease** in non-pregnant individuals, this regime is generally avoided in patients **planning pregnancy** due to its known **teratogenic potential**. - Use in early pregnancy is associated with specific defects like **aplasia cutis**, often necessitating a switch to PTU if conception occurs. *Carbimazole block and replace regime* - This regime uses high-dose antithyroid drugs to block thyroid hormone production combined with **Levothyroxine** supplementation. - The inclusion of **Levothyroxine** makes this regime unsuitable for pregnancy, as it complicates accurate assessment of fetal and maternal thyroid function and may lead to poor **fetal thyroid control**. *Radioiodine therapy* - **Radioiodine therapy** is definitively contraindicated during **pregnancy** and requires patients to delay conception for at least **6 months** post-treatment. - Given the patient's plan to conceive within the next 6 months, this option is inappropriate due to the necessary waiting period and absolute contraindication. *Propranolol alone* - **Propranolol** is effective for symptomatic control of **hyperthyroidism**, alleviating symptoms like **palpitations**, anxiety, and tremor. - However, it does not treat the underlying **thyrotoxicosis** by reducing thyroid hormone synthesis and therefore cannot be used as monotherapy for Graves' disease.

Question 113: A 69-year-old man with type 2 diabetes presents to the emergency department with confusion. His wife reports he has had diarrhoea and vomiting for 4 days. On examination, he is drowsy but rousable, blood pressure 95/60 mmHg, heart rate 105 bpm. Capillary glucose is 42.8 mmol/L. Blood tests show sodium 152 mmol/L, urea 18.4 mmol/L, creatinine 185 µmol/L, serum osmolality 348 mOsm/kg. Venous blood gas shows pH 7.36, ketones 0.4 mmol/L. What is the diagnosis?

A. Diabetic ketoacidosis
B. Hyperosmolar hyperglycaemic state (Correct Answer)
C. Euglycaemic diabetic ketoacidosis
D. Acute kidney injury with hyperglycaemia
E. Mixed DKA and HHS

Explanation: ***Hyperosmolar hyperglycaemic state*** - This diagnosis is confirmed by the combination of extreme **hyperglycaemia** (42.8 mmol/L), severe **hyperosmolality** (348 mOsm/kg), and the absence of significant **ketonemia** (0.4 mmol/L) or **acidosis** (pH 7.36). - It typically presents in elderly **type 2 diabetics** with a long history of symptoms (4 days of diarrhoea and vomiting) leading to profound **dehydration** as evidenced by hypotension and acute kidney injury. *Diabetic ketoacidosis* - Characterized by the triad of hyperglycemia, significant **ketonemia** (>3.0 mmol/L), and **metabolic acidosis** (pH <7.3), which are absent here (ketones 0.4 mmol/L, pH 7.36). - Typically presents more acutely in **type 1 diabetes** and includes symptoms like abdominal pain and Kussmaul respirations, which are not described. *Euglycaemic diabetic ketoacidosis* - Defined by the presence of **ketoacidosis** (acidosis and ketonemia) despite having **normal or only mildly elevated blood glucose** (<11 mmol/L). - This patient’s glucose levels are extremely high (42.8 mmol/L), and his **blood pH** is within the normal range, ruling out this condition. *Acute kidney injury with hyperglycaemia* - While the patient does have **acute kidney injury** (elevated urea and creatinine) and **hyperglycaemia**, these are components of the broader syndrome of HHS. - This option fails to capture the defining characteristic of severe **hyperosmolality** and the overall clinical picture of a diabetic emergency. *Mixed DKA and HHS* - This diagnosis requires meeting the diagnostic criteria for both DKA and HHS, specifically significant **ketosis** and **metabolic acidosis** occurring alongside extreme hyperosmolality. - Since the **pH is 7.36** (normal) and **ketones are 0.4 mmol/L** (below diagnostic thresholds), the criteria for the DKA component are not met.

Question 114: What is the recommended frequency for diabetic retinopathy screening in adults with type 1 or type 2 diabetes who have no evidence of retinopathy?

A. Every 6 months
B. Annually (Correct Answer)
C. Every 2 years
D. Every 3 years
E. Every 5 years

Explanation: ***Annually***- For adults with **Type 1** or **Type 2 diabetes** who show no signs of retinopathy, the standard clinical recommendation is an **annual retinal screening** to detect early microvascular changes.- **Annual screening** is crucial because diabetic retinopathy is a major cause of **preventable blindness**, and regular checks allow for timely intervention if damage begins.*Every 6 months*- **Six-month intervals** are typically reserved for patients who already have **pre-existing retinopathy** or for monitoring during **pregnancy**.- Using this frequency for patients with no evidence of disease would lead to unnecessary clinical burden without significant diagnostic gain.*Every 2 years*- While some health systems consider **biennial screening** for patients with consistently stable **glycemic control**, the current standard of care for most guidelines remains annual.- Extending the interval to **2 years** may miss rapid progression if a patient's metabolic state happens to deteriorate suddenly.*Every 3 years*- A **3-year interval** is too long and increases the risk of **proliferative retinopathy** or **macular edema** developing unnoticed between exams.- Most international specialist bodies, such as the **ADA** and **NHS**, do not support a three-year gap for initial screening phases.*Every 5 years*- Screening **every 5 years** is inadequate for the management of chronic diabetes because **microvascular complications** can progress significantly within this timeframe.- Routine eye exams for diabetics require much more frequent monitoring than the general population due to the specific risks of **hyperglycemia-induced retinal damage**.

Question 115: A 48-year-old woman presents with a 6-month history of constipation, dry skin, weight gain of 8kg, and fatigue. Blood tests show TSH 42.1 mU/L (0.5-5.0), free T4 6.2 pmol/L (9-25), and positive thyroid peroxidase antibodies. What is the most appropriate initial levothyroxine dose for this patient?

A. 100 micrograms once daily
B. 50 micrograms once daily with dose increase every 3-4 weeks (Correct Answer)
C. 25 micrograms once daily with dose increase every 4 weeks
D. 75 micrograms once daily
E. 150 micrograms loading dose then 100 micrograms daily

Explanation: ***50 micrograms once daily with dose increase every 3-4 weeks***- For adults under 65 without **cardiac disease**, an initial **Levothyroxine** dose of 50 mcg is appropriate to begin treatment and minimize adverse effects.- The dose should be **titrated** every 3-4 weeks based on **TSH levels** until the patient's TSH is within the target therapeutic range.*100 micrograms once daily*- Starting with a full replacement dose like **100 micrograms** might induce **iatrogenic hyperthyroidism** or cardiac strain in some patients, even without known cardiac disease.- This option does not mention the critical step of **gradual dose titration** and monitoring, which is essential for safe and effective management of hypothyroidism.*25 micrograms once daily with dose increase every 4 weeks*- A starting dose of **25 micrograms** is typically reserved for **elderly patients** or those with **pre-existing ischaemic heart disease** to prevent cardiac complications.- For a 48-year-old woman without known cardiac risk factors, this dose would be **sub-therapeutic** and delay achieving optimal thyroid function.*75 micrograms once daily*- **75 micrograms** is not a commonly recommended standard **initial starting dose** in clinical guidelines, which typically suggest 25, 50, or 100 mcg increments.- Like other single-dose options, it fails to include the essential component of **biochemical monitoring** and subsequent dose adjustments, which are crucial for effective treatment.*150 micrograms loading dose then 100 micrograms daily*- **Loading doses** of levothyroxine are specifically indicated only for life-threatening conditions like **Myxoedema Coma**, which is not the case for this patient.- Administering such a high initial dose to a stable patient with hypothyroidism could precipitate dangerous **thyrotoxic symptoms** or cardiac events.

Question 116: A 23-year-old woman with type 1 diabetes for 9 years presents to the emergency department with vomiting and abdominal pain. Capillary glucose is 24.6 mmol/L, ketones 4.2 mmol/L. Venous blood gas shows pH 7.18, bicarbonate 11 mmol/L, potassium 5.8 mmol/L. What is the correct initial fluid and potassium replacement strategy?

A. 0.9% sodium chloride without potassium chloride at 1000 ml/hour initially (Correct Answer)
B. 0.9% sodium chloride with 40 mmol/L potassium chloride at 500 ml/hour
C. 0.45% sodium chloride with 40 mmol/L potassium chloride at 500 ml/hour
D. Hartmann's solution without potassium at 500 ml/hour
E. 0.9% sodium chloride with 20 mmol/L potassium chloride at 1000 ml/hour

Explanation: ***0.9% sodium chloride without potassium chloride at 1000 ml/hour initially***- In **diabetic ketoacidosis (DKA)**, initial fluid resuscitation prioritizes **volume expansion** to restore perfusion and reduce counter-regulatory hormones, with **0.9% sodium chloride** given rapidly (1000 ml/hour for the first hour).- Given the patient's **hyperkalemia (K+ 5.8 mmol/L)**, adding potassium chloride to the initial fluid is contraindicated to prevent worsening **hyperkalemia**, which can lead to life-threatening arrhythmias.*0.9% sodium chloride with 40 mmol/L potassium chloride at 500 ml/hour*- Administering potassium with a serum level of **5.8 mmol/L** is dangerous and can precipitate severe **hyperkalemia**, especially before insulin has begun to shift potassium intracellularly.- An initial infusion rate of **500 ml/hour** is generally insufficient for the rapid volume repletion required in the first hour of DKA management.*0.45% sodium chloride with 40 mmol/L potassium chloride at 500 ml/hour*- **Hypotonic saline (0.45% NaCl)** is not recommended for initial DKA resuscitation as it is less effective for rapid volume expansion and carries a higher risk of **cerebral edema** due to rapid decreases in plasma osmolality.- Similar to the above, adding **potassium** when the patient is already hyperkalemic is inappropriate and risky.*Hartmann's solution without potassium at 500 ml/hour*- While balanced crystalloids like Hartmann's solution can be used, **0.9% sodium chloride** is the more commonly recommended and studied initial fluid for DKA, especially in patients who may have significant hyponatremia.- The infusion rate of **500 ml/hour** is too slow for the crucial initial fluid bolus needed to correct severe dehydration in DKA.*0.9% sodium chloride with 20 mmol/L potassium chloride at 1000 ml/hour*- Even a lower concentration of **potassium chloride (20 mmol/L)** should be withheld in the initial fluid given the patient's presenting **hyperkalemia (K+ 5.8 mmol/L)**.- Potassium replacement should only be initiated once serum potassium levels normalize or fall below 5.0-5.5 mmol/L, typically after insulin administration has begun.

Question 117: A 55-year-old woman with type 2 diabetes for 6 years presents for review. Her HbA1c is 64 mmol/mol despite maximal doses of metformin and a DPP-4 inhibitor. She has a BMI of 33 kg/m². She works as a lorry driver. eGFR is 68 ml/min/1.73m². Which is the most appropriate next step in her diabetes management?

A. Add an SGLT-2 inhibitor (Correct Answer)
B. Add pioglitazone
C. Add a GLP-1 receptor agonist
D. Add a sulphonylurea
E. Switch to basal-bolus insulin regimen

Explanation: ***Add an SGLT-2 inhibitor*** - **SGLT-2 inhibitors** are a preferred addition to triple therapy as they promote **weight loss** and have a very low risk of **hypoglycemia**, which is crucial for a **lorry driver** (Group 2 license). - The patient's **eGFR of 68 ml/min** is well within the acceptable range (typically >45 ml/min) for initiating this class of medication, which also offers **cardio-renal protective benefits**. *Add pioglitazone* - While effective for glycemic control, **pioglitazone** is associated with **weight gain** and fluid retention, which is undesirable given the patient's existing **obesity** (BMI 33). - It lacks the specific cardiovascular and renal benefits compared to SGLT-2 inhibitors, which are often prioritized in current guidelines. *Add a GLP-1 receptor agonist* - NICE guidelines typically suggest **GLP-1 receptor agonists** only if the **BMI is ≥35 kg/m²** or if insulin would have significant occupational implications due to weight. The patient's BMI is 33 kg/m². - Although she is a lorry driver, an **SGLT-2 inhibitor** is generally a more appropriate first choice in triple therapy intensification given her BMI and eGFR, due to its low hypoglycemia risk and weight loss benefits. *Add a sulphonylurea* - **Sulphonylureas** carry a significant risk of **hypoglycemia**, which poses a major safety risk and legal complication for a **lorry driver** under **DVLA regulations**. - This class often leads to **weight gain**, further complicating the management of her high BMI. *Switch to basal-bolus insulin regimen* - Transitioning to **insulin therapy** is premature as the patient has not yet exhausted appropriate **triple oral therapy** options and still has adequate renal function. - Insulin use requires strict **DVLA notification** and monitoring for commercial drivers due to the high risk of severe **hypoglycemic episodes**.

Question 118: A 64-year-old man with type 2 diabetes treated with metformin and gliclazide presents with a 4-month history of redness and swelling of his right foot. Examination reveals a warm, erythematous, swollen right foot with intact skin but a rocker-bottom deformity. Foot pulses are palpable. X-ray shows bone and joint destruction. What is the most likely diagnosis?

A. Diabetic foot osteomyelitis
B. Acute gout
C. Charcot neuroarthropathy (Correct Answer)
D. Septic arthritis
E. Cellulitis with deep vein thrombosis

Explanation: ***Charcot neuroarthropathy*** - The combination of **type 2 diabetes**, a warm, swollen foot with **intact skin**, and a classic **rocker-bottom deformity** is pathognomonic for Charcot foot. - **Palpable pulses** and extensive **bone and joint destruction** on X-ray in the absence of an ulcer help differentiate this from infectious or ischemic processes. *Diabetic foot osteomyelitis* - Usually occurs secondary to a **chronic skin ulcer** which acts as a portal for infection, whereas this patient has **intact skin**. - While X-rays show bone destruction, the clinical presentation of a **midfoot collapse** over 4 months without systemic illness favors a neuropathic over an infectious etiology. *Acute gout* - Typically presents as an **acute, exquisitely painful** episode localized to a single joint, most commonly the **first metatarsophalangeal joint**. - It does not cause the characteristic **rocker-bottom deformity** or the chronic, progressive bone destruction seen in this patient's midfoot. *Septic arthritis* - Presents with **acute onset** of severe pain, fever, and systemic toxicity, which are inconsistent with a **4-month history**. - Joint aspiration would typically reveal a **high white cell count** and organisms, rather than the structural architectural collapse seen here. *Cellulitis with deep vein thrombosis* - **Cellulitis** causes localized redness and warmth but would not result in **radiographic bone destruction** or structural foot deformity. - **Deep vein thrombosis** presents with calf swelling and pain but does not explain the **chronic joint destruction** and palpable foot pulses documented.

Question 119: A 17-year-old girl presents to the emergency department with a 3-week history of polyuria, polydipsia, and 6kg weight loss. She appears thin and mildly dehydrated. Blood glucose is 18.2 mmol/L. Urinalysis shows glucose 3+ and ketones 1+. Venous blood gas shows pH 7.38, bicarbonate 22 mmol/L. What is the most appropriate initial management?

A. Start basal-bolus subcutaneous insulin regimen and provide diabetes education (Correct Answer)
B. Give stat dose of intramuscular insulin and reassess in 2 hours
C. Commence oral metformin 500mg twice daily
D. Admit for observation and repeat blood tests in 6 hours
E. Start variable rate intravenous insulin infusion immediately

Explanation: ***Start basal-bolus subcutaneous insulin regimen and provide diabetes education*** - The patient presents with classic symptoms of **Type 1 Diabetes Mellitus** (weight loss, polyuria, polydipsia) but does not meet the criteria for **Diabetic Ketoacidosis (DKA)** as the pH and bicarbonate are within normal limits. - In the absence of DKA, the gold standard for management is starting a **basal-bolus subcutaneous insulin** regimen and initiating **structured education** and specialist team follow-up. *Give stat dose of intramuscular insulin and reassess in 2 hours* - **Intramuscular insulin** is not a standard route for the chronic management or stabilization of new-onset Type 1 diabetes and lacks a **sustained effect**. - Relying on a single stat dose without a long-term **basal-bolus plan** fails to address the underlying total insulin deficiency and risks glycemic rebound. *Commence oral metformin 500mg twice daily* - This patient likely has **Type 1 Diabetes**, characterized by absolute insulin deficiency, which requires **replacement insulin**, not oral biguanides. - **Metformin** is the first-line treatment for Type 2 diabetes and would be ineffective and potentially dangerous as monotherapy in this clinical scenario. *Admit for observation and repeat blood tests in 6 hours* - Delaying treatment in a patient with **significant hyperglycemia** and ketonuria increases the risk of progression to **life-threatening DKA**. - While observation is necessary, it must be accompanied by the active initiation of **insulin therapy** and fluid rehydration if indicated. *Start variable rate intravenous insulin infusion immediately* - **Variable rate intravenous insulin (VRIII)** is indicated for patients with **DKA**, surgical patients, or those unable to eat; it is not required for stable patients with normal pH and bicarbonate. - Using intravenous insulin in a stable patient is unnecessarily invasive and complicates the transition to a **long-term subcutaneous regimen**.

Question 120: A 26-year-old woman with type 1 diabetes is 16 weeks pregnant. Her pre-pregnancy HbA1c was 51 mmol/mol. She monitors blood glucose closely with targets of 5.3 mmol/L fasting and <7.8 mmol/L 1-hour post-prandial. Despite good compliance, she has experienced three episodes of severe hypoglycaemia requiring assistance in the past 4 weeks. Her current insulin regimen is insulin detemir 18 units morning and 14 units evening, with insulin aspart before meals. What change in her management approach is most appropriate?

A. Reduce basal insulin doses by 10-20% and accept slightly higher fasting glucose readings to prevent hypoglycaemia
B. Switch to continuous subcutaneous insulin infusion (pump therapy) to reduce hypoglycaemia risk
C. Continue current regimen as hypoglycaemia is expected in first and second trimester with tight control
D. Relax glucose targets to fasting <6.0 mmol/L and 1-hour post-prandial <8.5 mmol/L to reduce hypoglycaemia frequency (Correct Answer)
E. Add continuous glucose monitoring with hypoglycaemia alerts but maintain current targets and insulin doses

Explanation: ***Relax glucose targets to fasting <6.0 mmol/L and 1-hour post-prandial <8.5 mmol/L to reduce hypoglycaemia frequency*** - In cases of **recurrent severe hypoglycaemia** in pregnancy, **NICE guidelines** recommend relaxing blood glucose targets (fasting <6.0 mmol/L and 1-hour post-prandial <8.5 mmol/L) to ensure maternal safety. - While tight control is vital to prevent **macrosomia** and **congenital abnormalities**, problematic hypoglycaemia takes clinical priority and requires target adjustment. *Reduce basal insulin doses by 10-20% and accept slightly higher fasting glucose readings to prevent hypoglycaemia* - Adjusting insulin doses alone without formally **revising glucose targets** fails to address the underlying goal of treatment modifications in these patients. - Reducing insulin arbitrarily may lead to **hyperglycaemic peaks** if clinical targets are not systematically relaxed and monitored. *Switch to continuous subcutaneous insulin infusion (pump therapy) to reduce hypoglycaemia risk* - **CSII (Pump therapy)** can improve glycaemic variability, but it is not the immediate first-line response to severe hypoglycaemia when current **targets are too aggressive**. - Initiating pump therapy requires time for training and adjustment, whereas **relaxing targets** provides an immediate safety intervention. *Continue current regimen as hypoglycaemia is expected in first and second trimester with tight control* - While insulin sensitivity changes during pregnancy, **severe hypoglycaemia requiring assistance** is never an "expected" or acceptable outcome. - Failing to act on recurrent severe episodes puts the patient at risk of **hypoglycaemia unawareness** and life-threatening events. *Add continuous glucose monitoring with hypoglycaemia alerts but maintain current targets and insulin doses* - **CGM** is useful for identifying patterns, but it does not fix the fundamental issue of **targets being set too low** for this specific patient's physiology. - Alerts may reduce the severity of episodes, but they do nothing to reduce the **frequency of hypoglycaemia** if the physiological targets remain overly tight.

Question 121: A 33-year-old woman with Graves' disease has been taking carbimazole 20mg once daily for 6 months. She now presents with a 2-day history of sore throat, fever, and general malaise. Examination shows temperature 38.4°C, pulse 92 bpm, and pharyngeal erythema. What is the most appropriate immediate management?

A. Continue carbimazole and prescribe oral penicillin V for pharyngitis
B. Stop carbimazole immediately and arrange urgent full blood count (Correct Answer)
C. Reduce carbimazole dose to 10mg daily and review in 1 week
D. Continue carbimazole, arrange routine blood tests, and prescribe symptomatic treatment
E. Stop carbimazole and commence propylthiouracil as alternative antithyroid drug

Explanation: ***Stop carbimazole immediately and arrange urgent full blood count***- **Agranulocytosis** is a rare but life-threatening side effect of **carbimazole**, and a sore throat with fever in a patient on this medication must be treated as a medical emergency.- The drug must be **stopped immediately**, and an **urgent Full Blood Count (FBC)** is required to check for a **neutrophil count** (typically <0.5 x 10⁹/L in agranulocytosis).*Continue carbimazole and prescribe oral penicillin V for pharyngitis*- Prescribing antibiotics without checking the blood count is dangerous as it may mask **sepsis** while the underlying **bone marrow suppression** continues.- Carbimazole must not be continued if there is any clinical suspicion of **agranulocytosis** until the FBC result is known.*Reduce carbimazole dose to 10mg daily and review in 1 week*- **Agranulocytosis** is an idiosyncratic reaction, not strictly dose-dependent; merely reducing the dose does not eliminate the risk of fatal infection.- Waiting one week for review is inappropriate as **neutropenic sepsis** can progress rapidly and lead to death within days.*Continue carbimazole, arrange routine blood tests, and prescribe symptomatic treatment*- Routine blood tests take too long; **urgent medical attention** is required to prevent severe infection in an immunocompromised patient.- Symptomatic treatment alone fails to address the potentially lethal drop in **white blood cells** caused by the medication.*Stop carbimazole and commence propylthiouracil as alternative antithyroid drug*- **Propylthiouracil** (PTU) also carries a significant risk of agranulocytosis and frequently shows **cross-reactivity** with carbimazole-induced bone marrow suppression.- Switching to another thionamide is contraindicated if the patient has experienced a severe reaction like agranulocytosis with the first drug.

Question 122: A 71-year-old woman with type 2 diabetes for 18 years, hypertension, and previous myocardial infarction attends for medication review. Current medications include metformin 1g twice daily, empagliflozin 10mg once daily, and atorvastatin 80mg once daily. Her HbA1c is 69 mmol/mol (target <53 mmol/mol), eGFR is 42 ml/min, and urinary albumin:creatinine ratio is 45 mg/mmol. Blood pressure is 142/86 mmHg. Considering her cardiovascular and renal risk, what is the most appropriate addition to optimize her diabetes management?

A. Add sitagliptin 50mg once daily (DPP-4 inhibitor) dose-adjusted for renal function
B. Add semaglutide (GLP-1 receptor agonist) with proven cardiovascular benefit (Correct Answer)
C. Increase empagliflozin to 25mg once daily for enhanced glucose lowering
D. Add gliclazide MR 30mg once daily for additional glucose control
E. Add pioglitazone 15mg once daily given cardiovascular disease

Explanation: ***Add semaglutide (GLP-1 receptor agonist) with proven cardiovascular benefit*** - In patients with **established cardiovascular disease** (previous MI) and CKD, a **GLP-1 receptor agonist** with proven benefit is recommended to reduce the risk of major adverse cardiovascular events (MACE). - Semaglutide is safe and effective to use at an **eGFR of 42 ml/min**, providing both glycaemic control and significant **cardioprotective and renoprotective** benefits. *Add sitagliptin 50mg once daily (DPP-4 inhibitor) dose-adjusted for renal function* - While sitagliptin is weight-neutral and safe in renal impairment, it has demonstrated **cardiovascular neutrality** rather than the superiority needed for this high-risk patient. - **GLP-1 agonists** are preferred over DPP-4 inhibitors in this clinical scenario due to the patient's history of **myocardial infarction**. *Increase empagliflozin to 25mg once daily for enhanced glucose lowering* - The **glucose-lowering efficacy** of SGLT2 inhibitors decreases significantly as **eGFR** declines below 45-60 ml/min; therefore, increasing the dose is unlikely to reach the HbA1c target. - The **cardiovascular and renal protection** offered by SGLT2 inhibitors is already being achieved at the 10mg dose and is not significantly enhanced by up-titration. *Add gliclazide MR 30mg once daily for additional glucose control* - Sulfonylureas like gliclazide increase the risk of **hypoglycemia** and weight gain, which is undesirable in a patient with **cardiovascular disease**. - They provide no specific **cardiovascular or renal protection**, making them a lower-priority choice compared to GLP-1 receptor agonists. *Add pioglitazone 15mg once daily given cardiovascular disease* - Pioglitazone is associated with **fluid retention** and an increased risk of **heart failure**, which is a significant concern in a patient with a previous **myocardial infarction**. - Although it has some secondary stroke prevention data, the risk-to-benefit ratio in **chronic kidney disease** and ischemic heart disease is less favorable than GLP-1 therapy.

Question 123: A 38-year-old woman presents with a thyroid nodule. Ultrasound shows a 2.8cm solid hypoechoic nodule with irregular margins, microcalcifications, and taller-than-wide shape. There is no lymphadenopathy. Thyroid function tests are normal. Fine needle aspiration cytology is reported as 'Thy3f - follicular lesion/follicular neoplasm.' Which factor most significantly increases the probability of malignancy in this scenario?

A. The size of the nodule being greater than 2cm diameter
B. The Thy3f cytology result indicating indeterminate follicular lesion
C. The ultrasound features showing microcalcifications and irregular margins (Correct Answer)
D. The patient's age being under 40 years old
E. The presence of a solid rather than cystic nodule

Explanation: ***The ultrasound features showing microcalcifications and irregular margins***- High-risk ultrasound features such as **microcalcifications**, **irregular margins**, and a **taller-than-wide shape** are highly specific for thyroid malignancy, particularly **papillary thyroid carcinoma**.- These features significantly increase the **U-classification** (e.g., U4/U5 or TIRADS 4/5), indicating a high probability of cancer regardless of nodule size or a Thy3f cytology result.*The size of the nodule being greater than 2cm diameter*- While larger nodules (especially >4cm) may have a slightly increased risk, **size alone** (2.8cm in this case) is not as strong a predictor of malignancy as specific morphological characteristics.- Many large nodules are **benign multinodular goiters**, whereas small nodules with suspicious ultrasound signs are more concerning.*The Thy3f cytology result indicating indeterminate follicular lesion*- A **Thy3f (follicular neoplasm/suspicious for follicular neoplasm)** result has a malignancy risk of approximately **15-30%**, which is significant but less predictive than highly suspicious ultrasound morphology.- Cytology cannot definitively distinguish between a **follicular adenoma** (benign) and a **follicular carcinoma** (malignant), often necessitating diagnostic surgery rather than confirming malignancy.*The patient's age being under 40 years old*- While extremes of age (<20 or >60) are generally considered higher risk, being **under 40** (the patient is 38) is not as strong a predictor of malignancy compared to ultrasound characteristics.- In differentiated thyroid cancer, younger age is often associated with a **better prognosis** and lower mortality rates.*The presence of a solid rather than cystic nodule*- **Solid nodules** are more frequently malignant than purely cystic ones, but many benign nodules are also solid.- This feature is **less specific** for malignancy compared to the highly suspicious combination of microcalcifications and irregular margins seen on ultrasound.

Question 124: A 54-year-old man with type 2 diabetes presents with a painless ulcer on the plantar aspect of his right first metatarsal head. The ulcer probes to bone. The surrounding skin is warm with mild erythema extending 2cm from the ulcer edge. He is systemically well with temperature 37.2°C. Foot pulses are palpable. X-ray shows soft tissue swelling but no obvious bony changes. What is the most appropriate next step in management?

A. Arrange MRI of the foot to assess for osteomyelitis and commence intravenous antibiotics (Correct Answer)
B. Commence oral flucloxacillin and arrange urgent vascular surgery referral
C. Debride the ulcer, take wound swab for culture, and commence oral broad-spectrum antibiotics
D. Refer for urgent surgical debridement and amputation of affected toe
E. Apply offloading device and arrange routine podiatry follow-up in 2 weeks

Explanation: ***Arrange MRI of the foot to assess for osteomyelitis and commence intravenous antibiotics*** - The **probe-to-bone test** is a highly accurate clinical sign for diagnosing **osteomyelitis** in diabetic foot ulcers, indicating the need for aggressive management. - **MRI** is the gold standard for diagnosing osteomyelitis, offering superior sensitivity and specificity in detecting early **bone marrow edema** and infection before X-ray changes become apparent. *Commence oral flucloxacillin and arrange urgent vascular surgery referral* - **Oral antibiotics** are typically insufficient for confirmed or highly suspected osteomyelitis, which requires parenteral (intravenous) administration for adequate bone penetration. - An **urgent vascular surgery referral** is not immediately indicated as foot pulses are palpable, suggesting that significant macrovascular ischemia is not the primary issue at this stage. *Debride the ulcer, take wound swab for culture, and commence oral broad-spectrum antibiotics* - **Wound swabs** from chronic ulcers are often contaminated with colonizing bacteria and may not accurately reflect the causative organisms of **deep bone infection**, making a bone biopsy more reliable. - Starting **oral broad-spectrum antibiotics** without confirming osteomyelitis and with limited penetration for bone infection is suboptimal given the high clinical suspicion. *Refer for urgent surgical debridement and amputation of affected toe* - **Amputation** is a definitive treatment and typically considered after failed conservative management or in cases of severe, irreversible tissue necrosis or limb-threatening infection, which is not described here. - While **surgical debridement** may be necessary, it's usually performed after confirming osteomyelitis with imaging and initiating appropriate antibiotic therapy. *Apply offloading device and arrange routine podiatry follow-up in 2 weeks* - While **offloading** is crucial for ulcer healing, waiting two weeks for follow-up is inappropriate and potentially dangerous given the strong suspicion of **osteomyelitis**, which requires urgent intervention. - This approach significantly delays definitive diagnosis and treatment, increasing the risk of **infection progression** and potential complications.

Question 125: A 47-year-old woman presents to the emergency department with confusion and agitation. She has a history of type 2 diabetes. Her capillary glucose is 48.2 mmol/L. Blood tests show sodium 152 mmol/L, potassium 4.8 mmol/L, urea 18.2 mmol/L, creatinine 156 μmol/L, and serum osmolality 348 mOsm/kg. Venous blood gas shows pH 7.38, bicarbonate 22 mmol/L. Urinalysis shows glucose 4+ but ketones are negative. What is the most critical difference in initial fluid management compared to diabetic ketoacidosis?

A. Colloid solutions should be used initially due to severe hypovolaemia
B. 0.9% sodium chloride should be avoided; 0.45% sodium chloride is preferred initially
C. Fluid replacement should be more gradual over 48 hours rather than 24 hours to avoid cerebral oedema (Correct Answer)
D. Potassium supplementation should be started immediately regardless of serum level
E. Larger fluid volumes of 1000 ml/hour are required due to more severe dehydration

Explanation: ***Fluid replacement should be more gradual over 48 hours rather than 24 hours to avoid cerebral oedema*** - In **Hyperosmolar Hyperglycaemic State (HHS)**, patients have significant **hyperosmolality** and a large fluid deficit, often greater than in DKA. - Rapid correction of this high osmolality can lead to dangerous **cerebral oedema**, necessitating a slower, more controlled rehydration strategy over **48 hours**. *Colloid solutions should be used initially due to severe hypovolaemia* - **Crystalloids**, particularly **0.9% sodium chloride**, are the standard initial fluid of choice for restoring intravascular volume in HHS. - **Colloid solutions** are not routinely recommended for initial resuscitation in HHS unless there are specific indications like profound shock unresponsive to crystalloids. *0.9% sodium chloride should be avoided; 0.45% sodium chloride is preferred initially* - **Isotonic 0.9% sodium chloride** is essential for initial volume expansion and improving renal perfusion in HHS. - **Hypotonic 0.45% sodium chloride** is typically introduced later in treatment once the patient is hemodynamically stable and serum sodium is either stable or decreasing too slowly. *Potassium supplementation should be started immediately regardless of serum level* - Potassium management in HHS is similar to DKA, where supplementation is guided by **serum potassium levels** and renal function. - With a serum potassium of 4.8 mmol/L, immediate aggressive supplementation regardless of the level is not indicated and could cause dangerous **hyperkalaemia**. *Larger fluid volumes of 1000 ml/hour are required due to more severe dehydration* - While patients with HHS are severely dehydrated, aggressive fluid rates like **1000 ml/hour** are generally reserved for those in **hypovolaemic shock**. - The primary goal in HHS is a **slower, more controlled rate** of fluid administration to safely correct hyperosmolality and avoid **cerebral oedema** and fluid overload.

Question 126: A 59-year-old man with type 2 diabetes for 8 years presents for diabetic eye screening. Fundoscopy reveals multiple microaneurysms and dot-blot haemorrhages in both eyes, with venous beading and intraretinal microvascular abnormalities in the left eye. No cotton wool spots or new vessels are seen. Visual acuity is 6/9 in both eyes. What is the most appropriate classification and management of this retinopathy?

A. Moderate non-proliferative retinopathy; routine annual screening adequate
B. Severe non-proliferative retinopathy; urgent ophthalmology referral within 2 weeks (Correct Answer)
C. Moderate non-proliferative retinopathy; ophthalmology referral within 6-13 weeks
D. Proliferative retinopathy; immediate same-day ophthalmology referral required
E. Mild non-proliferative retinopathy; repeat screening in 6 months

Explanation: ***Severe non-proliferative retinopathy; urgent ophthalmology referral within 2 weeks***- The presence of **venous beading** and **intraretinal microvascular abnormalities (IRMA)** in the left eye, alongside microaneurysms and dot-blot hemorrhages, fulfills the criteria for severe non-proliferative diabetic retinopathy (NPDR) under the **4-2-1 rule**.- Severe NPDR has a high risk of progression to **proliferative retinopathy** and warrants an urgent **ophthalmology referral** within 2 weeks for close monitoring and potential intervention like panretinal photocoagulation to prevent vision loss.*Moderate non-proliferative retinopathy; routine annual screening adequate*- Moderate NPDR is characterized by multiple **microaneurysms** and **dot-blot hemorrhages**, but it lacks the high-risk features of **venous beading** or **IRMA** observed in this patient.- Routine **annual screening** is inadequate for severe NPDR, which requires prompt specialist assessment due to its elevated risk of progression.*Moderate non-proliferative retinopathy; ophthalmology referral within 6-13 weeks*- The presence of **IRMA** and **venous beading** exceeds the diagnostic criteria for moderate NPDR, making this classification inaccurate.- A referral timeframe of **6-13 weeks** is typically reserved for stable moderate NPDR or maculopathy without immediate sight-threatening features, which does not apply to this patient's condition.*Proliferative retinopathy; immediate same-day ophthalmology referral required*- **Proliferative retinopathy (PDR)** is defined by the presence of **neovascularization** (new vessels on the disc or elsewhere) or **pre-retinal/vitreous hemorrhage**, which are explicitly noted as absent in this case.- An **immediate same-day ophthalmology referral** is typically reserved for acute complications of PDR, such as acute vitreous hemorrhage or tractional retinal detachment, which are not present here.*Mild non-proliferative retinopathy; repeat screening in 6 months*- **Mild NPDR** is characterized by the presence of only **microaneurysms**, without other significant retinal changes like hemorrhages, cotton wool spots, or IRMA/venous beading.- The finding of **venous beading** and **IRMA** signifies substantial retinal ischemia, making a mild classification and a **6-month follow-up** inadequate and potentially harmful.

Question 127: A 22-year-old woman with type 1 diabetes for 10 years attends for review. She uses an insulin pump with continuous glucose monitoring. Her glucose profile shows frequent nocturnal hypoglycaemia at 3-4am, followed by elevated glucose readings at 7am (ranging 12-16 mmol/L). Her HbA1c is 68 mmol/mol. What is the most likely explanation for the morning hyperglycaemia?

A. Dawn phenomenon due to physiological nocturnal growth hormone and cortisol surge
B. Somogyi effect with counter-regulatory response to nocturnal hypoglycaemia (Correct Answer)
C. Insufficient basal insulin throughout the night requiring overall rate increase
D. Dietary protein from evening meal causing delayed glucose rise
E. Psychological insulin restriction due to fear of hypoglycaemia

Explanation: ***Somogyi effect with counter-regulatory response to nocturnal hypoglycaemia*** - The **Somogyi effect** is characterized by an initial episode of **nocturnal hypoglycaemia** (as documented at 3-4 am) which triggers a counter-regulatory response, involving the release of hormones like **glucagon, cortisol, and growth hormone**. - This hormonal surge leads to **rebound hyperglycaemia** in the morning (elevated glucose readings at 7 am), perfectly explaining the patient's observed glucose profile. *Dawn phenomenon due to physiological nocturnal growth hormone and cortisol surge* - The **Dawn phenomenon** also results in morning hyperglycaemia but is distinctly characterized by the **absence of preceding hypoglycaemia** during the night. - Glucose levels would typically show a **gradual rise** from stable or slightly elevated nocturnal levels, not a dip to 3-4 mmol/L followed by a surge. *Insufficient basal insulin throughout the night requiring overall rate increase* - **Insufficient basal insulin** would typically lead to a **progressive and sustained rise** in glucose levels throughout the night, without any preceding hypoglycaemia. - Increasing basal insulin in this scenario would be inappropriate as it would likely **exacerbate the nocturnal hypoglycaemia** at 3-4 am, leading to potential severe adverse events. *Dietary protein from evening meal causing delayed glucose rise* - While high **dietary protein** or fat can cause a delayed postprandial glucose increase, it typically manifests within a few hours of the meal and **would not explain** the observed pattern of nocturnal **hypoglycaemia** followed by a sharp rebound. - This mechanism does not account for the distinct dip in glucose levels that precedes the morning hyperglycaemia. *Psychological insulin restriction due to fear of hypoglycaemia* - **Psychological insulin restriction** (under-dosing insulin) would typically lead to **persistently elevated** glucose levels throughout the night and morning, as insufficient insulin is consistently administered. - This explanation does not fit the pattern of distinct **nocturnal hypoglycaemia** followed by a counter-regulatory rise, which suggests a physiological rather than behavioral issue.

Question 128: A 76-year-old woman with type 2 diabetes, chronic kidney disease stage 4 (eGFR 22 ml/min), and heart failure is reviewed in clinic. Her current medications include metformin 500mg twice daily, gliclazide 80mg twice daily, and bisoprolol 2.5mg once daily. Her HbA1c is 75 mmol/mol and she has had two episodes of hypoglycaemia in the past month. What is the most appropriate modification to her diabetes management?

A. Stop metformin; continue gliclazide at reduced dose of 40mg twice daily
B. Stop metformin and gliclazide; commence SGLT2 inhibitor for renal and cardiac benefits
C. Stop metformin and gliclazide; commence DPP-4 inhibitor with dose adjustment for renal function (Correct Answer)
D. Continue current therapy but reduce gliclazide to 40mg once daily only
E. Stop metformin and gliclazide; commence insulin therapy for better glycaemic control

Explanation: ***Stop metformin and gliclazide; commence DPP-4 inhibitor with dose adjustment for renal function*** - **Metformin** is contraindicated in patients with an **eGFR <30 ml/min**, as seen in this patient with **CKD stage 4 (eGFR 22 ml/min)**, due to the significant risk of **lactic acidosis**. - **Gliclazide**, a sulfonylurea, should be stopped due to the patient's history of **hypoglycemia** and **advanced CKD**, which increases the risk of drug accumulation and further hypoglycemic events. **DPP-4 inhibitors** are a suitable alternative as they have a **low risk of hypoglycemia** and are safe in CKD, requiring dose adjustment (except linagliptin). *Stop metformin; continue gliclazide at reduced dose of 40mg twice daily* - While stopping metformin is appropriate, continuing **gliclazide** (a sulfonylurea) at any dose is risky given the patient's **eGFR of 22 ml/min** and recent **hypoglycemia**, as it remains a high-risk medication for severe hypoglycemia in this context. - The reduced renal clearance of gliclazide in **CKD stage 4** means that even a lower dose still carries an unacceptable risk of drug accumulation and recurrent hypoglycemic episodes. *Stop metformin and gliclazide; commence SGLT2 inhibitor for renal and cardiac benefits* - Most **SGLT2 inhibitors** are generally not initiated for **glycemic control** when the **eGFR is <30 ml/min** due to significantly reduced glucose-lowering efficacy at this stage of kidney disease. - Although SGLT2 inhibitors provide **cardiac and renal protection**, they would be insufficient to adequately address the patient's **HbA1c of 75 mmol/mol** and achieve satisfactory glycemic control in this specific clinical scenario. *Continue current therapy but reduce gliclazide to 40mg once daily only* - Continuing **metformin** with an **eGFR of 22 ml/min (CKD stage 4)** is a major safety breach and strongly contraindicated due to the high risk of **lactic acidosis**. - This option fails to address the contraindication of metformin and only partially mitigates the risk of hypoglycemia from gliclazide, which should ideally be discontinued entirely. *Stop metformin and gliclazide; commence insulin therapy for better glycaemic control* - While insulin can effectively lower blood glucose, commencing **insulin therapy** significantly increases the risk of further **hypoglycemic episodes**, which the patient has already experienced recently. - **DPP-4 inhibitors** offer a safer, less complex, and less invasive initial therapeutic modification with a lower risk of hypoglycemia compared to insulin, especially in an elderly patient with renal impairment.

Question 129: A 41-year-old woman presents with a 3-month history of anxiety, tremor, heat intolerance, and weight loss of 6 kg. Examination reveals a pulse of 104 bpm, fine tremor, and a smooth, non-tender, symmetrically enlarged thyroid gland with no nodules. TSH is <0.01 mU/L and free T4 is 38 pmol/L. TPO antibodies are negative. What is the most appropriate next investigation to determine the underlying cause?

A. TSH receptor antibodies (TRAb) measurement
B. Fine needle aspiration cytology of the thyroid gland
C. Thyroid ultrasound scan to assess gland vascularity and nodules
D. Thyroid uptake scan with radioactive iodine or technetium (Correct Answer)
E. Repeat thyroid function tests in 6 weeks to confirm persistent hyperthyroidism

Explanation: ***Thyroid uptake scan with radioactive iodine or technetium*** - A **thyroid uptake scan** is the most appropriate next step to differentiate between functional causes like **Graves' disease** (diffuse high uptake) and inflammatory causes like **thyroiditis** (low/absent uptake). - In this patient with **overt hyperthyroidism** and a smooth goiter, determining if there is *de novo* hormone synthesis or release of preformed hormone is critical for guiding therapy. *TSH receptor antibodies (TRAb) measurement* - While **TRAb** is highly specific for **Graves' disease**, a negative result would still require further investigation to differentiate other causes of thyrotoxicosis, such as thyroiditis. - An **uptake scan** provides broader diagnostic utility by assessing the *functional activity* of the thyroid gland, which is essential to distinguish between causes of hyperthyroidism. *Fine needle aspiration cytology of the thyroid gland* - **Fine needle aspiration (FNA)** is used to evaluate for **malignancy** in suspicious thyroid nodules and is not indicated for a smooth, symmetrically enlarged thyroid without nodules. - FNA has no role in the diagnosis of **hyperthyroidism** or differentiating between the various causes of thyrotoxicosis. *Thyroid ultrasound scan to assess gland vascularity and nodules* - **Ultrasound** is excellent for detecting **nodal anatomy** and overall gland structure but is less definitive than an uptake scan for assessing the *biochemical function* of the thyroid tissue. - Although increased **vascularity (Doppler)** can suggest Graves' disease, it is generally considered a secondary modality to nuclear medicine scans for definitively categorizing the etiology of thyrotoxicosis. *Repeat thyroid function tests in 6 weeks to confirm persistent hyperthyroidism* - Repeating **thyroid function tests** would unnecessarily delay treatment for a patient who is already **symptomatic** with significantly elevated **free T4** and suppressed **TSH**. - The diagnosis of **thyrotoxicosis** is already established; the current clinical priority is identifying the specific **underlying cause** to start appropriate management.

Question 130: A 35-year-old man with type 1 diabetes presents to the emergency department with vomiting and abdominal pain. Blood glucose is 22.4 mmol/L, venous pH 7.28, bicarbonate 14 mmol/L, and ketones 4.2 mmol/L. He is alert and orientated. He weighs 70 kg. Following initial fluid resuscitation with 0.9% sodium chloride, what is the most appropriate initial insulin regimen?

A. Fixed rate intravenous insulin infusion at 0.1 units/kg/hour (7 units/hour) (Correct Answer)
B. Intravenous insulin bolus of 10 units followed by 6 units/hour infusion
C. Subcutaneous insulin aspart 15 units immediately then hourly blood glucose monitoring
D. Fixed rate intravenous insulin infusion at 0.05 units/kg/hour (3.5 units/hour)
E. Continue usual subcutaneous insulin and add intravenous insulin at 2 units/hour

Explanation: ***Fixed rate intravenous insulin infusion at 0.1 units/kg/hour (7 units/hour)***- This is the **standard initial management** for **Diabetic Ketoacidosis (DKA)**, as per **Joint British Diabetes Societies (JBDS)** guidelines, focusing on reversal of acidosis and ketogenesis.- The dose of **0.1 units/kg/hour** (7 units/hour for a 70 kg patient) is specifically calculated to effectively **suppress ketogenesis**, resolve acidosis, and gradually lower blood glucose by a target of **3 mmol/L/hour**.*Intravenous insulin bolus of 10 units followed by 6 units/hour infusion*- **Insulin boluses** are generally **not recommended** in DKA management, as they can increase the risk of **hypokalemia** and potentially **cerebral edema**, especially in children.- The priority is a steady, controlled reduction in glucose and ketones achieved through a continuous infusion, rather than a rapid and potentially dangerous drop.*Subcutaneous insulin aspart 15 units immediately then hourly blood glucose monitoring*- **Subcutaneous insulin** is **contraindicated** in the initial management of DKA due to **poor peripheral perfusion** and dehydration, leading to unpredictable absorption and delayed action.- **Intravenous insulin** is mandatory to ensure rapid onset of action, reliable delivery, and the ability to immediately titrate or stop delivery if necessary.*Fixed rate intravenous insulin infusion at 0.05 units/kg/hour (3.5 units/hour)*- A fixed-rate infusion of **0.05 units/kg/hour** is generally considered **insufficient** to adequately suppress the high levels of counter-regulatory hormones and stop **ketone production** in typical DKA.- This lower rate might be considered in very specific circumstances, such as in patients with extreme **insulin sensitivity** or children, but the standard adult starting dose is higher.*Continue usual subcutaneous insulin and add intravenous insulin at 2 units/hour*- While **long-acting basal insulin** can be continued in some DKA protocols, **short-acting subcutaneous insulin** must be stopped once a fixed-rate intravenous infusion is commenced to avoid insulin stacking.- An additional **intravenous insulin** rate of only 2 units/hour is far too low to adequately address the metabolic requirements needed to switch off **lipolysis** and ketogenesis in an acute DKA presentation for a 70 kg patient.

Question 131: A 29-year-old woman with type 1 diabetes for 15 years is planning pregnancy. Her current HbA1c is 64 mmol/mol. She takes insulin glargine and insulin aspart, and also takes ramipril 5mg daily for microalbuminuria. What is the most important medication change required before conception?

A. Switch from insulin glargine to NPH insulin as it has better pregnancy safety data
B. Discontinue ramipril and commence alternative blood pressure medication if needed (Correct Answer)
C. Add metformin to improve glycaemic control and reduce insulin requirements
D. Change to twice-daily mixed insulin regimen for more stable glucose control
E. Increase insulin doses by 50% in anticipation of increased requirements in pregnancy

Explanation: ***Discontinue ramipril and commence alternative blood pressure medication if needed*** - **ACE inhibitors** like **ramipril** are strictly **contraindicated** in pregnancy due to their association with **fetal renal dysgenesis**, skull hypoplasia, and **oligohydramnios**. - Women planning pregnancy must switch to safer alternatives such as **labetalol**, **nifedipine**, or **methyldopa** before conception to prevent teratogenicity. *Switch from insulin glargine to NPH insulin as it has better pregnancy safety data* - Modern **long-acting insulin analogues** like **glargine** and **detemir** are now considered safe for use during pregnancy according to major clinical guidelines. - Switching to **NPH** is not a priority and may destabilize glycemic control in a patient already established on a stable basal-bolus regimen. *Add metformin to improve glycaemic control and reduce insulin requirements* - While **metformin** is used in Type 2 diabetes or GDM, it is not standard management for **Type 1 diabetes** preconception care. - The primary focus for improving her **HbA1c** should be optimizing her established **basal-bolus insulin** doses and frequent monitoring. *Change to twice-daily mixed insulin regimen for more stable glucose control* - **Biphasic (mixed) insulin** regimens generally provide less flexibility and poorer glycemic control compared to **basal-bolus** regimens in Type 1 diabetes. - Maintaining a **basal-bolus** or **insulin pump** therapy is preferred during pregnancy to achieve tight glycemic targets safely. *Increase insulin doses by 50% in anticipation of increased requirements in pregnancy* - Insulin requirements typically **decrease** in the first trimester before increasing significantly in the second and third trimesters. - Prophylactically increasing doses pre-conception would cause dangerous **hypoglycemia**; doses should be adjusted reactively based on frequent blood glucose monitoring.

Question 132: A 68-year-old woman with type 2 diabetes for 12 years presents with a 6-month history of progressive numbness and burning pain in both feet, worse at night. Examination reveals reduced pin-prick sensation to mid-calf bilaterally and absent ankle reflexes. Vibration sense is reduced. Monofilament testing shows reduced sensation at multiple plantar sites. What is the most appropriate explanation for these findings?

A. These findings represent early diabetic neuropathy affecting only small nerve fibres
B. The sensory loss pattern indicates peripheral vascular disease rather than neuropathy
C. The clinical presentation demonstrates mixed small and large fibre diabetic neuropathy (Correct Answer)
D. Absent ankle reflexes alone confirm the diagnosis without need for further assessment
E. The symptoms are likely due to vitamin B12 deficiency from metformin therapy

Explanation: ***The clinical presentation demonstrates mixed small and large fibre diabetic neuropathy*** - This patient exhibits **small fibre** involvement (numbness, burning pain, and reduced pin-prick sensation) and **large fibre** involvement (reduced vibration sense and absent ankle reflexes). - The progressive, symmetric, "stocking" distribution of sensory loss in a long-term diabetic patient is the classic hallmark of **Distal Symmetric Polyneuropathy (DSPN)**.*These findings represent early diabetic neuropathy affecting only small nerve fibres* - Small fibre neuropathy primarily causes **pain and temperature deficits** but does not typically cause the **loss of vibration sense** or **absent ankle reflexes** seen here. - The involvement of **monofilament testing** and reduced vibration indicates that large myelinated fibres are also significantly compromised.*The sensory loss pattern indicates peripheral vascular disease rather than neuropathy* - Peripheral vascular disease (PVD) typically presents with **intermittent claudication**, absent pulses, or skin changes like pallor and coolness, which are not described. - The "stocking" sensory deficit and purely **neurological exam findings** (reflexes and sensation) point directly to a neuropathic rather than ischemic origin.*Absent ankle reflexes alone confirm the diagnosis without need for further assessment* - While **absent ankle reflexes** are a common finding in diabetic neuropathy, they can also occur with normal aging or other lumbosacral pathologies. - A clinical diagnosis requires a constellation of findings, including **sensory testing** (pin-prick, vibration, monofilament) and a consistent history, not just one isolated sign.*The symptoms are likely due to vitamin B12 deficiency from metformin therapy* - While metformin can cause **Vitamin B12 deficiency**, which leads to neuropathy, the patient's 12-year history of diabetes makes **hyperglycemia-induced nerve damage** a more statistically likely cause. - B12 deficiency neuropathy often involves prominent **proprioception loss** and can be associated with megaloblastic anemia, which is not suggested by the findings.

Question 133: A 44-year-old woman undergoes thyroid function tests as part of an investigation for fatigue. Results show TSH 0.05 mU/L (0.5-5.0), free T4 28 pmol/L (10-22), and free T3 8.2 pmol/L (3.5-6.5). What is the most appropriate classification of her thyroid status?

A. Subclinical hypothyroidism
B. Primary hypothyroidism
C. Subclinical hyperthyroidism
D. Overt hyperthyroidism (Correct Answer)
E. Secondary hypothyroidism

Explanation: ***Overt hyperthyroidism*** - The patient's thyroid function tests show a **suppressed TSH** (0.05 mU/L, below the normal range) and **elevated free T4** (28 pmol/L, above normal) and **elevated free T3** (8.2 pmol/L, above normal). - This combination of low TSH with high free T4 and free T3 is the hallmark diagnostic criteria for **overt primary hyperthyroidism**. *Subclinical hypothyroidism* - This condition is characterized by an **elevated TSH** (above the reference range) with **normal free T4** and **normal free T3** levels. - The patient's TSH is low, and her free T4 and T3 are elevated, which contradicts the definition of subclinical hypothyroidism. *Primary hypothyroidism* - Typically presents with a **high TSH** and a **low free T4** (and often low free T3), indicating primary thyroid gland failure. - The patient's results show a low TSH and high free T4/T3, which is the exact opposite biochemical picture of primary hypothyroidism. *Subclinical hyperthyroidism* - This is defined by a **low or suppressed TSH** in the presence of **normal free T4** and **normal free T3** levels. - Although the TSH is suppressed, the **free T4 and free T3 levels are elevated**, which means the condition has progressed beyond subclinical to overt hyperthyroidism. *Secondary hypothyroidism* - This condition occurs due to **pituitary or hypothalamic dysfunction**, leading to an **inappropriately normal or low TSH** in conjunction with a **low free T4**. - While the patient has a low TSH, her free T4 and free T3 levels are high, indicating an excess of thyroid hormones, not a deficiency as seen in hypothyroidism.

Question 134: A 52-year-old man with newly diagnosed type 2 diabetes attends for dietary advice. His BMI is 32 kg/m², HbA1c is 58 mmol/mol, and he takes no other medications. He asks about alcohol consumption. What is the most appropriate advice regarding alcohol intake for patients with diabetes?

A. Complete abstinence from alcohol is recommended for all patients with diabetes
B. Limit intake to no more than 14 units per week spread over at least 3 days (Correct Answer)
C. Alcohol consumption should be limited to no more than 21 units per week for men
D. Occasional binge drinking is acceptable as long as weekly totals remain low
E. Alcohol intake has no effect on blood glucose control and requires no special advice

Explanation: ***Limit intake to no more than 14 units per week spread over at least 3 days***- Current **UK clinical guidelines** state that patients with diabetes should follow the same alcohol limits as the general population, which is **14 units per week** for both men and women.- It is advised to spread consumption over **three or more days** to avoid the risks associated with heavy drinking episodes and to maintain better metabolic control.*Complete abstinence from alcohol is recommended for all patients with diabetes*- **Complete abstinence** is not medically required for diabetes management unless the patient has specific complications like **severe hypertriglyceridemia** or **pancreatitis**.- Moderate consumption is generally safe provided the patient is aware of the **caloric content** and potential for delayed **hypoglycemia**.*Alcohol consumption should be limited to no more than 21 units per week for men*- The limit of **21 units for men** is based on outdated guidelines; current recommendations have been lowered to align with the **14-unit limit** for everyone.- Consuming 21 units increases the risk of **weight gain** (due to empty calories) and potentially worsening **HbA1c levels**.*Occasional binge drinking is acceptable as long as weekly totals remain low*- **Binge drinking** should be strictly avoided as it significantly increases the risk of **severe hypoglycemia** by inhibiting **gluconeogenesis** in the liver.- It also contributes to higher **blood pressure** and increased cardiovascular risk, which is already a concern in patients with **Type 2 Diabetes**.*Alcohol intake has no effect on blood glucose control and requires no special advice*- Alcohol can significantly affect **glycemic control**; it can cause hypoglycemia in those on insulin/secretagogues or contribute to **hyperglycemia** if mixed with sugary drinks.- Large amounts of alcohol contribute to **weight gain** and **insulin resistance**, making it an essential topic for dietary education in **newly diagnosed** patients.

Question 135: Which of the following is the correct target HbA1c for an adult with type 2 diabetes managed on lifestyle and metformin alone, according to NICE guidelines?

A. 53 mmol/mol (7.0%)
B. 58 mmol/mol (7.5%)
C. 64 mmol/mol (8.0%)
D. 48 mmol/mol (6.5%) (Correct Answer)
E. 75 mmol/mol (9.0%)

Explanation: ***48 mmol/mol (6.5%)*** - According to **NICE guidelines**, the target HbA1c for patients managed by **lifestyle modifications alone** or by **lifestyle plus a single drug** not associated with hypoglycemia (like **metformin**) is 48 mmol/mol. - This aggressive target is set because **metformin** has a low risk of causing **hypoglycemia**, allowing for tighter glycemic control to prevent **microvascular complications**. *53 mmol/mol (7.0%)* - This is the target HbA1c level recommended when a patient is prescribed a drug associated with **hypoglycemia**, such as a **sulfonylurea** or **insulin**. - It is also the threshold at which **treatment intensification** (adding a second drug) should be considered if the HbA1c rises to this level or above. *58 mmol/mol (7.5%)* - This value is not a standard target for an otherwise healthy adult on metformin but may be considered as an **individualized target** for specific clinical scenarios. - It represents a level where **glycemic control** is suboptimal for most young or fit patients, needing a review of medication adherence or lifestyle. *64 mmol/mol (8.0%)* - This higher target is generally reserved for patients with **significant frailty**, limited **life expectancy**, or those where the risks of intensive treatment outweigh the benefits. - Targets are often relaxed to this level in the **elderly** to prevent falls or other adverse events resulting from tight control. *75 mmol/mol (9.0%)* - An HbA1c of 75 mmol/mol indicates poor metabolic control and is well above the recommended **therapeutic range** for any standard NICE guideline category. - Patients at this level are at a significantly increased risk of developing **long-term complications** such as neuropathy, retinopathy, and nephropathy.

Question 136: A 31-year-old woman with type 1 diabetes attends the emergency department with nausea and vomiting. She is 26 weeks pregnant. Blood tests show: glucose 14.2 mmol/L, pH 7.26, bicarbonate 13 mmol/L, ketones 3.4 mmol/L. She is alert and oriented. According to current UK guidance for managing DKA in pregnancy, which of the following insulin infusion rates and glucose thresholds is most appropriate?

A. Fixed rate intravenous insulin at 0.1 units/kg/hour; add 10% dextrose when glucose <14 mmol/L (Correct Answer)
B. Fixed rate intravenous insulin at 0.05 units/kg/hour; add 10% dextrose when glucose <10 mmol/L
C. Fixed rate intravenous insulin at 0.1 units/kg/hour; add 10% dextrose when glucose <10 mmol/L
D. Variable rate intravenous insulin guided by hourly blood glucose; add 5% dextrose when glucose <14 mmol/L
E. Fixed rate intravenous insulin at 0.05 units/kg/hour; add 10% dextrose when glucose <14 mmol/L

Explanation: ***Fixed rate intravenous insulin at 0.1 units/kg/hour; add 10% dextrose when glucose <14 mmol/L*** - In pregnancy, **Diabetic Ketoacidosis (DKA)** often occurs at lower blood glucose levels; thus, **10% dextrose** is initiated early (when glucose is <14 mmol/L) to allow the **Fixed Rate Intravenous Insulin Infusion (FRIII)** to continue clearing ketones without causing hypoglycemia. - The standard weight-based dose for FRIII is **0.1 units/kg/hour** (using pre-pregnancy or booking weight) to effectively suppress ketogenesis and treat the metabolic acidosis. *Fixed rate intravenous insulin at 0.05 units/kg/hour; add 10% dextrose when glucose <10 mmol/L* - An insulin rate of **0.05 units/kg/hour** is insufficient for the initial management of DKA, as it may not provide enough insulin to shut down **ketone production**. - A glucose threshold of **10 mmol/L** is used for non-pregnant adults, but is too low for pregnant patients who carry a higher risk of **euglycemic DKA** and fetal distress. *Fixed rate intravenous insulin at 0.1 units/kg/hour; add 10% dextrose when glucose <10 mmol/L* - While the insulin rate of **0.1 units/kg/hour** is correct, the glucose threshold for adding dextrose is inappropriate for the physiological state of pregnancy. - Waiting until glucose is **<10 mmol/L** increases the risk of maternal hypoglycemia and potential **fetal compromise** due to reduced placental glucose transfer. *Variable rate intravenous insulin guided by hourly blood glucose; add 5% dextrose when glucose <14 mmol/L* - **Variable Rate Intravenous Insulin Infusion (VRIII)** is not the gold standard for acute DKA management; **Fixed Rate (FRIII)** is required to suppress lipolysis and resolve ketosis. - **10% dextrose** is preferred over 5% dextrose in pregnancy to provide a more concentrated calorie source to maintain maternal glucose levels while insulin continues. *Fixed rate intravenous insulin at 0.05 units/kg/hour; add 10% dextrose when glucose <14 mmol/L* - Although the dextrose threshold matches pregnancy guidelines, the **0.05 units/kg/hour** insulin dose is half of the recommended starting rate. - Inadequate insulin dosing delays the resolution of **acidemia** and **ketonaemia**, which is dangerous for both the mother and the fetus.

Question 137: Which of the following patients with newly diagnosed type 2 diabetes should be commenced on dual therapy with metformin and an SGLT2 inhibitor at diagnosis, according to NICE guidelines?

A. A 58-year-old man with HbA1c 62 mmol/mol, BMI 32 kg/m², and no complications
B. A 52-year-old woman with HbA1c 68 mmol/mol, previous myocardial infarction 2 years ago, and eGFR 72 mL/min/1.73m² (Correct Answer)
C. A 65-year-old man with HbA1c 58 mmol/mol, BMI 28 kg/m², and chronic kidney disease stage 3a
D. A 70-year-old man with HbA1c 64 mmol/mol, heart failure with reduced ejection fraction, and eGFR 38 mL/min/1.73m²
E. A 48-year-old woman with HbA1c 74 mmol/mol, BMI 35 kg/m², and no established cardiovascular disease

Explanation: ***A 52-year-old woman with HbA1c 68 mmol/mol, previous myocardial infarction 2 years ago, and eGFR 72 mL/min/1.73m²***- According to **NICE guidelines (NG28)**, patients with **established atherosclerotic cardiovascular disease (ASCVD)**, such as a previous myocardial infarction, should be offered dual therapy with **Metformin and an SGLT2 inhibitor** at diagnosis.- The patient's **eGFR 72 mL/min/1.73m²** allows for safe initiation of an SGLT2 inhibitor, providing significant **cardiovascular protection** and improving glycemic control.*A 58-year-old man with HbA1c 62 mmol/mol, BMI 32 kg/m², and no complications*- In the absence of established cardiovascular disease, **heart failure**, or **chronic kidney disease**, **Metformin monotherapy** remains the first-line treatment for newly diagnosed type 2 diabetes.- Dual therapy at diagnosis is reserved for specific high-risk conditions, which are not present in this patient.*A 65-year-old man with HbA1c 58 mmol/mol, BMI 28 kg/m², and chronic kidney disease stage 3a*- While SGLT2 inhibitors are beneficial for **chronic kidney disease (CKD)**, the primary NICE recommendation for immediate dual therapy at diagnosis emphasizes those with **established ASCVD** or **heart failure**.- For a patient with **CKD stage 3a (eGFR 45-59)** and a relatively lower HbA1c, initial management typically involves **Metformin** (if eGFR >30 and stable), with an SGLT2i considered as an add-on later.*A 70-year-old man with HbA1c 64 mmol/mol, heart failure with reduced ejection fraction, and eGFR 38 mL/min/1.73m²*- Although SGLT2 inhibitors are indicated for **heart failure with reduced ejection fraction (HFrEF)**, an **eGFR of 38 mL/min/1.73m²** (CKD stage 3b) is often below the initiation threshold for some SGLT2 inhibitors for *glycemic* purposes (typically eGFR >45 mL/min/1.73m²).- While SGLT2 inhibitors can be *continued* and sometimes *initiated* at lower eGFRs for heart failure/CKD benefits irrespective of glycemic control, the woman with previous MI and good eGFR is a clearer candidate for *initial* dual therapy for standard glycemic and CV benefits.*A 48-year-old woman with HbA1c 74 mmol/mol, BMI 35 kg/m², and no established cardiovascular disease*- Despite a high **HbA1c of 74 mmol/mol** and **obesity**, the absence of established **atherosclerotic cardiovascular disease**, **heart failure**, or **CKD** means initial dual therapy with an SGLT2 inhibitor is not mandated by NICE guidelines at diagnosis.- This patient would typically start on **Metformin monotherapy**, with escalation to dual or triple therapy (potentially including an SGLT2i or GLP-1 RA for weight/glycemic control) if glycemic targets are not met.

Question 138: A 56-year-old woman with type 2 diabetes presents for review. Her current medications include metformin 1g twice daily, empagliflozin 25mg once daily, and dulaglutide 1.5mg once weekly. Her HbA1c is 54 mmol/mol (7.1%), BMI is 29 kg/m², and blood pressure is 138/82 mmHg. Urine albumin:creatinine ratio is 4.2 mg/mmol (normal <3) confirmed on two occasions. eGFR is 68 mL/min/1.73m². She has no retinopathy and no history of cardiovascular disease. Which of the following additional medications would provide the greatest benefit in reducing her risk of progressive chronic kidney disease?

A. Amlodipine 5mg once daily
B. Ramipril 5mg once daily (Correct Answer)
C. Aspirin 75mg once daily
D. Atorvastatin 20mg once daily
E. Dapagliflozin 10mg once daily

Explanation: ***Ramipril 5mg once daily*** - In patients with **Type 2 diabetes** and **microalbuminuria** (ACR > 3 mg/mmol), an **ACE inhibitor** or ARB is the first-line treatment for **renoprotection**, regardless of baseline blood pressure. - Ramipril reduces intraglomerular pressure and provides specific **anti-proteinuric effects** that slow the progression to end-stage renal disease. *Amlodipine 5mg once daily* - While effective for **hypertension**, calcium channel blockers like amlodipine lack the specific **renoprotective mechanisms** offered by blockade of the renin-angiotensin system. - It is generally used as a second or third-line agent if blood pressure remains elevated after maximizing **ACE inhibitor** therapy. *Aspirin 75mg once daily* - Aspirin is indicated for **secondary prevention** in patients with established cardiovascular disease, but this patient has no current history of such events. - It does not have a direct role in slowing the progression of **diabetic nephropathy** or reducing albuminuria. *Atorvastatin 20mg once daily* - Statins are critical for reducing overall **cardiovascular risk** in diabetic patients, especially those with renal impairment. - However, they do not provide the same targeted benefit in reducing **albuminuria** or delaying the worsening of **CKD** as ACE inhibitors do. *Dapagliflozin 10mg once daily* - This patient is already taking **empagliflozin**, and there is no clinical benefit or indication for combining two different **SGLT2 inhibitors**. - SGLT2 inhibitors do provide renoprotection, but this benefit is already being utilized through her current prescription.

Question 139: What is the diagnostic criterion for diabetic ketoacidosis according to current UK guidelines?

A. Blood glucose >11 mmol/L, pH <7.35, bicarbonate <15 mmol/L, ketonaemia >3 mmol/L
B. Blood glucose >11 mmol/L, pH <7.3, bicarbonate <15 mmol/L, ketonaemia >3 mmol/L (Correct Answer)
C. Blood glucose >13.9 mmol/L, pH <7.3, bicarbonate <18 mmol/L, ketonuria 2+ or more
D. Blood glucose >11 mmol/L, pH <7.35, bicarbonate <18 mmol/L, ketonaemia >5 mmol/L
E. Blood glucose >13.9 mmol/L, pH <7.2, bicarbonate <15 mmol/L, ketonaemia >3 mmol/L

Explanation: ***Blood glucose >11 mmol/L, pH <7.3, bicarbonate <15 mmol/L, ketonaemia >3 mmol/L*** - According to **JBDS guidelines**, the diagnostic triad of DKA requires **ketonaemia (>3 mmol/L)**, **hyperglycaemia (>11 mmol/L)** or known diabetes, and **acidosis (pH <7.3 or bicarbonate <15 mmol/L)**. - This combination confirms the presence of systemic ketosis and metabolic acidosis necessary for a DKA diagnosis in the UK. *Blood glucose >11 mmol/L, pH <7.35, bicarbonate <15 mmol/L, ketonaemia >3 mmol/L* - This option uses a **pH threshold of <7.35**, which is the general limit for normal physiological pH but too high for the specific diagnosis of DKA. - In DKA, the **acidosis must be more severe (pH <7.3)** to meet the standard diagnostic criteria. *Blood glucose >13.9 mmol/L, pH <7.3, bicarbonate <18 mmol/L, ketonuria 2+ or more* - A **bicarbonate <18 mmol/L** and **glucose >13.9 mmol/L** align more closely with older **American Diabetes Association (ADA)** guidelines rather than current UK practice. - While **ketonuria 2+** is acceptable if blood ketones cannot be measured, the primary diagnostic thresholds for glucose and bicarbonate provided here are incorrect for the UK. *Blood glucose >11 mmol/L, pH <7.35, bicarbonate <18 mmol/L, ketonaemia >5 mmol/L* - **Ketonaemia >5 mmol/L** actually indicates **severe DKA** requiring senior involvement, rather than the initial entry threshold for diagnosis. - The **pH (<7.35)** and **bicarbonate (<18 mmol/L)** values are both too high to satisfy the precise UK definition of DKA. *Blood glucose >13.9 mmol/L, pH <7.2, bicarbonate <15 mmol/L, ketonaemia >3 mmol/L* - While the **pH <7.2** would certainly meet the criteria for DKA, it is a marker of **moderate severity** rather than the minimum diagnostic cut-off of **pH <7.3**. - The **glucose value (>13.9 mmol/L)** is unnecessarily high, as DKA can be diagnosed with levels as low as **11 mmol/L** or even lower in euglycaemic DKA cases.

Question 140: A 67-year-old man with type 2 diabetes for 20 years presents to his GP with a painless ulcer on the sole of his right foot that he noticed 2 weeks ago. He has reduced sensation in both feet to monofilament testing. The ulcer is 2 cm in diameter, located over the first metatarsal head, with granulation tissue at the base but no purulent discharge. His foot pulses are palpable and capillary refill time is 2 seconds. There is no cellulitis or systemic features of infection. An X-ray of the foot shows no evidence of osteomyelitis. Which of the following is the most important immediate management?

A. Commence oral antibiotics and arrange follow-up in 2 weeks
B. Refer to vascular surgery for consideration of revascularisation
C. Arrange urgent debridement in the operating theatre
D. Refer to multidisciplinary foot clinic within 24 hours (Correct Answer)
E. Apply topical antimicrobial dressing and review in 1 week

Explanation: ***Refer to multidisciplinary foot clinic within 24 hours***- This patient presents with a **neuropathic diabetic foot ulcer**, characterized by a painless ulcer on a pressure point (first metatarsal head) and **reduced sensation** from long-standing diabetes.- According to **NICE guidelines**, any new diabetic foot ulcer requires urgent referral to a **multidisciplinary foot care service (MDFT)** within **24 hours** for specialized assessment, offloading, and wound management to prevent complications. *Commence oral antibiotics and arrange follow-up in 2 weeks*- This ulcer shows **no signs of infection** (no purulent discharge, cellulitis, or systemic features), so empirical oral antibiotics are not indicated at this stage.- A 2-week follow-up for a **diabetic foot ulcer** is too long and significantly increases the risk of rapid deterioration and severe complications without specialized care. *Refer to vascular surgery for consideration of revascularisation*- The patient has **palpable foot pulses** and a normal **capillary refill time** of 2 seconds, indicating adequate peripheral arterial perfusion.- The primary etiology here is **neuropathy**, not significant peripheral arterial disease, making urgent vascular surgical referral unnecessary. *Arrange urgent debridement in the operating theatre*- The ulcer base shows healthy **granulation tissue** and there is no evidence of extensive necrosis, deep infection, or gas gangrene requiring urgent operating theatre debridement.- Minor debridement may be necessary and can be performed by a **podiatrist** within the specialized foot clinic setting, not necessarily requiring an operating theatre. *Apply topical antimicrobial dressing and review in 1 week*- Managing a **diabetic neuropathic ulcer** solely with topical antimicrobial dressings in primary care is insufficient given the patient's **loss of protective sensation** and high risk of complications.- **Topical antimicrobials** are not recommended for clean, granulating ulcers without signs of infection and do not address the critical need for pressure relief and specialist care.

Question 141: A 42-year-old man presents with a 2-day history of fever, malaise, and severe neck pain radiating to his jaw. He had an upper respiratory tract infection 3 weeks ago. On examination, his temperature is 38.4°C and his thyroid gland is enlarged, firm, and exquisitely tender. Blood tests show: TSH <0.01 mU/L, free T4 34 pmol/L, ESR 72 mm/hr, CRP 86 mg/L. Which of the following investigation findings would most strongly support the likely diagnosis?

A. Positive TSH receptor antibodies
B. Raised radioiodine uptake on thyroid scintigraphy
C. Multiple thyroid nodules on ultrasound
D. Low radioiodine uptake on thyroid scintigraphy (Correct Answer)
E. Positive anti-thyroid peroxidase antibodies

Explanation: ***Low radioiodine uptake on thyroid scintigraphy***- A **low or absent radioiodine uptake** is characteristic of **Subacute (De Quervain's) Thyroiditis**, as inflammation causes follicular cell destruction, preventing iodine trapping despite high circulating thyroid hormone levels from leakage.- This finding confirms that the thyrotoxicosis is due to **leakage of preformed hormone** rather than **excessive new hormone synthesis**, which would show high uptake.*Positive TSH receptor antibodies*- These antibodies are diagnostic for **Graves' disease**, an autoimmune condition causing hyperthyroidism, which typically presents with a painless goiter and often ophthalmopathy or pretibial myxedema.- The patient's **exquisitely tender thyroid**, recent viral infection, and significantly elevated inflammatory markers (**ESR, CRP**) are inconsistent with **Graves' disease**.*Raised radioiodine uptake on thyroid scintigraphy*- **Increased radioiodine uptake** indicates an **overactive thyroid gland** actively synthesizing excessive hormones, as seen in **Graves' disease** or **toxic multinodular goiter**.- In **Subacute Thyroiditis**, the inflamed and damaged follicular cells lose their ability to concentrate iodine, leading to *low* rather than *raised* uptake.*Multiple thyroid nodules on ultrasound*- While **multiple thyroid nodules** can be a cause of hyperthyroidism (toxic multinodular goiter), this condition typically develops slowly in older patients and does not present with acute pain, fever, or marked inflammatory markers.- Ultrasound in **De Quervain's thyroiditis** may show diffuse hypoechoic areas but **multiple distinct nodules** are not its primary diagnostic feature.*Positive anti-thyroid peroxidase antibodies*- **Anti-thyroid peroxidase (TPO) antibodies** are strongly associated with **Hashimoto's thyroiditis**, an autoimmune condition leading to hypothyroidism and typically presenting with a firm, painless goiter.- Although transiently positive in some other thyroid conditions, these antibodies are not the primary diagnostic indicator for the acute, painful, and self-limiting nature of **Subacute Thyroiditis**.

Question 142: A 25-year-old woman with type 1 diabetes for 12 years attends for her annual screening appointment. She is asymptomatic with an HbA1c of 62 mmol/mol (7.8%). Digital retinal photography shows microaneurysms and scattered dot haemorrhages in both eyes, but no cotton wool spots, venous beading, or new vessels. Her albumin:creatinine ratio is 2.8 mg/mmol (normal <3), blood pressure is 124/78 mmHg, and monofilament testing of her feet is normal. What is the appropriate follow-up interval for diabetic retinopathy screening in this patient?

A. Repeat screening in 3 months
B. Urgent referral to ophthalmology within 2 weeks
C. Routine referral to ophthalmology within 13 weeks
D. Repeat screening in 6 months (Correct Answer)
E. Repeat screening in 12 months

Explanation: ***Repeat screening in 6 months*** - The patient exhibits features of **background (mild non-proliferative) diabetic retinopathy**, specifically microaneurysms and **dot hemorrhages** without more advanced lesions. - According to diabetic eye screening guidelines, the presence of these findings without **maculopathy** or pre-proliferative changes necessitates a shortened surveillance interval of **6 months** to monitor for progression. *Repeat screening in 3 months* - A **3-month interval** is not a standard surveillance frequency within national diabetic eye screening protocols for mild non-proliferative changes. - This interval is generally too frequent for stable **background retinopathy** and does not align with clinical pathway recommendations. *Urgent referral to ophthalmology within 2 weeks* - Urgent 2-week referrals are reserved for **proliferative diabetic retinopathy** (new vessels) or sudden, severe vision loss. - This patient lacks high-risk features such as **neovascularization** or vitreous hemorrhage that would trigger an emergency specialist assessment. *Routine referral to ophthalmology within 13 weeks* - Routine ophthalmology referral is indicated for **maculopathy** or **moderate-to-severe non-proliferative retinopathy** (e.g., cotton wool spots, venous beading). - Since the patient has only microaneurysms and lacks **exudates** or significant hemorrhages near the macula, primary screening surveillance is sufficient over referral. *Repeat screening in 12 months* - **Annual (12-month) screening** is only appropriate for patients who show **no evidence of retinopathy** in digital photography. - Because microaneurysms and hemorrhages are already present, the risk of progression is higher, making the standard **yearly interval** unsafe.

Question 143: A 58-year-old woman is found to have a TSH of 8.2 mU/L (normal 0.5-5.0) and free T4 of 11 pmol/L (normal 9-25) on routine blood tests. She has no symptoms and no goitre on examination. Anti-thyroid peroxidase (anti-TPO) antibodies are strongly positive. Her lipid profile shows total cholesterol 6.8 mmol/L and LDL cholesterol 4.2 mmol/L. She has no other significant medical history and takes no regular medications. What is the most appropriate management?

A. Reassure and repeat thyroid function tests in 3 months (Correct Answer)
B. Commence levothyroxine 50 micrograms daily
C. Commence levothyroxine 25 micrograms daily
D. Commence atorvastatin and repeat thyroid function tests in 3 months
E. Arrange thyroid ultrasound before deciding on treatment

Explanation: ***Reassure and repeat thyroid function tests in 3 months*** - The patient has **subclinical hypothyroidism**, defined by an **elevated TSH** (8.2 mU/L) and a **normal free T4** (11 pmol/L) in an **asymptomatic** individual with no goitre. - For **asymptomatic** patients with TSH < 10 mU/L, guidelines recommend **observation** and **retesting** thyroid function in 3-6 months to confirm persistent elevation before initiating therapy, even with positive anti-TPO antibodies. *Commence levothyroxine 50 micrograms daily* - **Levothyroxine** treatment is typically reserved for **overt hypothyroidism** or **subclinical hypothyroidism** with TSH > 10 mU/L, or if the patient is symptomatic, pregnant, or has a goitre. - Initiating treatment prematurely in an **asymptomatic** patient with TSH < 10 mU/L risks **unnecessary medication** and potentially **iatrogenic hyperthyroidism**. *Commence levothyroxine 25 micrograms daily* - Although 25 mcg is a common starting dose, it is not yet indicated as the diagnosis of persistent subclinical hypothyroidism needs to be confirmed with **repeat testing** in this **asymptomatic** patient. - Many cases of subclinical hypothyroidism, especially with TSH < 10 mU/L, can **normalize spontaneously** or remain stable without progression, making early intervention unnecessary. *Commence atorvastatin and repeat thyroid function tests in 3 months* - **Subclinical hypothyroidism** can cause **dyslipidemia**, but the initial approach is to **manage the thyroid dysfunction** first, if treatment becomes indicated. - Correcting thyroid function often leads to an **improvement in lipid profiles**, potentially reducing or eliminating the need for **statin therapy**. *Arrange thyroid ultrasound before deciding on treatment* - A **thyroid ultrasound** is primarily indicated for evaluating **thyroid nodules** or a palpable goitre, neither of which is present or the main concern here. - The diagnosis of **subclinical hypothyroidism** is biochemical, and the presence of **anti-TPO antibodies** indicates an autoimmune cause; imaging does not alter the management threshold for **asymptomatic subclinical hypothyroidism**.

Question 144: A 19-year-old man with type 1 diabetes for 8 years is reviewed in the diabetes clinic. Over the past 6 months, his HbA1c has risen from 58 mmol/mol to 76 mmol/mol (9.1%). He reports multiple episodes of hypoglycaemia, particularly in the evenings, followed by high glucose readings the next morning. He is currently on a basal-bolus insulin regimen with insulin glargine 28 units at bedtime and insulin aspart before meals. His continuous glucose monitoring shows significant glycaemic variability. What is the most likely explanation for his morning hyperglycaemia?

A. Dawn phenomenon
B. Somogyi effect (Correct Answer)
C. Waning insulin effect
D. Inadequate basal insulin dosing
E. Insulin antibody formation

Explanation: ***Somogyi effect*** - The **Somogyi effect** occurs when **nocturnal hypoglycaemia** triggers a surge in counter-regulatory hormones (glucagon, adrenaline, and cortisol), leading to **rebound hyperglycaemia** by morning. - This patient's history of **evening hypoglycaemia** followed by high morning readings is the classic presentation of this phenomenon. *Dawn phenomenon* - This refers to early morning hyperglycaemia caused by the physiological release of **growth hormone** and **cortisol** between 4 AM and 8 AM. - Unlike the Somogyi effect, it is **not preceded by hypoglycaemia** and is a steady climb rather than a rebound from a low. *Waning insulin effect* - Occurs when the duration of the **basal insulin** (like glargine) does not last a full 24 hours, leading to a rise in glucose levels before the next dose. - This would cause a gradual rise in blood sugar throughout the night without the **nocturnal hypoglycaemic episodes** reported by this patient. *Inadequate basal insulin dosing* - If the basal insulin dose was simply too low, the patient would experience **persistent hyperglycaemia** throughout the day and night. - It does not explain the **significant glycaemic variability** or the specific pattern of evening lows followed by morning highs. *Insulin antibody formation* - **Insulin antibodies** can neutralize insulin or prolong its action, leading to erratic blood glucose patterns and increased insulin requirements. - This is **extremely rare** with modern recombinant insulin analogues and does not typically follow a predictable diurnal pattern like the Somogyi effect.

Question 145: A 34-year-old woman who is 8 weeks pregnant presents with fatigue and palpitations. She has no significant past medical history. Examination reveals a fine tremor, warm peripheries, and a resting pulse of 98 bpm. Her thyroid is mildly enlarged but non-tender. Blood tests show: TSH <0.01 mU/L, free T4 28 pmol/L (normal 9-25), free T3 9.2 pmol/L (normal 3.5-7.8), and beta-hCG 85,000 IU/L. TSH receptor antibodies are negative. Which of the following is the most likely diagnosis?

A. Toxic multinodular goitre
B. De Quervain's thyroiditis
C. Hyperemesis gravidarum with secondary thyrotoxicosis
D. Graves' disease
E. Gestational transient thyrotoxicosis (Correct Answer)

Explanation: ***Gestational transient thyrotoxicosis*** - This condition is caused by high levels of **beta-hCG** in early pregnancy, which has structural similarity to **TSH** and cross-reacts with its receptor to stimulate the thyroid. - The diagnosis is confirmed by biochemical thyrotoxicosis in the **first trimester**, high hCG levels, and the absence of **TSH receptor antibodies** (TRAb). *Toxic multinodular goitre* - This typically presents in **older individuals** and is characterized by a nodular, irregular thyroid gland rather than mild, diffuse enlargement. - It results in autonomous thyroid hormone production that does not correlate with **pregnancy cycles** or hCG levels. *De Quervain's thyroiditis* - This is a subacute inflammatory condition that presents with a characteristically **painful, tender thyroid gland**, which is absent in this patient (non-tender). - It is usually preceded by a **viral upper respiratory tract infection** and is associated with an elevated ESR. *Hyperemesis gravidarum with secondary thyrotoxicosis* - While it involves hCG-induced thyrotoxicosis, this diagnosis requires the presence of **severe nausea and vomiting** causing dehydration and weight loss. - This patient presents with fatigue and palpitations but lacks the **severe gastrointestinal symptoms** characteristic of hyperemesis. *Graves' disease* - Graves' disease is the most common cause of hyperthyroidism in pregnancy but would typically feature **positive TSH receptor antibodies** (TRAb). - It is often associated with clinical signs like **ophthalmopathy** (exophthalmos) or pretibial myxedema, which are not present here.

Question 146: A 72-year-old woman with type 2 diabetes is brought to the emergency department with reduced consciousness. Her family reports she has been increasingly confused over the past 3 days with reduced oral intake. Her medications include metformin and gliclazide. On examination, she is deeply unresponsive (GCS 6), blood pressure 95/62 mmHg, pulse 118 bpm, temperature 37.8°C, and appears clinically dehydrated. Investigations show: capillary glucose 52.3 mmol/L, sodium 157 mmol/L, potassium 4.8 mmol/L, urea 28.2 mmol/L, creatinine 185 μmol/L, serum osmolality 382 mOsm/kg. Urinalysis shows no ketones. What is the calculated fluid deficit likely to be in this patient?

A. Approximately 5-7 litres
B. Approximately 8-10 litres (Correct Answer)
C. Approximately 11-13 litres
D. Approximately 14-16 litres
E. Approximately 3-5 litres

Explanation: ***Approximately 8-10 litres***- This patient presents with **Hyperosmolar Hyperglycaemic State (HHS)**, characterized by severe **hyperglycemia** (52.3 mmol/L), profound **hyperosmolality** (382 mOsm/kg), and clinical signs of severe dehydration, without significant ketosis.- The typical fluid deficit in HHS is significantly higher than in DKA, often ranging from **100-220 mL/kg**, which commonly translates to a total deficit of **8-10 litres** in an average adult patient. *Approximately 5-7 litres*- This fluid volume is more typical of the deficit seen in **Diabetic Ketoacidosis (DKA)**, which usually ranges from 3-6 litres.- Given the patient's extremely high **serum osmolality** (382 mOsm/kg), severe **hypernatremia** (157 mmol/L), and signs of significant organ hypoperfusion, the actual dehydration is much more profound than this range suggests. *Approximately 11-13 litres*- While some patients with very prolonged or severe HHS may accumulate such extensive fluid losses, this represents the **upper end** of the spectrum rather than the average expected deficit.- Overly aggressive initial fluid resuscitation based on this higher estimate carries risks like **cerebral oedema** or fluid overload, especially in an elderly patient. *Approximately 14-16 litres*- This volume indicates **extreme dehydration** and generally exceeds the typical calculated fluid deficit for patients presenting with the described laboratory parameters of HHS.- Rapid replacement of such a large volume can lead to serious complications, including **osmotic demyelination syndrome**, **cerebral oedema**, or acute cardiac decompensation due to fluid overload. *Approximately 3-5 litres*- This range is highly **inadequate** for a patient presenting with marked **hyperglycemia** (52.3 mmol/L), severe **hyperosmolality**, and clear evidence of **pre-renal azotemia** (urea 28.2 mmol/L, creatinine 185 μmol/L).- Such a low estimate fails to account for the massive and sustained **osmotic diuresis** that occurs over several days, leading to profound fluid depletion in HHS.

Question 147: A 45-year-old woman presents with palpitations, weight loss, and heat intolerance over the past 3 months. On examination, she has a diffuse, non-tender goitre, a resting pulse of 110 bpm, and lid lag. Blood tests reveal: TSH <0.01 mU/L, free T4 32 pmol/L (normal 9-25), free T3 12.8 pmol/L (normal 3.5-7.8). TSH receptor antibodies are positive. She is commenced on carbimazole 40mg daily. After 6 weeks, her thyroid function tests show: TSH <0.01 mU/L, free T4 14 pmol/L. What is the most appropriate next step in her management?

A. Continue current dose of carbimazole
B. Reduce carbimazole to 20mg daily (Correct Answer)
C. Stop carbimazole and commence propylthiouracil
D. Add levothyroxine 100 micrograms daily and continue carbimazole
E. Stop carbimazole and arrange radioiodine therapy

Explanation: ***Reduce carbimazole to 20mg daily*** - The patient's initial **free T4** was high (32 pmol/L) and has now normalized to 14 pmol/L, which is within the normal range (9-25 pmol/L) after 6 weeks on 40mg carbimazole. This indicates effective control of hyperthyroidism. - Reducing the dose is the appropriate next step in a **titration regimen** to prevent **iatrogenic hypothyroidism** while maintaining a euthyroid state. The **TSH** will remain suppressed for longer and should not primarily guide early dose adjustments. *Continue current dose of carbimazole* - Continuing 40mg daily would likely lead to **iatrogenic hypothyroidism** because the patient's **free T4** is already within the normal range. - The goal is to achieve euthyroidism, and maintaining a high dose risks **over-treatment** once thyroid hormone levels have normalized. *Stop carbimazole and commence propylthiouracil* - There is no indication to switch to **propylthiouracil (PTU)**, as the patient is responding well to carbimazole and PTU is generally reserved for specific situations like the **first trimester of pregnancy** or **carbimazole intolerance**. - Switching medications without a clear clinical reason unnecessarily complicates treatment and exposes the patient to potential new side effects. *Add levothyroxine 100 micrograms daily and continue carbimazole* - This approach describes a **block-and-replace regimen**, where a high dose of antithyroid drug completely blocks thyroid hormone production, and exogenous levothyroxine replaces it. - While a valid strategy, it is typically initiated from the outset if chosen, not introduced when a **titration regimen** is successfully bringing thyroid hormones to normal levels. *Stop carbimazole and arrange radioiodine therapy* - **Radioiodine therapy** is a definitive treatment for **Graves' disease** but is usually considered after a failed course of antithyroid drugs, relapse, or patient preference for definitive therapy. - The patient is responding well to **carbimazole**, so stopping it to proceed with radioiodine at this stage would be premature as medical management is still effective.

Question 148: A 62-year-old man with type 2 diabetes for 15 years attends his annual diabetes review. He is currently taking metformin 1g twice daily and gliclazide 160mg twice daily. His HbA1c is 68 mmol/mol (8.4%). His BMI is 32 kg/m², blood pressure is 142/88 mmHg, and his eGFR is 48 mL/min/1.73m². He has no history of cardiovascular disease but has background diabetic retinopathy. Which of the following would be the most appropriate addition to his treatment regimen?

A. Sitagliptin 100mg once daily (Correct Answer)
B. Empagliflozin 10mg once daily
C. Pioglitazone 30mg once daily
D. Insulin glargine 10 units at bedtime
E. Exenatide 10 micrograms twice daily

Explanation: ***Sitagliptin 100mg once daily*** - **Sitagliptin**, a DPP-4 inhibitor, is considered a suitable addition to metformin and sulphonylurea (triple therapy) because it is **weight-neutral** and generally well-tolerated. - While the dose typically needs adjustment to **50mg** for an eGFR between 30-44 mL/min/1.73m², it remains a safer choice in **chronic kidney disease** (CKD Stage 3a) compared to many other agents. *Empagliflozin 10mg once daily* - **SGLT2 inhibitors** have reduced glycemic efficacy as the **eGFR** declines, and while they have cardiorenal benefits, initiation guidelines often require higher renal function for glucose lowering specifically. - Although some guidelines now allow use down to lower eGFRs, it is not the classic first-line choice for triple therapy in this clinical scenario compared to **DPP-4 inhibitors**. *Pioglitazone 30mg once daily* - **Pioglitazone** is associated with **weight gain**, which is undesirable in this patient with a **BMI of 32 kg/m²**. - It also carries a risk of **fluid retention** and peripheral edema, which can be problematic in patients with declining **renal function**. *Insulin glargine 10 units at bedtime* - While effective for glycemic control, **insulin** is usually reserved for when triple oral therapy fails or if the **HbA1c** is significantly higher. - It carries a high risk of **hypoglycemia** and significant **weight gain**, making it less favorable than adding a third oral agent first. *Exenatide 10 micrograms twice daily* - **GLP-1 receptor agonists** like exenatide are usually recommended only if triple therapy with oral agents is ineffective or if the patient's **BMI is >35 kg/m²**. - Many **GLP-1 analogues** require cautious use or are contraindicated in significant **renal impairment** (eGFR <30-50 mL/min/1.73m² depending on the specific preparation).

Question 149: A 28-year-old woman with type 1 diabetes presents to the emergency department with vomiting and abdominal pain. She has been unwell for 2 days with a urinary tract infection. On examination, she is drowsy with a respiratory rate of 28/min and has a fruity odour on her breath. Her capillary blood glucose is 26.4 mmol/L. Venous blood gas shows: pH 7.18, bicarbonate 12 mmol/L, and ketones 5.2 mmol/L. Which of the following is the most appropriate initial fluid management?

A. 0.9% sodium chloride 1000 mL over 1 hour (Correct Answer)
B. 0.45% sodium chloride 1000 mL over 1 hour
C. Hartmann's solution 1000 mL over 1 hour
D. 5% dextrose 1000 mL over 1 hour
E. 0.9% sodium chloride with potassium chloride 40 mmol/L over 1 hour

Explanation: ***0.9% sodium chloride 1000 mL over 1 hour***- The patient presents with **Diabetic Ketoacidosis (DKA)**, and the priority is volume replacement using an **isotonic crystalloid** to restore circulatory volume.- **0.9% sodium chloride** is the fluid of choice for initial resuscitation to correct dehydration and improve renal perfusion in DKA management.*0.45% sodium chloride 1000 mL over 1 hour*- This is a **hypotonic solution** which can lead to a rapid drop in serum osmolality and increase the risk of **cerebral edema**.- It is generally reserved only for cases of severe hypernatremia and is not indicated for initial **DKA fluid resuscitation**.*Hartmann's solution 1000 mL over 1 hour*- While it is a balanced crystalloid, **Hartmann's solution** contains lactate which might interfere with the monitoring of **ketone clearance** and acid-base status during DKA treatment.- National guidelines traditionally favor **0.9% saline** as the standard initial fluid for volume expansion in diabetic emergencies.*5% dextrose 1000 mL over 1 hour*- Administering **5% dextrose** initially is contraindicated as the patient is already severely **hyperglycemic** (26.4 mmol/L).- Dextrose-containing fluids are only introduced later in the protocol once blood glucose levels fall below **14 mmol/L** to prevent hypoglycemia while insulin continues.*0.9% sodium chloride with potassium chloride 40 mmol/L over 1 hour*- **Potassium** should not be added to the first bag of resuscitation fluid until the patient's **serum potassium** level is confirmed by laboratory testing.- Patients often present with **hyperkalemia** initially due to the shift of ions out of cells in acidosis, and premature administration can lead to dangerous cardiac arrhythmias.

Practice by Chapter

Diabetes complications and screening

Practice Questions

Diabetic emergencies (DKA, HHS)

Practice Questions

Thyroid disorders

Practice Questions

Type 1 diabetes

Practice Questions

Type 2 diabetes

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free

Endocrinology & Diabetes — MCQs

Endocrinology & Diabetes — MCQs

On this page